Document:

amag_EX_10_42

		

			Exhibit 10.42

		

		

			 

		

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

		
			ANTARES PHARMA, INC.
		

		
			 
		

		
			AND
		

		
			 
		

		
			LUMARA HEALTH INC.
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			DEVELOPMENT AND LICENSE AGREEMENT
		

		
			 
		

		
			SEPTEMBER 30, 2014
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

 
		

		
			DEVELOPMENT AND LICENSE AGREEMENT
		

		
			 
		

		
			This Development and License Agreement ("Agreement") is made and entered into as of the 30th day of September, 2014 (the "Effective Date") by and between Antares Pharma, Inc., a Delaware corporation, with offices located at 100 Princeton South, Suite 300, Ewing, NJ 08628 ("Antares"), and Lumara Health Inc., a Delaware corporation, with a corporate address at 16640 Chesterfield Grove Road, Suite 200, Chesterfield, MO 63005 ("Lumara"). Antares and Lumara are sometimes referred to herein individually as a "Party" and collectively as the "Parties", and references to "Antares" and "Lumara" shall include their respective Affiliates.
		

		
			 
		

		
			Recitals
		

		
			 
		

		
			WHEREAS,   Lumara is engaged in discovering, developing and marketing pharmaceutical products, including 17-alpha hydroxyprogesterone caproate ("HPC").
		

		
			 
		

		
			WHEREAS, Antares is engaged in the research and development of certain drug delivery devices, including auto-injection systems and the development and marketing of pharmaceutical products.
		

		
			 
		

		
			WHEREAS, Lumara desires to obtain, and Antares desires to grant to Lumara, an exclusive, worldwide license to Antares' [***] auto-injection system or similar device for use with HPC in the Field (as defined below) upon the terms and conditions set forth in this Agreement.
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained in this Agreement, the Parties hereto agree as follows:
		

		
			 
		

		
			ARTICLE 1 
		

		
			 
		

		
			DEFINITIONS
		

		
			 
		

		
			As used herein, the following terms shall have the following meanings assigned to them in this Article and shall include the plural as well as the singular:
		

		
			 
		

		
			1.1     "Adverse Event" means any untoward medical occurrence associated with the use of the Product (whether or not Product Approval has been achieved) in humans or subjects, without regard to a causal relationship between Drug, Device and the event as set forth in 21 CFR 312 & 314, as amended from time to time.
		

		
			 
		

		
			 
		

		
			1.2     "Adverse Event Report" means any oral, written or electronically transmitted report of any Adverse Event.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

1.3     "Affiliate" means any Person that directly (or indirectly through one or more intermediaries) controls, is controlled by, or is under common control with a Party. For purposes of this definition only, the terms "controls," "controlled," and "control" means (i) the direct or indirect ability or power to direct or cause the direction of the management and policies of an entity or otherwise direct the affairs of such entity, whether through ownership of equity, voting securities, beneficial interest, by contract, or  otherwise, or (ii) the ownership, directly or indirectly, of at least 50% of the voting  securities (or other comparable ownership interest for an entity other than a corporation) of a Party.
		

		
			 
		

		
			1.4     "Antares Device Development" means the conduct of all activities by Antares or Lumara on their behalf consistent with the Device Development Plan that are reasonably required to complete development of the Device for the use of the Product in the Field, including: (i) regulatory affairs, pre-clinical studies and clinical trials in accordance with the cGLPs, cGCPs and cQSRs or other designated quality standards and Applicable Laws; (ii) all activities relating to developing the ability to manufacture Devices, including, without limitation, tooling development and delivery technologies related to Devices and components thereof, industrial and mechanical design, and manufacturing and quality assurance technical support until such time as manufacturing of Devices intended for commercial sale of Product commences and, thereafter, to the extent required under Applicable Law for continued commercial sale of Product; and usability studies as agreed to by the Parties.
		

		
			 
		

		
			1.5     "Antares Device Development Payments" means those payments made by Lumara to Antares, with respect to Antares Device Development as set forth in the Device Development Plan.
		

		
			 
		

		
			1.6     "Antares' Fully Burdened Manufacturing Costs" means those costs actually incurred by Antares related directly to the acquisition of materials and their conversion into salable Devices or Products, as the case may be. [***].
		

		
			 
		

		
			1.7     "Antares Indemnities" shall have the meaning set forth in Section 16.2 hereof.
		

		
			 
		

		
			1.8     "Antares Know-How" means all Information that is owned or Controlled by Antares as of the Effective Date or at any time during the term of this Agreement, and that is useful, necessary, or required for, or related to, the development, manufacture, use, commercialization or exploitation of [***], the Device and/or Product, or to otherwise proceed with the undertakings envisioned by this Agreement. Antares Know-How does not include Antares Patent Rights.
		

		
			 
		

		
			1.9     "Antares Patent Rights"  means all Patent Rights in the Territory that are owned, including jointly owned, or Controlled by Antares as of the Effective Date or at any time during the term of this Agreement that Cover [***], the Device and/or Product, or that otherwise Cover a method, apparatus, composition or process that is useful, necessary, or required for, or related to, the development, manufacture, use, commercialization or exploitation of [***], the Device and/or Product including improvements and next generations thereof, or to otherwise proceed with the undertakings envisioned by this Agreement, including without limitation the Patent Rights associated with the patents and patent applications identified in Exhibit B, and including any Patent Rights within the Program Intellectual Property owned solely or jointly by Antares 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

hereunder. Antares Patent Rights do not include Antares Know-How.
		

		
			 
		

		
			1.10     "Antares Sole Invention" shall have the meaning set forth in Section 12.l(b) hereof.
		

		
			 
		

		
			1.11     "Antares Trademarks" means all trademarks, service marks, trade dress, trade names, and Internet domain names (together with the goodwill of the business symbolized by the foregoing), including all registrations and registration applications throughout the Territory that are owned or Controlled by Antares as of the Effective Date or at any time during the term of this Agreement, and that are useful, necessary, or required for, or related to, the development, manufacture, use, commercialization or exploitation, including any packaging, promotional materials, package inserts and labeling, of the Device and/or Product, or to otherwise  proceed with the undertakings envisioned by this
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

Agreement, including without limitation, [***] and such other trademarks identified in Exhibit C.
		

		
			 
		

		
			1.12     "Applicable Laws" means all applicable statutes, ordinances, regulations, rules and orders of any kind whatsoever of any Governmental Authority, including, without limitation, the Anti-kickback Statute (42 U.S.C. § 1320a-7b, et. seq.), Prescription Drug Marketing Act, Generic Drug Enforcement Act of 1992 (21 U.S.C. § 3359, et. seq.), the Federal Food Drug and Cosmetics Act, Resource Conservation and Recovery Act, Clean Water Act, Clean Air Act, the Drug Enforcement Act, Occupational Safety and Health Act, cGMP, cGCP, cGLP, cQSR and any comparable laws of any foreign jurisdiction, all as amended from time to time.
		

		
			 
		

		
			1.13     "cGCP" means the then current Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials promulgated or endorsed by the U.S. Food and Drug Administration ("FDA") (or in the case of foreign jurisdictions, comparable regulatory standards), including those regulations or guidelines expressed or implied in the regulatory filings made with respect to [***], the Device or Product with the FDA or foreign regulatory agents.
		

		
			 
		

		
			1.14     "cGLP" means the then current Good Laboratory Practices promulgated or endorsed by the FDA (or in the case of foreign jurisdictions, comparable regulatory standards), including those procedures expressed or implied in the regulatory filings made with respect to [***], the Device or Product with the FDA or foreign regulatory agents.
		

		
			 
		

		
			1.15     "cGMP" means current Good Manufacturing Practices as defined in the U.S. regulations 21 CFR § 210 et. seq., and the European Economic Community Guide to Good Manufacturing Practices for Medicinal Products (Vol. IV Rules Governing Medicinal Products in the European Community 1992), and foreign equivalents.
		

		
			 
		

		
			1.16     "cQSRs" means current Quality System Regulations as defined in the U.S. Code of Federal Regulations, 21 CFR Part 820 and, in the case of foreign jurisdictions, comparable regulatory standards.
		

		
			 
		

		
			1.17     "Calendar Quarter" means a three-month period ending on March 31, June 30, September 30, or December 31.
		

		
			 
		

		
			1.18     "Calendar Year" means the twelve-month period ending on December 31.
		

		
			 
		

		
			1.19     "Commercially Reasonable Efforts" means such efforts that are consistent with the efforts and resources normally used by similarly situated companies in the same industry as Lumara in the exercise of its reasonable business discretion relating to the research, development and commercial progression of a potential pharmaceutical product owned by it or to which it has exclusive rights, with similar product characteristics as the Product, which is of similar market potential at a similar stage in its development or product life as the Product, taking into account issues of scientific risk, patent coverage, safety and efficacy, product profile, competitiveness of the marketplace, proprietary
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

position, the regulatory structure involved and profitability (including pricing and reimbursement status achieved or likely to be achieved) and other relevant factors, including without limitation, technical, legal, scientific and/or medical factors. Without limiting the foregoing, Commercially Reasonable Efforts will include, inter alia, Lumara's: (i) prompt assignment of responsibility for such obligation to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (ii) setting annual objectives for carrying out such obligations, and (iii) allocating resources designed to advance progress with respect to such objectives, provided that the occurrence of any or all of the foregoing events shall not be required to establish use of Commercially Reasonable Efforts.
		

		
			 
		

		
			1.20    "Confidential Information" shall have the meaning set forth in Section 17.1 of this Agreement.
		

		
			 
		

		
			1.21     "Controlled" means the ability to grant a license or sublicense as provided for herein without violating the terms of any agreement or other arrangement with any Third Person.
		

		
			 
		

		
			1.22     "Cover" (including variations thereof such as "Covering", "Covered", and "Coverage") means that the development, manufacture, use, import, export, offer for sale or sale of the item(s) referred to would but for the licenses granted hereunder, infringe a Valid Claim.
		

		
			 
		

		
			1.23     "Damages" shall have the meaning set forth in Section 16.2 hereof.
		

		
			 
		

		
			1.24     "Device" means the [***] auto-injection system device, designed and developed to incorporate a Prefilled Syringe for delivery of the Drug and any improvements or modifications thereof made pursuant to this Agreement, or such other Antares-proprietary device as agreed to by Antares designed and developed to deliver the Drug pursuant to this Agreement.
		

		
			 
		

		
			1.25     "Device Development Plan" shall have the meaning set forth in Section 2.2 of this Agreement, an initial draft of which is attached hereto as Exhibit D.
		

		
			 
		

		
			1.26     "DHF" means the Design History File that Antares will establish and maintain for Devices inside and outside the Field that will contain or reference all records and submissions necessary to demonstrate that the design was developed in accordance with the approved Device Development Plan.
		

		
			 
		

		
			1.27     "Discontinuance Election" shall have the meaning set forth in Section 12.4 hereof.
		

		
			 
		

		
			1.28     "DMF" means a Device Master File, or other similar terminology, such as the term is defined in 21 C.F.R. 814.3(d) and is consistent with FDA Pre-Market Approval Manual (HHS Publication FDA 97-4212, January 1998), or comparable filings accepted by any Regulatory Authority in a country or jurisdiction outside the U.S. The DMF shall include, without limitation, the specifications for quality testing, design verification,
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

process validation and release of Devices, in addition to any other information necessary for development, manufacture and release of Devices.
		

		
			 
		

		
			1.29     "Drug" means 17-alpha hydroxyprogesterone caproate.
		

		
			 
		

		
			1.30     "Effective Date" shall have the meaning set forth in the first paragraph of this Agreement.
		

		
			 
		

		
			1.31     "FDA" means the U.S. Food and Drug Administration, or any successor federal agency, having responsibility over Regulatory Approval in the U.S.
		

		
			 
		

		
			1.32     "FD&C Act" means the U.S. Food, Drug and Cosmetic Act (21 U.S.C. §301 et. seq.), as amended from time to time, together with any rules and regulations promulgated thereunder. FD&C Act shall also be deemed to include the Applicable Laws pertaining to the Product in any particular country or region in the Territory.
		

		
			 
		

		
			1.33     "Field" means all uses of the Drug in humans or animals.
		

		
			 
		

		
			1.34     "Governmental Authority" means any court tribunal, arbitrator, agency, commission, official or other instrumentality of any federal, state, or other political subdivision, or supranational body, domestic or foreign.
		

		
			 
		

		
			1.35     "IND" means an Investigational New Drug application (together with all additions, deletions, and supplements thereto) filed with the FDA or any equivalents of such items in countries within the Territory outside the U.S.
		

		
			 
		

		
			1.36     "Information" means any and all information, data, items, material and knowledge in the Field or otherwise related to drug delivery including, without limitation, any and all suggestions, descriptions, ideas, inventions (whether or not patentable), know-how, trade secrets, techniques, strategies, methods, syntheses, processes, practices, skills, experience, documents, apparatus, devices, chemical formulations, compounds, composition of matter, chemical samples, assays, screens, databases, database structures and data analysis methods in the Field or otherwise related to drug delivery.
		

		
			 
		

		
			1.37     "Infringed Licensed Technology" shall have the meaning set forth in Section 15.1 hereof.
		

		
			 
		

		
			1.38     "Intellectual Property Rights" means all intellectual property rights, including, without limitation all Patent Rights, copyrights, trademarks, trade secret rights and know-how rights.
		

		
			 
		

		
			1.39     "Joint Project Team" shall have the meaning set forth in Section 3.1 hereof.
		

		
			 
		

		
			1.40     "Joint Invention" shall have the meaning set forth in Section 12.l(c) hereof.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

1.41     "Licensed Technology" means Antares Patent Rights, Antares Trademarks and Antares Know-How.
		

		
			 
		

		
			1.42     "Lumara Indemnities" shall have the meaning set forth in Section 16.3, hereof.
		

		
			 
		

		
			1.43     "Lumara Sole Invention" shall have the meaning set forth in Section 12.l(a) hereof.
		

		
			 
		

		
			1.44     "Lumara Trademarks" means all trademarks, service marks, trade dress, trade names, and Internet domain names (together with the goodwill of the business symbolized by the foregoing), including all registrations and registration applications throughout the Territory that are owned or Controlled by Lumara as of the Effective Date  or at any time during the term of this Agreement, and that are useful, necessary, or required for, or related to, the development, manufacture, use, commercialization or exploitation, including any packaging, promotional materials, package inserts and labeling, of the Product, or to otherwise proceed with the undertakings envisioned by this Agreement, including without limitation, Makena® and such other trademarks identified in Exhibit E.
		

		
			 
		

		
			1.45     "Manufacturing Agreement" shall have the meaning set forth in Section 10.1 of this Agreement.
		

		
			 
		

		
			1.46     "Net Sales" shall mean, with respect to a Product, the gross amount invoiced by Lumara, its Affiliates or any sublicensee thereof to Third Persons or the sale of the Product in the Territory, less:
		

		
			 
		

		
			 
		

		
			(a)   Trade, quantity and cash discounts allowed;
		

		
			 
		

		
			(b)   Refunds, rebates, chargebacks, retroactive price adjustments, recalls, bad debt, price protection and shelf stock adjustments, and any other allowances or credits which effectively reduce the net selling price, all in accordance with U.S. GAAP;
		

		
			 
		

		
			(c)   Actual Product returns and allowances;
		

		
			 
		

		
			(d)   Any tax imposed on the production, sale, delivery or use of the Product, including, without limitation, sales, use, excise or value added taxes, with the exception of income taxes;
		

		
			 
		

		
			(e)   Payments required by Applicable Law to be made under Medicaid, Medicare or other government special medical assistance programs, annual assessed FDA user fees (including establishment fees for facilities and product fees for the NDA) and similar fees assessed by Regulatory Authorities in other jurisdictions amortized on a Calendar Quarter basis;
		

		
			 
		

		
			(f)   Freight, postage, shipping and insurance, handling and other transportation costs actually incurred by Lumara; and
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(g)   Any other similar and customary deductions which are properly recorded as a reduction of Net Sales under U.S. GAAP consistently applied.
		

		
			 
		

		
			Such amounts shall be determined from the books and records of Lumara or its sublicensee, maintained in accordance with U.S. GAAP or, in the case of sublicensees, such similar accounting principles, consistently applied. Lumara further agrees that in determining such amounts, it will use Lumara's then current standard procedures and methodology, including Lumara's then current standard exchange rate methodology for the translation of foreign currency sales into U.S. dollars or, in the case of sublicensees, such similar methodology, consistently applied.
		

		
			 
		

		
			1.47     "NDA" means (a) the single application or set of applications (together with all additions, deletions, and supplements (sNDA) thereto) for Products and/or pre-market approval to make and sell commercially both a formulation of Drug and a compatible commercial Device to be marketed as the Product, filed by Lumara with the appropriate Regulatory Authority within the Territory, and (b) any related registrations with or notifications to the appropriate Regulatory Authority within the Territory.
		

		
			 
		

		
			1.48     "Orange Book" means the Approved Drug Products with Therapeutic Equivalence Evaluations published and periodically updated by the FDA, including any successor publication or foreign equivalent.
		

		
			 
		

		
			1.49     "Patent Right(s)" means (a) patents and patent applications (including provisional applications and applications for certificates of invention); (b) any patents issuing from such patent applications (including certificates of invention); (c) all patents and patent applications claiming the priority date(s) of any of the foregoing; (d) any reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing and any patents issuing thereon; (e) term extensions, supplementary protection certificates and other governmental action which provide exclusive rights to a product beyond the original patent expiration date; and (f) all foreign equivalent of any of the foregoing (a)-(e) throughout the world.
		

		
			 
		

		
			1.50     "Permitted Person" shall have the meaning set forth in Section  17.2 hereof.
		

		
			 
		

		
			1.51     "Person" means a natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any Governmental Authority or any other entity or organization.
		

		
			 
		

		
			1.52     "Prefilled Syringe" means the prefilled syringe containing the formulated Drug for incorporation into the Device.
		

		
			 
		

		
			1.53     "Pricing Approval" means such approval, agreement, determination or governmental decision establishing prices for Product that can be charged to consumers
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

and/or will be reimbursed by Governmental Authorities in countries in the Territory where Governmental Authorities or Regulatory Authorities of such country approve or determine pricing for pharmaceutical products for reimbursement or otherwise.
		

		
			 
		

		
			1.54     "Product" means the fully packaged Device for auto-injection delivery of the Drug incorporating a Prefilled Syringe.
		

		
			 
		

		
			1.55     "Product Development Program" means the program of development activities for Antares Device Development set forth in or otherwise contemplated by the Device Development Plan (as amended from time to time) as more fully described in Article 2 of this Agreement.
		

		
			 
		

		
			1.56     "Product Launch" means the first commercial sale of a Product by Lumara or its sublicensees in the country at issue following Regulatory Approval and Pricing Approval for such Product in such country.
		

		
			 
		

		
			1.57     "Program Intellectual Property" shall have the meaning set forth in Section 12.1 hereof.
		

		
			 
		

		
			1.58     "Quality Agreement" or "QA" means the document between the Parties to be entered into pursuant to section 10.3(b) hereof which describes certain quality expectations and responsibilities relating to the development, manufacture, release testing and supply of the Devices and assembly and packaging of the Product and provides Lumara the right to perform quality audits of Antares consistent with the terms of the QA.
		

		
			 
		

		
			1.59     "Recipient" shall have the meaning set forth in Section 17.1 hereof.
		

		
			 
		

		
			1.60     "Regulatory Approval" means (a) in the U.S., approval by the FDA of any one or more of the following, an NDA, sNDA, 510K or similar application for marketing approval, and satisfaction of any related applicable FDA registration and notification requirements (if any), together with any other approval necessary to make and sell    Products commercially in the U.S.; and (b) in any country other than the U.S., approval by Regulatory Authorities having jurisdiction over such country of a single application or set of applications comparable to an NDA or similar application for marketing approval and satisfaction of any related applicable regulatory and notification requirements, if any, together with any other approval necessary to make and sell Products commercially in such country, and the grant of Pricing Approval.
		

		
			 
		

		
			1.61     "Regulatory Authority" means, in a particular country or jurisdiction, any applicable government regulatory authority involved in granting Regulatory Approval and/or, to the extent required in such country or jurisdiction, Pricing Approval of Product in such country or jurisdiction, including, without limitation, (a) in the U.S., the FDA, and any other applicable Governmental Authority or Regulatory Authority in the U.S. having jurisdiction over the Product, and any successor Governmental Authority having substantially the same function, and (b) any foreign equivalent thereof and any successor Governmental Authority having substantially the same function.
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

1.62     "Regulatory Material" means regulatory correspondence, submissions, notifications, registrations, approvals and/or other filings, to the extent such material is generated under the terms of this Agreement and is solely related to the Field, made to or with a Regulatory Authority that may be necessary to develop, manufacture, market, sell or otherwise commercialize Product, including, without limitation, clinical trial data, toxicology studies, IND, NDA, 51OK, clinical trial exemption, Pricing Approvals, and any other foreign equivalents.
		

		
			 
		

		
			1.63     "Royalty Period" means [***].
		

		
			 
		

		
			1.64     "Safety Information Document" shall have the meaning set forth in Section 4.3 hereof.
		

		
			 
		

		
			1.65     "Serious Adverse Event" means any Adverse Event with the following conditions: death, life-threatening, hospitalization, persistent or significant disability, congenital anomaly/birth defect, any other serious event requiring medical intervention, or as "Serious Adverse Event" is otherwise defined by other Regulatory Authority or the FDA in 21 CFR 312 & 314 as amended from time to  time.
		

		
			 
		

		
			1.66     "Serious Adverse Event Report" means any oral, written or electronically transmitted report of any Serious Adverse Event.
		

		
			 
		

		
			1.67     "Territory" means the entire world.
		

		
			 
		

		
			1.68     "Third Person" means any Person or entity other than Lumara, Antares, or an Affiliate or sublicensee of either of them.
		

		
			 
		

		
			1.69     "Third Person Claim" shall have the meaning set forth in Section 16.2 hereof.
		

		
			 
		

		
			1.70     "Third Person Rights" shall have the meaning set forth in Section 8.2 hereof.
		

		
			 
		

		
			1.71     "United States" or "U.S." means the United States of America, including its territories and possessions.
		

		
			 
		

		
			1.72     "U.S. Regulatory Approval" means the first date on which Lumara shall have received Regulatory Approval for a Product in the U.S.
		

		
			 
		

		
			1.73     "U.S. Regulatory Submission" means the first submission and acceptance for filing by a Regulatory Authority of all Regulatory Materials necessary for the manufacture, market and sale of Product in the U.S.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

1.74     "Valid Claim" means any claim in any issued, unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction following exhaustion of all possible appeal processes, and which has not been admitted to be invalid or unenforceable through reissue, reexamination or disclaimer.
		

		
			 
		

		
			1.75     "[***]" auto injector system, including the specific Device described in Exhibit F, [***].
		

		
			 
		

		
			ARTICLE 2
		

		
			 
		

		
			PRODUCT DEVELOPMENT PROGRAM
		

		
			 
		

		
			2.1     Purpose and Scope of Development. In accordance with, and subject to, the terms described herein, the Parties agree to collaborate in the research and development of the Device for the ultimate purposes of manufacturing and commercializing the Product in the Field in the Territory ("Product Development Program").
		

		
			 
		

		
			2.2     Preparation of Device Development Plan.  In the event Lumara, in its sole discretion, within thirty (30) days after completion of a meeting between Lumara and the FDA regarding Product development decides to continue development of the Product, Antares shall develop and prepare for Lumara's review and acceptance if satisfactory, an update to the Device Development Plan set forth on Exhibit D, which shall include  Antares' budgeted costs and project timelines for work to be performed on Antares Device Development and development of the Product by the Parties and paid for by Lumara in milestone-based payment amounts set forth therein as more specifically described in Section 2.4. The Parties may from time to time by mutual agreement amend the Device Development Plan or create additional Device Development Plans to provide for the development of additional Devices and Products.
		

		
			 
		

		
			2.3     Responsibilities of the Parties .
		

		
			 
		

		
			(a)     General. Each Party shall have responsibility for development activities as set forth in the Device Development Plan.
		

		
			 
		

		
			(b)     Lumara's Responsibilities. Lumara shall be responsible for overseeing the overall Product Development Program, undertaking clinical development of the Product through Regulatory Approval, and commercializing the Product, including:
		

		
			 
		

		
			(i)     Undertaking clinical development for the Device and Product in accordance with the Device Development Plan;
		

		
			 
		

		
			(ii)     Addressing all clinical and development issues that arise during the course of the Product Development Program
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(iii)     Undertaking regulatory filings for the Product or Drug, including payment of any applicable fees and promptly notifying Antares of correspondence and filings with Regulatory Authorities and providing copies of annual reports related to the Device filed with the Regulatory Authorities within forty-five (45) days after submission, and obtaining marketing approval for the Product in the Territory;
		

		
			 
		

		
			(iv)     Providing a preservative-free formulation of formulated Drug in a bulk packaging configuration to be used for Prefilled Syringe filling and finishing;
		

		
			 
		

		
			(v)      Providing formulated Drug product into a Prefilled Syringe for assembly with the Device into each Product;
		

		
			 
		

		
			(vi)     Investigating and handling of all Product complaints, including filing Adverse Drug Experience ("ADE") reports with the FDA, or foreign equivalent report with the appropriate Regulatory Authority;
		

		
			 
		

		
			(vii)      Receiving Product at a destination chosen by Lumara for final Product release and distribution;
		

		
			 
		

		
			(viii)      Providing Antares with general, non-proprietary project support from working knowledge of the Drug; and
		

		
			 
		

		
			(ix)      Providing distribution, inventory management, sales, promotion and commercialization of the Product.
		

		
			 
		

		
			(c)      Antares' Responsibilities. Antares shall be responsible for developing the Device in accordance with the Device Development Plan, for supporting Lumara's development of the Product under the Product Development Program, and for supporting Lumara's commercialization of the Products, including
		

		
			 
		

		
			(i)      Developing and supplying the Device in accordance with the agreed to specifications for clinical requirements;
		

		
			 
		

		
			(ii)      Providing reasonable support to Lumara's lead on all clinical development, issue resolution and program oversight;
		

		
			 
		

		
			(iii)       [***];
		

		
			 
		

		
			(iv)      Providing clinical supply of the Devices and Products to Lumara as needed for clinical development;
		

		
			 
		

		
			(v)      Providing commercial supply of the fully manufactured and packaged Product to Lumara's chosen destination for final release and distribution by Lumara;
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(vi)      Providing Lumara general, non-proprietary project support from working knowledge of the Device and prefilled syringe assembly;
		

		
			 
		

		
			(vii)      Promptly passing along to Lumara any Product complaints received by Antares and providing reasonable support to Lumara's lead in investigating and handling all Product complaints; and
		

		
			 
		

		
			(viii)     Providing appropriate support to Lumara's lead in obtaining Regulatory Approval (including, sNDA approval).
		

		
			 
		

		
			ARTICLE 3
		

		
			 
		

		
			GOVERNANCE AND ADMINISTRATIVE MATTERS
		

		
			 
		

		
			3.1     Joint Project Team. No later than forty-five (45) days after the Effective Date, the Parties shall form a Joint Project Team for the Product Development Program. The Joint Project Team shall be responsible for overall direction and management of the Product Development Program. The operation and authority of the Joint Project Team shall be as follows:
		

		
			 
		

		
			(a)      Responsibilities. The primary objectives of the Joint Project Team shall include the preparation, modification (if appropriate) and implementation of one or more development plans to address fully, consistent with the terms of this Agreement, the key registration and supply elements reasonably necessary for the research, development, manufacture, and clinical testing registration activities related to Antares Device development and the Device, and any formulation of the Drug specifically developed for use with a Device and Product, (each a "Device Development Plan"). The Joint Project Team shall from time to time review and, if appropriate, recommend revisions to the  Device Development Plan. The Joint Project Team also shall monitor the progress of the Product Development Program and periodically review the results of the Product Development Program and make recommendations as appropriate. In addition, no later than one hundred eighty (180) days after the Effective Date, the Joint Project Team shall prepare and adopt the Safety Information Document.
		

		
			 
		

		
			(b)      Representation. Each Party shall appoint three (3) representatives, or such other number of representatives as agreed to by the Parties, to serve on the Joint Project Team. The representatives of a Party may be changed from time to time at the discretion of each Party upon written notification by the Party making such change to the other.
		

		
			 
		

		
			(c)      Meetings. The Joint Project Team shall meet from time to time as determined by the Joint Project Team members, with the Parties alternating hosting the meeting. It is expected that the Joint Project Team shall meet at least four (4) times per Calendar Year or as otherwise agreed by the Joint Project Team members. Such meetings may be in person, via videoconference or via telephone conference at such times and places as are agreeable to the members of the Joint Project Team. Consultants and non-member employees of the Parties may attend meetings of the Joint Project Team as required to
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

further the Product Development Program. Minutes of all such meetings setting forth decisions of the Joint Project Team relative to the Product Development Program will be prepared by the Party hosting the meeting and distributed within fifteen (15) business days after the meeting. Such minutes will become official when agreed to by all members of the Joint Project Team no later than fifteen (15) business days after published. Each Party will bear all expenses associated with attendance of its employees and consultants at such meetings.
		

		
			 
		

		
			(d)      Decisions. Decisions of the Joint Project Team shall be made by unanimous vote, with each Party having one vote regardless of its number of representatives on the Joint Project Team. If the Joint Project Team is unable to resolve any issue or dispute, then the issue shall be resolved pursuant to Section 20.2 [***].
		

		
			 
		

		
			3.2     Quarterly Status Report. During the Product Development Program, each Party shall provide the Joint Project Team with a quarterly status report no later than 15 days after the end of each calendar quarter that generally summarizes research and development efforts conducted by such Party under the Product Development Program during such Calendar Quarter at issue. Such report shall include, without limitation, a general summary of important events and/or milestones achieved, personnel changes, learning points and other matters that the Joint Project Team may deem appropriate.
		

		
			 
		

		
			3.3     Subcontracting Permitted. The Parties acknowledge and agree that portions of the work involved in the Product Development Program may be performed on behalf of the Party responsible for such work thereunder by Third Persons provided that the Joint Project Team shall have previously approved using such Third Person.
		

		
			 
		

		
			3.4     Meeting Expenses. Each Party will be responsible for its expenses associated with the attendance of its employees and consultants at meetings related to the activities contemplated by this Agreement.
		

		
			 
		

		
			ARTICLE 4
		

		
			 
		

		
			REGULATORY
		

		
			 
		

		
			4.1     Regulatory Filings. As of the Effective Date, and pursuant to the terms of this Agreement, Lumara will assume responsibility for all regulatory filings related to the Product, and shall timely file applicable patents to the Orange Book. Antares shall be responsible for preparing, filing and maintaining the Regulatory Material relating to the Device in support of Lumara's regulatory filings. As between the Parties, Lumara shall own all Regulatory Material relating to the Drug and Product in the Field and any future Drugs or Products in the Field (including but not limited to variants of existing Drug or
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

Product) developed under the terms of this Agreement, and Antares shall own all Regulatory Material relating to the Device and any future Devices developed under the terms of this Agreement and Lumara shall retain a right to reference such Regulatory Materials during the term of this Agreement and thereafter as necessary to comply with Applicable Laws to maintain Product registration, as otherwise required by any Regulatory Authority, or as otherwise reasonably required by Lumara related to the activities conducted under this Agreement including the development, manufacture, use, sale, offer for sale, import or export of Products conducted under this Agreement.
		

		
			 
		

		
			(a)      Preparation, Maintenance and Ownership. Lumara, or its sublicensees, shall be responsible for the preparation of any Regulatory Materials, including regulatory filings and/or suitable applications required in order to conduct clinical trials and achieve Regulatory Approval (including, without limitation, achievement of marketing approval) for the Product and shall be the owner and party of record for all such Regulatory Materials to the extent permitted by Applicable Laws. [***]. Lumara, or its sublicensees, shall further be responsible for managing all interactions regarding such Regulatory Materials with all Regulatory Authorities in the Territory. Antares shall cooperate with Lumara as Lumara reasonably requires in preparing such Regulatory Materials or in managing such interactions with Regulatory Authorities. Lumara, or its sublicensees, shall determine in its discretion those countries of the Territory where marketing is intended.
		

		
			 
		

		
			(b)      Access to Device Files. With respect to any DMFs and DHFs of Antares related to the Device inside the Field, and outside the Field to the extent applicable to the Field, for so long as the licenses granted to Lumara hereunder remain in full force  and effect, Antares hereby grants to Lumara access to, and a right of reference to, such DMFs and DHFs. For the avoidance of doubt, Lumara's right to access such DMFs and DHFs shall include Lumara's right to incorporate Information otherwise contained in Antares' DMFs and DHFs into any Lumara regulatory submission or Regulatory Material submitted to a Regulatory Authority in the Territory pursuant to the terms of this Agreement.
		

		
			 
		

		
			4.2     Quality Assurance Audit. Lumara, at its own expense, shall have the right to conduct quality assurance audits with respect to all facilities, operations, and    laboratories where work under this Agreement is conducted by Antares, or on its behalf by subcontractors, (including, without limitation, work conducted by Antares related to the Device Development Plan) and to verify Antares' conformance with applicable cGMP, cGLP, cGCP, cQSRs and other regulatory requirements including, without limitation, verifying appropriate inventory control and material accountability systems with respect to the Device, Prefilled Syringes and Products. Such audits shall only be conducted upon reasonable notice during business hours. [***].
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

4.3     Adverse Event Reporting. During the Product Development Program, and until and after Regulatory Approval of the Product and, and until and after Product Launch, Lumara will report Adverse Events and Serious Adverse Events which occur during the development of Product to Antares and the relevant Regulatory Authorities promptly according to the applicable regulations. Antares will cooperate and provide Lumara with  all information and assistance necessary or desirable for Lumara to carry out and comply with any regulatory requirements of such Regulatory Authorities. In addition, Antares will report to Lumara Adverse Events and Serious Adverse Events which occur during the development of the Device and Product and, after Product Launch, Antares will report to Lumara Serious Adverse Events and spontaneously reported Adverse Events of which it becomes aware and has the right to disclose, as such events relate to the use of Devices for other products, within two (2) working days of Antares' initial receipt of such information, in order that Lumara can fulfill its obligations to the appropriate regulatory authorities. Finally, Antares will supply specially formatted safety information to Lumara upon request, with reasonable notice, in order that Lumara can comply with FDA requirements for annual reports and safety updates. The specific details concerning the type of safety information, the appropriate format for such safety information, and the process for exchange of such information will be developed by the Joint Project Committee consistent with the requirements of the then current Lumara adverse reporting policies and consistent with those policies of the relevant Regulatory Authority ("Safety Information Document").
		

		
			 
		

		
			4.4     Product Complaints. Antares shall refer any complaints (including medical complaints) which it receives concerning the Device or the Product to Lumara within thirty-six (36) hours of Antares' receipt of such complaint; provided that all complaints concerning actual Product tampering, contamination or mix-up (e.g., wrong ingredients) shall be delivered within twenty-four (24) hours of Antares' receipt thereof. Antares shall not take any further action in connection with any such complaints without the consent of Lumara, but shall cooperate in the investigation and closure within [***] of any such complaints at the request of Lumara.
		

		
			 
		

		
			 
		

		
			4.5     Regulatory Inspections. Antares shall promptly advise Lumara of any notice of regulatory inspection or other regulatory action related to this Agreement or any Device or Product and shall permit Lumara to be present during any inspection and to participate in the preparation of any response thereto.
		

		
			 
		

		
			ARTICLE 5 
		

		
			 
		

		
			LICENSE
		

		
			 
		

		
			5.1     Exclusive License to Lumara. Antares hereby grants to Lumara a sole and exclusive, royalty-bearing license in the Territory, with the right to sublicense, subject to Antares' prior written consent which consent shall not be unreasonably withheld or delayed, through one or more levels of sublicensees, under the Licensed Technology (subject to Section 12.6) and Antares' interest in Program Intellectual Property to develop,
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

use, sell, offer for sale and import and export Products and Devices for use in Products in the Field. [***]. Without limiting the generality of the foregoing license grant, Lumara acknowledges that the foregoing license grant does not grant Lumara the right under the Licensed Technology to sell, offer for sale, import or export any product that delivers the Drug other than a Product developed by the Parties under the Product Development Program pursuant to this Agreement without Antares' prior written consent. For avoidance of doubt, nothing herein shall prevent Lumara from developing, selling, offering for sale, importing or exporting any product that delivers the Drug and that does not require a license to Licensed Technology. Further notwithstanding the foregoing exclusive license grant to Lumara, Antares shall retain during the Product Development Program nonexclusive rights to Licensed Technology described in this Section 5.1 but only to the extent useful or necessary to fulfill its obligations under the Product Development Program or other obligations hereunder.
		

		
			 
		

		
			5.2     Assistance. Each Party shall promptly provide the other with all Information included in Licensed Technology, in the case of Antares, or in Intellectual Property Rights owned or controlled by Lumara, in the case of Lumara, that is, in each case, reasonably useful or necessary for the other Party to exploit the licenses granted in this Agreement or to perform such Party's obligations. Moreover, each Party shall provide the other with reasonable technical assistance in connection with such disclosure of Information.
		

		
			 
		

		
			5.3     Right to Intellectual Property. The Parties agree that all rights and  licenses granted under or pursuant to Article 5 and Article 12 of this Agreement are, [***].
		

		
			 
		

		
			5.4     License to Antares. Subject to the terms and conditions of this Agreement, Lumara hereby grants to Antares during the term of this Agreement a non-exclusive, royalty-free license in the Field in the Territory under Intellectual Property Rights owned or controlled by Lumara and Lumara's interest in Program Intellectual Property to use, export and import the Drug solely for the purposes of fulfilling its obligations under this Agreement.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

ARTICLE 6
		

		
			 
		

		
			EXCLUSIVITY
		

		
			 
		

		
			6.1     Exclusivity Restrictions.  [***].
		

		
			 
		

		
			6.2     No Restriction on Lumara. Notwithstanding anything contained within this Agreement, Lumara shall not be restricted or limited in any way by this Agreement (except with respect to a Product) with respect to its right to develop, seek regulatory approval for, manufacture, sell, distribute, license, import, export or otherwise commercialize the Drug or any product containing, or delivering the Drug in the Territory.
		

		
			 
		

		
			ARTICLE 7
		

		
			 
		

		
			COMMERCIAL  RIGHTS
		

		
			 
		

		
			7.1     Marketing and Commercialization. Subject to the terms described in this Agreement, Lumara shall have the sole and exclusive right, at its own expense, to obtain Regulatory Approval, and to market, sell, promote, distribute and otherwise commercialize Products in the Field, including, without limitation, preparation of promotional materials, direct-to-consumer advertising, samples, and sales representatives, in each country in the Territory that Lumara elects to market the Product as Lumara may deem appropriate. Lumara shall control the marketing plans for Product in the Field, and the packaging materials for the Product which, unless Lumara determines otherwise, shall be sold solely under Lumara's trademarks, trade dress and logos, with the exception of trademarks, trade dress and logo applied to the Devices, which shall be the sole responsibility of Antares. Lumara agrees to use Commercially Reasonable Efforts to effect a Product Launch of the first Product in the U.S. within 90 days of receiving final Regulatory Approval in the U.S. for such Product provided that Lumara shall not be required to effect a Product Launch unless and until Product stability tests have qualified a Product shelf life of at least 15 months.
		

		
			 
		

		
			7.2      [***].
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

ARTICLE 8
		

		
			 
		

		
			COMPENSATION TO ANTARES
		

		
			 
		

		
			8.1     Up-Front Payments
		

		
			 
		

		
			(a)      Letter Agreement Payment. Antares acknowledges that Lumara made an initial Antares Device Development Payment to Antares in the amount of [***] upon execution of that certain Letter Agreement between Antares Pharm, Inc. and Lumara Health Inc. dated June 10, 2014 which led to this Agreement, [***] of which shall be used for the purpose set forth in Section 8.l(b), and [***] of which shall be used for the purpose set forth in Section 8.l(c).
		

		
			 
		

		
			(b)      Development and License Agreement Payment.  Within ten (10) days after the Effective Date of this Agreement, Lumara shall pay Antares an additional Antares Device Development Payment of [***].
		

		
			 
		

		
			(c)      Tooling and Process Validation Payment. Within ten (10) days after the Effective Date of this Agreement, Lumara shall pay Antares an additional Antares Device Development Payment of [***] for the purpose of initiating tooling and process validation for the 1 mL dose shown as item 3.1 on page 13 of the initial Device Development Plan attached hereto.
		

		
			 
		

		
			8.2     Royalties
		

		
			 
		

		
			(a)         Royalty Rates. Subject to the provisions of this Agreement, beginning upon Product Launch and during the Royalty Period for such Product, Lumara shall pay Antares on a Calendar Quarterly basis the lesser of any of the following royalties that apply to each particular Product sold in a particular country:
		

		
			 
		

		
			(i)      For aggregate annual worldwide Net Sales of Products up to and including [***], and for aggregate annual worldwide Net Sales of Products greater than [***], on Lumara's Net Sales for those  Products that are Covered by a Valid Claim of a patent within the Licensed Technology in the country in which such Products are sold. It is understood that such royalties will be applied incrementally; or
		

		
			 
		

		
			(ii)       [***] on Lumara's Net Sales for those Products that are not Covered by a Valid Claim of a patent within the Licensed Technology in the country in which such Products are sold; or
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(iii)       [***] on Lumara's Net Sales of Product in a country in the Territory in which there are [***] products with an Orange Book (or foreign equivalent) listed, A-rated  substitutable generic equivalent to the Product being sold.
		

		
			 
		

		
			(iv)       [***].
		

		
			 
		

		
			(b)         Royalty Calculations. Royalties shall be calculated on a Product-by-Product and country-by-country basis from the Net Sales of each individual Product. By way of example, if the annual aggregate worldwide Net Sales of a Product equals [***] in a given year, Lumara would pay Antares royalties for that year of (i) [***] on Net Sales of each Product sold in a country having a patent covering the sale of such Product in such country for such sales occurring prior to reaching aggregate worldwide annual Net Sales of [***], (ii) [***] on Net Sales of each Product sold in a country having a patent covering the sale of such Product in such country for such sales occurring after reaching aggregate worldwide annual Net Sales of [***], it being understood that royalties will be applied incrementally, (iii) [***] on Net Sales of each Product sold in a country having no patent covering the sale of such Product in such country, (iv) [***] on Net Sales of each Product sold in a country where such Product is subject to two (2) or fewer generic products (as described above) even if the sale of such Product is otherwise covered by a patent in such country and (v) [***].
		

		
			 
		

		
			(c)         Multiple Patents. Royalties payable under this Section 8.2 will be payable only once with respect to a particular sale of Product regardless of there being more than one Antares Patent Right applicable to such Product.
		

		
			 
		

		
			(d)         Access to Third Person Rights.  If at any time during the term of this Agreement access to a Third Person's intellectual property rights becomes necessary, advantageous or reasonably useful to make, use, sell, offer for sale and/or import a Product in the Field ("Third Person Rights"), Lumara or Antares shall have the right to acquire access to such Third Person Rights via a license or otherwise as described in this Section 8.2(d). Any decision to access such Third Person Rights will be discussed by the Joint Project Team. To the extent such Third Person Rights are solely related to the Drug, Lumara may acquire access to such Third Person Rights and shall be responsible for any acquisition cost to be paid to such Third Person (i.e., all consideration paid in connection with such acquisition including, without limitation, signing-fees, milestone payments and royalties) ("Access Costs") relating to such access. To the extent such Third Person Rights are unrelated to the Drug incorporated in the Product but is otherwise related to the  Product, Antares will have the first right, but not the obligation, to acquire access for Lumara to such Third Person Rights, in which case Antares shall be responsible for any related Access Costs.  If Antares fails to acquire access to such Third Person Rights within a reasonable period of time following discussion by the Joint Project Team (but not to exceed ninety (90) days), Lumara will have the right, but not the obligation, to acquire such
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

access, in which case Lumara shall be responsible for any related Access Costs, provided, however, that Lumara may credit any such Access Costs incurred against any royalties or other payments otherwise payable to Antares under this Agreement.
		

		
			 
		

		
			(e)         Current Royalty Obligations (as of Effective Date). Notwithstanding anything to the contrary in this Agreement (including, without limitation, Section 8.2(e)), both Parties acknowledge and hereby agree that each is solely responsible for any and all royalty obligations that have accrued or may accrue in the future with respect to any agreements and/or arrangements that such Party may have agreed to prior to the Effective Date.
		

		
			 
		

		
			(f)         Royalty Payments. Lumara shall pay royalties owed to Antares under this Section 8.2 as follows:
		

		
			 
		

		
			(1)                Duration of Royalties Paid for Products. During the Royalty Period (such period being determined for each Product on an individual Product basis and country-by-country basis), royalty payments hereunder shall be paid by Lumara to Antares on Net Sales of each Product for the particular country and Product at issue.
		

		
			 
		

		
			(2)                Payment Terms. Royalty payments due Antares under this Section 8.2 will be paid by Lumara for Net Sales made by Lumara not later than [***] following the end of each Calendar Quarter and each such royalty payment shall be accompanied by a report in writing showing the Calendar Quarter for which such royalty payment applies on a Product-by-Product basis, the amount of Net Sales during such Calendar Quarter for which a royalty payment is due on a country-by-country basis and the total royalty payment due. Notwithstanding the foregoing, with respect to any sublicensee's sales of Product, Lumara shall report its sublicensee's Net Sales to Antares (and pay any royalties on such sublicensee's Net Sales to Antares not previously paid by Lumara's sublicensee) as of the next Calendar Quarter payment from the time Lumara receives such information from its  sublicensee. Antares or its representatives shall have the right to audit Lumara's records with respect to such reports in accordance with Section 11.2 of this Agreement.
		

		
			 
		

		
			8.3     Milestones. In addition to the royalty payments provided in Section 8.2 above, Lumara shall make the following non-refundable milestone payments to Antares with respect to the Product within sixty (60) days following the first occurrence of each of the following events:
		

		
			
		

		

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

	
					
						 

					
					
						 

				
	
					
						Milestone 

					
					
						Payment

				
	
					
						Events

					
					
						(U.S. Dollars)

				
	
					
						 

					
					
						 

				
	
					
						First time Calendar Year Net Sales for a Product total at least [***].

					
					
						[***]

				
	
					
						First time Calendar Year Net Sales for a Product total at least [***].

					
					
						[***]

				
	
					
						Total Milestone Payments

					
					
						[***]

				

		
			 
		

		
			Each such milestone payment shall be made by Lumara to Antares only once, and only for the first Product to reach such milestone, regardless of how many times such milestone is reached by the Parties during the term of this Agreement. In no event shall Lumara be required to pay more than one milestone payment with respect to Net Sales made in the same Calendar Year, or shall Lumara be required to make aggregate milestone payments to Antares under this Agreement in excess of [***]. The Parties agree that milestone payments are not, and shall not be deemed to be, royalties for purposes of Section 365(n) of the U.S. Bankruptcy Code.
		

		
			 
		

		
			8.4     Development Expenses.  [***]. Lumara shall pay Antares the development-milestone based payments set forth in the Device Development Plan to complete all development of the Device under this Agreement. Lumara shall only fund Antares' portion of the manufacturing development expenses to the extent such expenses were previously agreed to by the Parties in the Device Development Plan. Antares shall provide technical advice, consulting and other information as Lumara may reasonably request. Lumara shall pay Antares for such manufacturing development expenses within thirty (30) days after the completion and invoice approved by Lumara, to Lumara's satisfaction of each related milestone set forth in the Device Development Plan, and only the amounts corresponding to each such milestone as set forth therein in full satisfaction of the corresponding manufacturing development expenses.
		

		
			 
		

		
			8.5     Currency of Payment/Exchange Rates. All payments to be made under this Agreement shall be made in U.S. Dollars, regardless of the country(ies) in which sales are made. For the purposes of computing Net Sales in a currency other than U.S. Dollars, such currency shall be converted into U.S. Dollars as calculated at the average rates of exchange for the applicable period as published by the Federal Reserve Bank of New York.
		

		
			 
		

		
			8.6     Taxes. Any and all taxes levied on account of royalties or milestone payments accruing under this Article 8 shall be paid by Antares. If laws or regulations require withholding of taxes, such taxes will be deducted by Lumara or its sublicensee from such remittable royalties or milestone payments and will be paid by Lumara or its sublicensee to the proper taxing authority. Proof of each payment shall be sent to Antares within ninety (90) days following December 31st of each reporting year. During the term of this Agreement, Antares and Lumara agree to treat sales as if the sales are made by a U.S. company.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

8.7     No Surviving Royalties. For clarification, notwithstanding any applicable continuation of the licenses provided in Article 5 of this Agreement, Lumara shall have no further obligation to make royalty payments following the expiration or termination of this Agreement.
		

		
			 
		

		
			 
		

		
			ARTICLE 9
		

		
			 
		

		
			USE OUTSIDE FIELD
		

		
			 
		

		
			Each Party shall have a non-exclusive right, with the right to grant licenses and sublicenses, to use the Joint Inventions for all other uses outside the Field, [***].
		

		
			 
		

		
			ARTICLE 10
		

		
			 
		

		
			SUPPLY OF DEVICES
		

		
			 
		

		
			10.1     Exclusive Supplier. The Parties hereby acknowledge that Antares is the exclusive supplier of all of Lumara's requirements for the Devices and Product within the Territory during the term of this Agreement, [***].
		

		
			 
		

		
			10.2     Manufacturing of the Product. Within sixty (60) days following the Effective Date of this Agreement, the Parties shall meet to discuss manufacturing arrangements related to the Product. The Parties agree that Antares shall be the supplier, or be responsible for the manufacture through a Third Person, of the Device and assembly and packaging of the Product, and the Parties shall enter into a mutually acceptable manufacturing agreement providing for such manufacture and supply of the Device and Product (the "Manufacturing Agreement") within [***] of the Effective Date of this Agreement. The Manufacturing Agreement shall include those terms set forth in Section 10.3 below, and such other terms as the Parties may agree. To the extent Antares utilizes any Third Person to perform some or all of its obligations under the Manufacturing Agreement, such Third Person, and the terms upon which it shall provide
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

services for Antares, shall be subject to approval by Lumara in its sole discretion. From the Effective Date of this Agreement until the execution of the Manufacturing Agreement, Lumara may submit purchase orders to Antares to purchase quantities of the Device, provided, however, that no less than [***] Devices may be ordered on any individual purchase order.
		

		
			 
		

		
			10.3     Manufacturing Agreement. The Manufacturing Agreement shall provide for the following terms, in addition to other terms typically included in manufacturing agreements for devices in the medical device industry.
		

		
			 
		

		
			(a)      Responsibilities of the Parties. Antares will be responsible for Device manufacturing and Product assembly and finishing, and any portion of such Device manufacturing and Product assembly and packaging performed by Third Persons on Antares' behalf, including, without limitation, activities such as maintaining the DHF and DMF, complaint investigation, and the oversight of production. Lumara or its designee will be responsible for manufacture and formulation of any Drug and the Prefilled Syringe for assembly with the Device into the Product by Antares and for final Product release for sale.  Antares will work with Lumara to integrate the Device, Drug and Prefilled Syringe into a Product for commercial sale. Antares and Lumara will together identify appropriate Third Persons for various aspects of Device manufacturing and Product assembly and packaging. While it is anticipated that Antares and Lumara will make any decision for such Third Person selection jointly, Antares will have final decision-making authority regarding the use of a Third Person to manufacture any aspect of the Device, and Lumara will have final decision-making authority regarding the use of a Third Person to manufacture any aspect  of the Product other than the Device, and Lumara shall have the right to specify the final assembly packaging and labeling for Product, including the combination of the  components thereof and with respect to final release of the Product for sale.
		

		
			 
		

		
			(b)      Development of QA.  No later than [***] after the Effective Date, the Parties shall prepare and adopt the QA. The Parties shall, at least annually, review the QA and shall modify it from time to time as necessary through a written amendment to the QA signed on behalf of each of the Parties by an authorized representative.
		

		
			 
		

		
			(c)      Manufacturing. Subject to the te1ms and conditions of the Manufacturing Agreement, Antares, or the Third Person acting on its behalf, will manufacture Devices and assemble and package Product for Lumara at the times and in the quantities set forth by Lumara in forecasts and purchase orders as more specifically provided in the Manufacturing Agreement. Antares, and the Third Person acting on its behalf, will ensure that each shipment of Devices: (i) will have been manufactured in accordance with the specifications, cGMP, and cQSR, in effect at the time of Manufacture, (ii) will not be adulterated or misbranded within the meaning of the FD&C Act by Antares, the Third Person acting on its behalf, or their agents, and (iii) will not have been manufactured or sold in violation of any Applicable Laws in any material respect.
		

		
			 
		

		
			(d)      Manufacturing Decisions. Antares shall have final decision-making authority with respect to any manufacturing issue related to manufacture of Devices so long as such decisions and decision-making does not impede Lumara's right to
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

commercialize Products hereunder, and Lumara shall have final decision-making authority with respect to any manufacturing issue related to the release for sale of Products.
		

		
			 
		

		
			(e)      Device Cost. The cost to Lumara of the Device and Product to be delivered by Antares will be as follows:
		

		
			 
		

		
			(i)  Cost of each Device loaded with a Prefilled Syringe (supplied by Lumara) to Lumara for clinical development and other non-commercial uses will be Antares' Fully Burdened Manufacturing Cost for the Device [***].
		

		
			 
		

		
			(ii)   Cost of each fully assembled and packaged Product to Lumara will be Antares' Fully Burdened Manufacturing Cost for the Device and assembly and packaging of the Product plus [***]. Parties estimate the cost plus [***] per device (exclusive of the cost of the Prefilled Syringe supplied by Lumara).
		

		
			 
		

		
			Antares warrants that the costs to manufacture the Devices and assemble and package the Products listed above are best estimates based upon: (i) [***] and (ii) volume projections provided by Lumara of Product sales in the Field. [***].
		

		
			 
		

		
			(f)      Back-up Supplier. At Lumara's request, and at Lumara's cost to the extent requested, Antares will qualify at least one back-up supplier for each critical component of the Device, as determined to be appropriate as part of the Device Development Plan. Notwithstanding the foregoing, Antares shall at Antares' cost develop, implement and maintain a redundancy plan reasonably acceptable to Lumara for molds, tooling and assemblies required for manufacturing the Devices, as more specifically set forth in Exhibit G.
		

		
			 
		

		
			(g)      Product Recall. Lumara, after consultation with Antares, shall have the right and responsibility to determine whether Product must or should be recalled. Lumara shall also be responsible for managing such recalls and Antares will cooperate with Lumara as Lumara may reasonably request. Lumara shall be responsible for all costs incurred due to a Product recall, provided, however, that to the extent that a recall relates to Antares' failure to deliver the Device in accordance with the specifications or relates to assembly and packaging Product, [***], Antares shall, in addition to repairing, replacing or refunding the purchase price of the
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

non-conforming Products (at the option of Lumara), reimburse Lumara for the direct and verifiable costs related to the recall. Antares' liability for any such direct and verifiable costs relating to a recall shall not exceed the amount paid to Antares by Lumara for Product during the [***] period preceding the date of the recall. Product recall costs incurred by Antares shall be specifically excluded from Antares Fully Burdened Manufacturing Cost.
		

		
			 
		

		
			(h)      Subcontracting. To ensure that the quality of the Products (and/or major components thereof) is maintained, Antares agrees to notify and consult with  Lumara in advance in the event that Antares desires to subcontract the manufacture of any of the Products (and/or major components thereof), provided that any such subcontract shall be consistent with and subject to the applicable obligations of Antares under this Agreement, including without limitation, obligations to maintain quality, practice GMP where applicable and satisfy regulatory compliance requirements, and that such subcontract shall not adversely affect the supply of Products to Lumara under this Agreement.
		

		
			 
		

		
			ARTICLE 11
		

		
			 
		

		
			RECORD-KEEPING AND AUDITS
		

		
			 
		

		
			11.1     Records Retention. The Parties shall keep complete and accurate records pertaining to the development, use and sale of Products in sufficient detail to permit the other Party to confirm, in the case of Antares, its research, development and manufacturing efforts hereunder, and in the case of Lumara, its development and commercialization efforts, and the accuracy of calculations of all payments due hereunder.
		

		
			 
		

		
			11.2     Audit Request.  Each of the Parties shall have the right to request in writing an audit of the records described in Section 11.1, at its own expense, once on an annual basis, to determine, with respect to any of the two (2) preceding Calendar Years, the correctness of any report or payment made under this Agreement. If a Party desires to audit such records, it shall utilize an independent, certified public accountant reasonably acceptable to the other Party, to examine financial records and may utilize an independent scientist reasonably acceptable to the other Party to audit scientific records. Such accountant/scientist shall be instructed to provide the Party desiring the audit a report on the findings of the agreed upon procedures which verifies any previous report made, payment submitted, or work performed by the audited Party during such period. The expense of such audit shall be borne by the auditing Party; provided, however, that if an error in favor of the auditing Party of more than [***] is discovered, then such expenses shall be paid by the audited Party. If the audit determines that additional amounts are owed to Antares, or that amounts were overpaid to Antares, during the audit period, Lumara shall pay Antares the additional amount owed to Antares, or Antares shall pay Lumara the overpaid amount, within forty-five (45) days of the date on which the paying Party receives the audit report. Any Information received by a Party pursuant to this Section 11.2 shall be deemed to be Confidential Information hereunder.
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

11.3      Survival. This Article 11 shall survive any termination of this Agreement for a period of two (2) years.
		

		
			 
		

		
			 
		

		
			ARTICLE 12
		

		
			 
		

		
			PROGRAM INTELLECTUAL PROPERTY
		

		
			 
		

		
			12.1      Ownership of Program Intellectual Property. Any and all Information, data, items, material and knowledge including, without limitation, any and all suggestions, descriptions, ideas, inventions (whether or not patentable), know-how, trade secrets, techniques, strategies, methods, syntheses, processes, practices, skills, experience, documents, apparatus, devices, chemical formulations, compounds, composition of matter, chemical samples, assays, screens, databases, database structures and data analysis  methods discovered, generated or developed within the scope and during the course of the Product Development Program regardless of inventorship ("Program Intellectual Property") shall be the property of the Parties as follows:
		

		
			 
		

		
			(a)      Program Intellectual Property Relating to Drug. Program Intellectual Property that relates solely to the Drug, but not to the Device (e.g., including, without limitation, uses for the Drug, methods or processes for using or manufacturing the Drug, formulations applicable to the Drug, dosing, absorption and blood levels of the Drug, including, without limitation, relating to sub-cutaneous absorption of the Drug, and analogs, derivatives, fragments, mimetics, conjugates and any excipients thereof) shall be the sole property of Lumara. Antares hereby assigns all of its rights, including all Patent Rights, to such Program Intellectual Property to Lumara, and such Program Intellectual Property so assigned shall be deemed to be “Lumara Sole Inventions".
		

		
			 
		

		
			(b)      Program Intellectual Property Relating to Device. Program Intellectual Property that relates solely to the Device, but not to the Drug (e.g., including, without limitation, uses for the Device, improvements to the Device, and methods or processes for manufacturing the Device) shall be the sole property of Antares. Lumara hereby assigns all of its rights, including all Patent Rights, to such Program Intellectual Property to Antares, and such Program Intellectual Property so assigned shall be deemed to be "Antares Sole Inventions".
		

		
			 
		

		
			(c)      Program Intellectual Property Relating to Combination of Drug and Device. Program Intellectual Property that relates to the combination of the Drug and the Device (e.g., including, without limitation, uses for the Product, improvements to the Product, results from using the Product and methods or processes for manufacturing the Product) shall be jointly owned by Lumara and Antares. Lumara hereby assigns an undivided joint interest in its ownership rights, including all Patent Rights, to such Program Intellectual Property to Antares, and Antares hereby assigns an undivided joint interest in its ownership rights, including all Patent Rights, to such Program Intellectual Property to Lumara, and such Program Intellectual Property so assigned by shall be deemed to be "Joint Inventions". Except as otherwise provided for under the exclusive license granted to
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

Lumara under Article 5 for use as Program Intellectual Property inside the Field, and under the provisions of Article 9 for use by either Party outside the Field, neither Party may use or license or sublicense the Joint Inventions without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed
		

		
			 
		

		
			(d)      Other Program Intellectual Property. The U.S. laws of inventorship shall govern the ownership of all other Program Intellectual Property that is not assigned to either Antares or Lumara pursuant to the ownership provisions of Sections 12.l(a), (b) or (c) hereof.
		

		
			 
		

		
			12.2     Cooperation. Each Party shall cooperate with the other in completing any patent applications or obtaining any other Patent Rights relating to both Sole and Joint Inventions that will be owned by the other Party. Each Party shall also cooperate with the other in executing and delivering any instrument required to assign, convey or transfer to such other Party its interest should such assignment, conveyance or transfer be required by the terms of this Agreement.
		

		
			 
		

		
			12.3     Ownership Review. No Party shall file a patent application on Program Intellectual Property until ownership as described in Section 12.1 is reasonably determined by the Parties after such Parties have had a reasonable opportunity to review and discuss the particular Program Intellectual Property at  issue.
		

		
			 
		

		
			12.4     Patent Filings. Antares shall be responsible at its own cost for the filing, prosecution and maintenance of all Antares Patent Rights including without limitation those listed on Exhibit B and shall not allow any such Antares Patent Rights to lapse without following the provisions of this Section 12.4. Upon written request by Lumara within 60 days after each Calendar Year-end, Antares shall provide Lumara with a report describing the status of the Antares Patent Rights. Such report shall include, at a minimum, the patent country, patent and application numbers, filing date, issue date, expiration date and any other relevant information.
		

		
			 
		

		
			(a)      Antares may, in the exercise of its sole discretion and at its own cost, prepare, file, prosecute and/or maintain patent applications for the Antares Sole Inventions and shall be responsible for related interference proceedings. Lumara may, in the exercise of its sole discretion and at its own cost, prepare, file, prosecute and/or maintain patent applications for Lumara Sole Inventions and shall be responsible for related interference proceedings. The Parties shall utilize an outside law firm acceptable to both Parties to prepare, file, prosecute and/or maintain patent applications for Joint Inventions and shall be responsible for related interference proceedings. The Parties shall share equally the costs associated with the use of such outside law firm in accordance with the terms of this Section 12.4.
		

		
			 
		

		
			(b)      Should any Party not wish to file, prosecute, maintain or issue any patent application for a Joint Invention in any particular country, that Party will so notify the other Party of its intentions ("Discontinuance Election"). Upon receipt of such Discontinuance Election, the other Party may elect to have the right to file, prosecute, maintain or issue any such patent or patent application at its own expense by providing
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

written notice of the same within thirty (30) days of its receipt of the Discontinuance Election. Upon such election: (i) the discontinuing Party shall grant the other Party any necessary authority to file, prosecute, issue and maintain such patent application and/or patent at issue; and (ii) shall assign such patent or patent application to the other Party. Until such assignment is complete, the discontinuing Party shall take reasonable efforts to maintain or otherwise ensure that patent protection will not be lost with respect to such patent and/or patent application provided the other Party does not unreasonably delay the assignment thereof.
		

		
			 
		

		
			12.5     Public Disclosure. Each Party agrees to make every reasonable effort to delay any public disclosure of the subject matter of any patent application related to Program Intellectual Property of which it is aware until after the filing of such patent application.
		

		
			 
		

		
			12.6     Product Trademarks 
		

		
			 
		

		
			(a)      Lumara will work collaboratively with Antares on the development, selection, and registration of Antares Trademarks and Lumara Trademarks, or any combinations thereof, appropriate for the Product and the particular countries within the Territory. In the event that Lumara and Antares fail to reasonably agree upon a selection of Antares Trademarks and Lumara Trademarks for the particular countries in the Territory, then Lumara shall have final decision-making authority with respect to such selection.
		

		
			 
		

		
			(b)      Acknowledgement of Rights in Antares Trademarks. Lumara acknowledges that Antares is the owner of all right, title and interest in and to the Antares Trademarks, and Lumara agrees not to adopt or use any of the Antares Trademarks in any manner whatsoever except as expressly provided in this Agreement. Lumara agrees not to apply for registration of any Antares Trademarks in the Territory or for any mark confusingly similar thereto.
		

		
			 
		

		
			(c)      Acknowledgement of Rights in Lumara Trademarks. Antares acknowledges that Lumara is the owner of all right, title and interest in and to the Lumara Trademarks, and Antares agrees not to adopt or use any of the Lumara Trademarks in any manner whatsoever except as expressly provided in this Agreement with respect to the manufacture and supply of Product to Lumara.  Antares agrees not to apply for registration of any Lumara Trademarks in the Territory or for any mark confusingly similar thereto.
		

		
			 
		

		
			(d)      Use of Antares Trademarks. Lumara agrees that the Antares Trademarks shall be used solely in connection with the marketing and sale of the Products and in accordance with Antares' specifications as to style, color and typeface as may be determined pursuant to Section 12.6(a). Antares shall at all times maintain quality control and final approval over all Products and Devices exhibiting Antares Trademarks. Lumara hereby agrees to notify Antares promptly of any infringement of any Antares Trademark in the Territory that Lumara has knowledge of.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

ARTICLE 13
		

		
			 
		

		
			REPRESENTATIONS, AND WARRANTIES AND COVENANTS
		

		
			 
		

		
			13.1     Antares Representations. Antares hereby represents, warrants and covenants to Lumara as follows:
		

		
			 
		

		
			(a)      Intellectual Property. That Antares has the requisite legal title and ownership under the Licensed Technology, including without limitation such Antares Patent Rights and Antares Trademarks listed in Exhibits B and C, respectively, necessary for it to fulfill its obligations under this Agreement, including, without limitation, the granting of the exclusive licenses in Article 5. There is no pending or threatened litigation, arbitration, government proceeding, or government investigation (and Antares has not received any communication relating thereto) which alleges that Antares' past activities relating to [***] devices or activities proposed under this Agreement, including, without limitation activities with respect to the Antares Patent Rights, infringe or misappropriate any of the Intellectual Property Rights of any Third Person. To the best knowledge of Antares, there is no Patent Right or other Intellectual Property Right of any Third Person that would be infringed or misappropriated by Lumara fulfilling any of its obligations or exercising any of its rights under this Agreement.
		

		
			 
		

		
			(b)      No Prior License.  That as of and prior to the Effective Date, Antares has not granted any license under Licensed Technology to develop, make, use, sell, offer for sale and/or import or export the Device and Product in the Field. Lumara shall have no liability on account of amounts due to any Third Person under any agreements of Antares.
		

		
			 
		

		
			(c)      Exclusivity.  That Antares hereby represents that as of the Effective Date, it does not have a commercial development and/or marketing agreement with any Third Person for the Device in the Field nor is Antares developing any Device for use in the Field except as provided for in this Agreement.
		

		
			 
		

		
			(d)      Full Disclosures.  That Antares has provided Lumara with all information that Lumara has requested for deciding the merits of entering into this Agreement.
		

		
			 
		

		
			(e)      Employee Obligations.  That all of its employees, officers, independent contractors and consultants who will work on the Product Development Program have legal obligations requiring, in the case of employees and officers,  assignment to Antares of all inventions made during the course of, and as a result of, their association with Antares and obligating the individual to maintain as confidential the confidential information of Antares, as well as the confidential information of a Third Person which Antares may receive.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(f)      Compliance with Laws. That in carrying out its work under the Product Development Program such work shall be carried out in compliance with any Applicable Laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at the site where such work is being conducted. Moreover, Antares represents and warrants that in connection with carrying out its work under the Product Development Program, as applicable, based on the specific work to be conducted, it will carry out such work under the Product Development Program in accordance with current cGLP, cGCP, cGMP and cQSRs.
		

		
			 
		

		
			(g)      No Debarment.  That it will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992, and will upon request certify in writing to Lumara that none of it, its employees, or any person providing services to Antares in connection with the collaboration contemplated by this Agreement have been debarred under the provisions of such Act.
		

		
			 
		

		
			(h)      Product Warranty.  That all Devices and Products manufactured by Antares, or a Third Person on behalf of Antares, when delivered to Lumara:
		

		
			 
		

		
			(i)      will be merchantable and fit for the purpose for which they are intended, (ii) will comply with applicable specifications and be free from any defects in materials or workmanship; (iii) will be delivered to Lumara free and clear of all liens and encumbrances; and (iv) will be in compliance with all Applicable Laws and regulations.
		

		
			 
		

		
			 
		

		
			13.2     Lumara Representations. Lumara hereby represents and warrants to Antares as follows:
		

		
			 
		

		
			(a)      Intellectual Property.  That Lumara has the requisite legal title and ownership under its Intellectual Property Rights necessary for it to fulfill its obligations under this Agreement, including, without limitation, the granting of the non-exclusive licenses in Article 5. There is no pending or threatened litigation, arbitration, government proceeding, or government investigation (and Lumara has not received any communication relating thereto) which alleges that Lumara's past activities relating to the Drug, or activities proposed under this Agreement, including, without limitation activities with respect to the Antares Patent Rights, infringe or misappropriate any of the Intellectual Property Rights of any Third Person. To the best knowledge of Lumara, there is no Patent Right or other Intellectual Property Right of any Third Person that would be infringed or misappropriated by Antares fulfilling any of its obligations or exercising any of its rights under this Agreement.
		

		
			 
		

		
			(b)      Employee Obligations. That all of its employees, officers, independent contractors and consultants have legal obligations requiring, in the case of employees and officers, assignment to Lumara of all inventions made during the course of, and as a result of, their association with Lumara, and obligating the individual to maintain as confidential the confidential information of Lumara, as well as the confidential information of a Third Person which Lumara may receive.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(c)      Compliance with Laws. That in carrying out its work under the Product Development Program such work shall be carried out in compliance with any Applicable Laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at the site where such work is being conducted. Moreover, Lumara represents and warrants that in connection with carrying out its work under the Product Development Program, as applicable based on the specific work to be conducted,  it will carry out such work under the Product Development Program in accordance with cGLP, cGCP, cGMP. Further, Lumara represents and warrants that it will commercialize Products only in compliance with Applicable Laws, including promotion of the Products only in accordance with its approved label and no off-label promotion of the Product.
		

		
			 
		

		
			(d)      No Debarment. That it will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992, and will upon request certify in writing to Antares that neither it, nor its employees, or any person providing services to Lumara in connection with the collaboration contemplated by this Agreement have been debarred under the provisions of such Act.
		

		
			 
		

		
			ARTICLE 14
		

		
			 
		

		
			INFRINGEMENT OF THIRD PERSON RIGHTS
		

		
			 
		

		
			14.1     Infringement Claims.  If the manufacture, use or sale of Product in the Territory and in the Field results in any claim, suit or proceeding lodged by a Third Person alleging patent infringement against Lumara or Antares (or their respective Affiliates or sublicensees), such Party shall promptly notify the other Party in writing. Subject to the indemnity provisions of Article 16, which shall be controlling, the Party subject to such claim, suit or proceeding shall have the right to defend and control the defense of any such claim, suit or proceeding, using counsel of its own choice; provided that if both Parties are subject to such claim, suit or proceeding, then the Parties shall promptly determine in good faith which Party will defend and control the defense of any such claim, suit or proceeding, using mutually acceptable counsel; and, provided further, that in no event shall any controlling Party enter into any settlement or make any admission that admits or concedes that any Patent Rights or other intellectual property rights of the other Party are invalid or unenforceable, or adversely affects their scope, without the prior written consent of the other Party. If the Parties cannot promptly determine in good faith (and in any event within five (5) business days of initiating discussions with respect thereto) which Party will    defend and control the defense of any such claim, suit or proceeding then Antares shall be the controlling Party for the defense if the Device itself is at issue (including selecting counsel), and Lumara shall be the controlling Party for the defense if the Device itself is not at issue and the Drug alone or Product is at issue (including selecting counsel).
		

		
			 
		

		
			ARTICLE 15
		

		
			 
		

		
			INFRINGEMENT BY THIRD PERSONS
		

		
			 
		

		
			15.1     Notice. If any of the Licensed Technology licensed under this Agreement is infringed and/or misappropriated by a Third Person ("Infringed Licensed Technology"),
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

the Party first having knowledge of such infringement/misappropriation shall promptly notify the other in writing. The notice shall set forth the facts of such infringement and/or misappropriation in reasonable detail.
		

		
			 
		

		
			15.2     Prosecution of Actions.
		

		
			 
		

		
			(a)     [***].
		

		
			 
		

		
			(b)     [***].
		

		
			 
		

		
			(c)     [***].
		

		
			 
		

		
			(d)     [***].
		

		
			 
		

		
			(e)     [***].
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

15.3     Infringement of Licensed Technology Outside the Field.
		

		
			 
		

		
			(a)       [***].
		

		
			 
		

		
			(b)       [***].
		

		
			 
		

		
			(c)       [***].
		

		
			 
		

		
			(d)       [***].
		

		
			 
		

		
			(e)      [***].
		

		
			 
		

		
			 
		

		
			 
		

		
			ARTICLE 16
		

		
			 
		

		
			MUTUAL INDEMNIFICATION
		

		
			 
		

		
			16.1     Responsibility and Control. Lumara and Antares shall each be solely responsible for the safety of its own employees, agents, licensees or sublicensees with respect to Product development, manufacturing, marketing, selling and detailing the Products, and each shall hold the other harmless with regard to any liability for damages or personal injuries resulting from acts of its respective employees or agents.
		

		
			 
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

16.2     Antares' Right to Indemnification. Lumara shall indemnify each of Antares, its successors and assigns, and the directors, officers, employees, and agents thereof (the "Antares Indemnitees"), defend and hold each Antares Indemnitee harmless from and against any and all liabilities, damages, losses, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation reasonable attorneys' fees) (any of the foregoing, "Damages") incurred by or asserted against any Antares Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurring as a result of a claim or demand made by a Third Person (a "Third Person Claim") against any  Antares Indemnitee because of (a) breach of any warranty made by Lumara pursuant to Section 13.2 hereof; (b) the Product, unless attributable to an item identified in Section 16.3  below which is under the responsibility of Antares; (c) the distribution or detailing of any Product by or on behalf of Lumara or its sublicensees, except to the extent such claim alleges infringement of any patent, other intellectual property rights or other proprietary rights of a Third Person; (d) any allegation that the manufacture, use, sale, offer for sale or importation of a Product infringes any patent, other intellectual property rights or other proprietary rights of a Third Person, except to the extent such infringement relates to the practice of the Antares Patent Rights or use of the Licensed Technology or the  manufacture, use, sale, offer for sale or importation of a Device (including a Device incorporated into a Product) or any delivery system including the Device; or (e) any breach of this Agreement by Lumara, except, in each such case, to the extent that such Damages  are finally determined to have resulted from the negligence or misconduct of Antares. Antares shall promptly notify Lumara of any Third Person Claim upon becoming aware thereof, and shall permit Lumara, at Lumara's cost, to defend against such Third Person Claim and to control the defense and disposition (including, without limitation, all  decisions to litigate, settle or appeal) of such claim, and shall cooperate in the defense thereof. Antares may, at its option and expense, have its own counsel participate in any proceeding that is under the direction of Lumara and shall cooperate with Lumara and its insurer in the disposition of any such matter.
		

		
			 
		

		
			16.3     Lumara's Right to Indemnification. Antares shall indemnify each of Lumara, its successors and assigns, and the directors, officers, employees, and agents thereof (the "Lumara Indemnitees"), defend and hold each Lumara Indemnitee harmless from and against any and all Damages incurred by or asserted against any Lumara Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurring as a result of a Third Person Claim against any Lumara Indemnitee because of (a) breach of any warranty made by Antares pursuant to Section 13.1 hereof; (b) any alleged defect in the design or functionality of the Device; (c) the failure of Antares or its agents to manufacture, process, test or package Devices according to specifications; (d) [***]; (e) the [***], warehousing or distribution of a Product by Antares, except to the extent such claim alleges infringement of any patent, other intellectual property rights or other proprietary rights of a Third Person; (f) any allegation
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

that the practice of the Antares Patent Rights or use of the Licensed Technology or the manufacture, use, sale, offer for sale or importation of a Device (including a Device incorporated into a Product) or any delivery system including the Device, in such cases, infringes any patent, other intellectual property rights or other proprietary rights of a Third Person; or (g) any breach of this Agreement by Antares, except, in each such case, to the extent that such Damages are finally determined to have resulted from the negligence or misconduct of Lumara or a sublicensee of Lumara. Lumara shall promptly notify Antares of any Third Person Claim upon becoming aware thereof, and shall permit Antares at Antares' cost to defend against such Third Person Claim and to control the defense and disposition (including, without limitation, all decisions to litigate, settle or appeal) of such Third Person Claim and shall cooperate in the defense thereof. Lumara may, at its option and expense, have its own counsel participate in any proceeding that is under the direction of Antares and will cooperate wit36h Antares or its insurer in the disposition of any such matter.
		

		
			 
		

		
			16.4     Insurance.  Each Party shall obtain and maintain insurance reasonably sufficient to cover its potential liability under this Agreement and shall provide evidence of such insurance to the other Party upon request.
		

		
			 
		

		
			16.5     Limitation of Liability. [***], neither Party shall be  liable to the other for any consequential, incidental, special, indirect or similar  damages whatsoever, including lost profits, sustained or incurred in connection with the Product or caused by Product defects, regardless of the form of action, whether in contract or tort or otherwise and whether or not such damages were foreseen or unforeseen.
		

		
			 
		

		
			ARTICLE 17
		

		
			 
		

		
			CONFIDENTIALITY
		

		
			 
		

		
			17.1     Confidentiality; Exceptions. Unless otherwise set forth in this Agreement, with respect to all Information disclosed or provided by, or on behalf of, either Party to the other or its designees in connection with this Agreement, whether provided orally, visually, electronically, in writing or in any other form, ("Confidential Information"), the Party receiving such Confidential Information ("Recipient") shall maintain the confidential and proprietary status of such Confidential Information, keep such Confidential Information and each part thereof within its possession or under its control, use all its reasonable efforts to prevent the disclosure of any Confidential Information to any other person, and use all its reasonable efforts to ensure that such Confidential Information is used only for those purposes specifically authorized by this Agreement. These mutual obligations of confidentiality shall apply until [***] following the later of expiration or termination of the Agreement, but such obligations shall not apply to any Information to the extent that such Information is:
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(a)      independently developed by such Party outside the scope and not in violation of this Agreement, as evidenced by such Party's contemporaneous written records;
		

		
			 
		

		
			(b)      in the public domain at the time of its receipt or thereafter becomes part of the public domain through no fault of or breach of this Agreement by the Recipient or by any person to whom the Recipient disclosed such Confidential Information; received without an obligation of confidentiality from a Third Person having the right to disclose such information; or
		

		
			(c)      released from the restrictions of this Section 17.1 by the express written consent of the disclosing Party.
		

		
			 
		

		
			Notwithstanding the provisions of Section 17.1 hereof, the Parties may, to the extent necessary, disclose and use Confidential Information (i) to secure patent protection for an invention developed as a result of the Product Development Program or, to obtain regulatory clearance or institutional or government approval to clinically test or market Product, or (ii) as required by law, statute, rule or court order to be disclosed (the disclosing Party shall, however, use reasonable efforts to obtain confidential treatment of any such disclosure, and consult with the other Party and permit the other Party to participate in seeking an appropriate protective order). Notwithstanding anything to the contrary contained herein, all Confidential Information previously disclosed by the Parties shall continue to be subject to the Confidential Disclosure Agreement, dated [***], between the Parties which shall survive the execution and termination of this Agreement.
		

		
			 
		

		
			17.2     Authorized Disclosures of Confidential Information.
		

		
			 
		

		
			(a)      Permitted Persons.  Each Party may disclose Confidential Information of the other Party, without such Party's prior written consent, to its directors, employees, agents, consultants, permitted suppliers, and other person or entities who need to know such Confidential Information to assist the Party in fulfilling its obligations or exploiting its rights hereunder ("Permitted Person"). As a result of a Party's non-performance of its obligations under this Agreement, the other Party may disclose such Confidential Information to Third Persons as necessary for such Third Person to perform such obligations of that Party, and to Third Persons who are board members or board observers, investors or potential investors, provided the other Party ensures that such Third Person is bound by an appropriate confidentiality agreement prior to disclosure of Confidential Information. The Party making such disclosure shall be responsible for any confidentiality breaches of this Agreement by any Permitted Person to the same extent as if the confidentiality breach was made by the Party.
		

		
			 
		

		
			(b)      Legally Required or Necessary.  Each Party may also disclose the Confidential Information of the other Party, without such Party's prior written consent, to any person, entity, or government or regulatory authority to the extent that the law requires such disclosure. Notwithstanding the foregoing, prior to disclosing the other Party's Confidential Information under this Subsection, the disclosing Party, to the extent practicable, will give the other Party a copy of the Confidential Information to be disclosed
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

and provide such Party a reasonable opportunity to comment on the necessity and the text of the proposed disclosure. The disclosing Party agrees to consider such comments in good faith and to reasonably avail itself of available means under the applicable law to minimize the disclosure of such Confidential Information.
		

		
			 
		

		
			(c)      Court Orders. Each Party may also disclose the Confidential Information of the other Party, without such Party's prior written consent, pursuant to an order of a Regulatory Authority or court of competent jurisdiction, provided that it promptly notifies the other Party of the required disclosure in order to provide such Party an opportunity to take legal action to prevent or limit such disclosure and, if asked, reasonably assists the other Party in pursuing such action.
		

		
			 
		

		
			(d)      Legal Actions.  Each Party may also disclose the Confidential Information of the other Party, without such Party's prior written consent, as is necessary to pursue or defend against a legal or regulatory action by one Party against the other with respect to this Agreement. A Party disclosing the other Party's Confidential Information, pursuant to this Subsection, will use reasonable efforts to minimize the disclosure of the other Party's Confidential Information, including, without limitation, by seeking to file pleadings under seal.
		

		
			 
		

		
			17.3     Return of Confidential Information.  Except as otherwise set forth herein, upon the earlier of the disclosing Party's written request or the expiration or termination of this Agreement, the Recipient shall return or destroy all copies of the disclosing Party's Confidential Information and certify promptly in writing that it has done so, provided that the Recipient shall be entitled to retain one (1) copy of the disclosing Party's Confidential Information in its secured files solely to monitor compliance with its obligations hereunder.
		

		
			 
		

		
			ARTICLE 18
		

		
			 
		

		
			PUBLICITY
		

		
			 
		

		
			18.1     Disclosure of Agreement. Neither Party to this Agreement may release any information to any Third Person regarding the terms or existence of this Agreement without the prior written consent of the other Party. This prohibition applies to press releases, educational and scientific conferences, promotional materials, governmental filings and discussions with public officials and the media. Notwithstanding the foregoing, however, this provision does not apply to any internal publications, or disclosures regarding this Agreement or related information to regulatory agencies such as the U.S. Food and Drug Administration, Securities and Exchange Commission, Federal Trade Commission and/or the Department of Justice which may be required by law, including requests for a copy of this Agreement or related information by tax authorities. Subject to the limitation set forth in the immediately preceding sentence, if any Party to this Agreement determines a release of information regarding the existence or terms of this Agreement is required by law, that Party will notify the other Party as soon as practical and give as much detail as possible in relation to the disclosure required. The Parties shall then
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

cooperate with respect to deciding what information will actually be released. The Parties shall have the right to review and comment on any such information to be included in such governmental filing, including any redactions of Confidential Information required by the governmental agency requiring the release of information. The Parties shall cooperate with respect to any filings under the Hart-Scott-Rodino Antitrust Improvements Act, 15 U.S.C.
		

		
			§18a et. seq., as appropriate. Such press release shall not in any way mention the financial terms or the pharmaceutical compounds governed by this Agreement.
		

		
			 
		

		
			18.2     Terminations. Both Parties agree that if this Agreement is terminated, neither Party will disclose its reasons for not proceeding to any Third Person without the express written consent of the other Party.
		

		
			 
		

		
			18.3     Publications. Except as otherwise provided in Section 18.1, neither Party shall disclose any information in the Field or derived under this Agreement to any Third Person without the prior written consent of the other Party, and for information outside the Field, neither party shall disclose any information derived under this Agreement to any Third Person without the prior written consent of the other Party, such consent for information outside the Field may not be unreasonably withheld. Furthermore, subject to and in addition to the consent requirement set forth above in this Section 18.3, each Party shall provide the other with an opportunity to review and comment upon, and remove any Confidential Information from, any proposed abstracts, manuscripts or proposed presentations that relate to the Field at least sixty (60) days prior to their intended submission for publication and agrees, upon request, not to submit such an abstract or manuscript for publication until the other Party is given a reasonable period of time to secure patent protection for any material in such publication which it believes to be patentable.
		

		
			 
		

		
			ARTICLE 19
		

		
			 
		

		
			TERM AND TERMINATION
		

		
			 
		

		
			19.1     Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in whole or in part as specifically provided in this Agreement, shall continue in force and effect and will expire upon [***].
		

		
			 
		

		
			19.2     Termination By Lumara. This Agreement may be terminated in its entirety by Lumara, upon Lumara's prior written notice to Antares:
		

		
			 
		

		
			(a)       [***] from the Effective Date provided that the effective date of such termination shall be at least forty-five (45) days after the date that written notice of such termination is sent to Antares provided, however, [***];
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(b)      Subject to Section 20.2, if Antares commits a material breach of this Agreement and such breach remains uncured for sixty (60) days following written notice of breach by Antares; or
		

		
			 
		

		
			(c)      Subject to Section 20.2, if Antares fails to supply Lumara's requirements of Products pursuant to Article 10 and under the Manufacturing Agreement, and such failure remains uncured for [***] following written notice of such failure to Antares;
		

		
			 
		

		
			(d)      If Antares is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit of creditors, or is subject to the appointment of a receiver for all or a substantial part of Antares' assets, and such petition, assignment or appointment prevents Antares (as a legal or as a practical matter) from performing its obligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacated within sixty (60) days.
		

		
			 
		

		
			19.3     Termination by Antares. This Agreement may be terminated in its entirety by Antares upon Antares' prior written notice to Lumara:
		

		
			 
		

		
			(a)      Subject to Section 20.2, if Lumara commits a material breach of this Agreement and such breach remains uncured for sixty (60) days following written notice of breach by Antares; or
		

		
			 
		

		
			(b)      If Lumara fails to submit the U.S. Regulatory Submission by [***] and [***],  provided that such date shall be extended until [***] (the "First Extension Period") upon Lumara making a date    extension payment to Antares of [***], until [***] (the "Second Extension Period") upon Lumara making an additional extension payment to Antares of [***] prior to the end of the First Extension Period for a cumulative total of [***], and until [***] upon Lumara making an additional extension payment to Antares of [***] prior to the end of the Second Extension Period for a cumulative total of [***]; or
		

		
			 
		

		
			(c)      If Lumara is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit of creditors, or is subject to the appointment of a receiver for all or a substantial part of Lumara's assets, and such petition, assignment or appointment prevents Lumara (as a legal or as a practical matter) from performing its obligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacated within sixty (60) days.
		

		
			 
		

		
			19.4     Remedies for Material Breach 
		

		
			 
		

		
			(a)      Remedies for Lumara. Subject to Sections 16.5 and 20.2, in the event of an uncured material breach by Antares that would entitle Lumara to terminate this Agreement under Section 19.2(b), [***].
		

		
			 
		

		
			(b)      Remedies for Antares. Subject to Sections 16.5 and 20.2, in the event of a uncured material breach by Lumara that would entitle Antares to terminate this Agreement under Section 19.3(a), [***].
		

		
			 
		

		
			19.5     Effect of Termination.
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

(a)      In the event Lumara terminates this Agreement pursuant to Section 19.2(a), or Antares terminates this Agreement pursuant to Section 19.3, then the licenses granted to Lumara under Section 5.1 shall terminate, and Lumara shall cease all use of the Licensed Technology and the using and selling of Products, provided, however, that Lumara may sell off any remaining inventory of Products existing on the date of termination for a period not to exceed [***] after the termination date.
		

		
			 
		

		
			19.6     Surviving Rights. Termination of this Agreement shall not terminate Lumara's obligation to pay all milestone payments, royalties and other payments that shall have accrued hereunder (including any milestone payments then accrued but not yet due under Section 8.3, and in the event this Agreement is terminated by Lumara pursuant to Section 19.2(a), including any milestone payments that would have accrued within [***] of the date of notice of termination). The obligations of the Parties under Article 5 (License), Article 8 (Compensation to Antares, but only with respect to payments accruing prior to and remaining unpaid upon termination or expiration of this Agreement, and in the event this Agreement is terminated by Lumara pursuant to Section l 9.2(a), to milestone payments that would have accrued within [***] of the date of notice of termination), Article 11 (Record-Keeping and Audits), Article 12 (Program Intellectual Property), Article 14 (Infringement of Third Person Rights), Article 16 (Mutual Indemnification), Article 17 (Confidentiality), Article 19 (Termination), and Article 20 (Miscellaneous) of this Agreement will survive the termination or expiration of this Agreement.
		

		
			 
		

		
			19.7     Accrued Rights, Surviving Obligations. Termination, relinquishment or expiration of the Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to (or as a result of, including, without limitation, rights available under law and equity) such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement.
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

ARTICLE 20
		

		
			 
		

		
			MISCELLANEOUS
		

		
			 
		

		
			20.1     Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the other Party for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so.
		

		
			 
		

		
			20.2     Dispute Resolution. The Parties recognize that disputes as to certain matters may from time to time arise which relate to either Party's rights and/or obligations hereunder. The Parties hereby agree that they will attempt in good faith to resolve any controversy, claim or dispute (collectively, a "Dispute") arising out of or relating to this Agreement promptly by negotiations. Any such Dispute which is not settled by the Parties within [***] after notice of such Dispute is given by one Party to the other in writing shall be referred to a senior executive of Lumara and of Antares who are authorized to settle such Disputes on behalf of their respective companies ("Senior Executives") and who, if possible, are not involved in the Dispute. The Senior Executives will meet for negotiations [***] of the end of the [***] negotiation period referred to above, at a time, place and manner mutually acceptable to both Senior Executives. If the Dispute has not been resolved within [***] after the end of the [***] negotiation period referred to above (which period may be extended by mutual agreement), then such Dispute shall be subject to any other remedy available under this Agreement or at law or equity.
		

		
			 
		

		
			20.3     Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder shall be assignable by any Party without the prior written consent of the other (which consent shall not be unreasonably withheld, conditioned or delayed); provided, however, that either Party may assign this Agreement to any wholly owned subsidiary or to any successor by merger or sale of substantially all of its business unit to which this Agreement relates. This Agreement shall be binding upon the successors and permitted assignees of the Parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee.
		

		
			 
		

		
			20.4     Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
		

		
			 
		

		
			20.5     Force Majeure. Neither Party shall be liable to the other for loss or damages or shall have any right to terminate this Agreement for any default or delay attributable to any force majeure event, including, but not limited to, acts of God, acts of government, war, fire, flood, earthquake, terrorist acts, strike, labor dispute and the like, if the Party affected shall give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for sixty (60) days
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

thereafter; provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause.
		

		
			 
		

		
			20.6     Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof):
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						If to Lumara, addressed to:

					
					
						Lumara Health Inc. Chesterfield Grove Road Suite 200

				
	
					
						[***]

					
					
						Chesterfield, MO 63005

				
	
					
						 

					
					
						314-645-6600

				
	
					
						 

					
					
						 

				
	
					
						If to Antares, addressed to:

					
					
						Antares Pharma, Inc.

				
	
					
						[***]

					
					
						100 Princeton South, Suite 300

				
	
					
						 

					
					
						Ewing, NJ 08628

				
	
					
						 

					
					
						609-359-3020

				

		
			 
		

		
			20.7     Amendment. No amendment, modification or supplement of any provision of the Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.
		

		
			 
		

		
			20.8     Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.
		

		
			 
		

		
			20.9      Counterparts. The Agreement may be executed simultaneously in two counterparts, either one of which need not contain the signature of more than one Party but both such counterparts taken together shall constitute one and the same agreement.
		

		
			 
		

		
			20.10     Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement.
		

		
			 
		

		
			20.11     Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to its choice of law rules.
		

		
			 
		

		
			20.12     Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision of the Agreement is held to be prohibited by or invalid under Applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity,
		

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

without invalidating the remainder of the Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.
		

		
			 
		

		
			 
		

		
			20.13     Entire Agreement of the Parties. This Agreement, including the Exhibits attached hereto, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties hereto, and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. In the event there is a discrepancy between the Exhibits and the Agreement, the Agreement shall control.
		

		
			 
		

		
			20.14     Jointly Prepared. This Agreement has been prepared jointly by both Parties and shall not be strictly construed against either Party.
		

		
			 
		

		
			20.15     Limitation of Liability. [***].
		

		
			 
		

		
			 
		

		
			IN WITNESS WHEREOF, the Parties hereto have as of the Effective Date duly executed this Agreement.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						LUMARA HEALTH INC.

					
					
						ANTARES PHARMA, INC.

				
	
					
						 

					
					
						 

				
	
					
						By:    /s/ Thomas S. McHugh

					
					
						By: /s/ Robert Apple

					
					
						 

				
	
					
						Name: Thomas S. McHugh

					
					
						Name: Robert Apple

					
					
						 

				
	
					
						Title: Chief Financial Officer

					
					
						Title: Chief Financial Officer and Chief Commercial Officer

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT A
		

		
			 
		

		
			INTENTIONALLY LEFT BLANK
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT B 
		

		
			 
		

		
			[***]
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT C
		

		
			 
		

		
			 
		

		
			[***]
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT D
		

		
			[***]
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT E
		

		
			 
		

		
			[***]
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT F
		

		
			 
		

		
			[***]
		

		
			
		

		
			

		 

 

		

			[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL

		

		

			TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED

		

		

			WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2

		

		

			PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

		

		

			 

		

EXHIBIT G
		

		
			 
		

		
			[***]EXHIBIT 4(a)(7)

 

 

 

 

JPMORGAN
CHASE FINANCIAL COMPANY LLC,

as Issuer

JPMORGAN CHASE & CO.,

as Guarantor

AND

DEUTSCHE BANK TRUST COMPANY AMERICAS,

as Trustee

Indenture

 

dated as of February 19, 2016

 

 

 

 

 

 

    

    

    

 

CROSS REFERENCE SHEET*

 

 

 

Provisions of Trust Indenture Act of 1939
and Indenture dated as of February 19, 2016 among JPMORGAN CHASE FINANCIAL COMPANY LLC, as Issuer, JPMORGAN CHASE & CO.,
as Guarantor, and DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee:

 

	Section of the Act	 	Section of Indenture
	310(a)(1) and (2)	 	
        ‎‎6.09

        

	310(a)(3) and (4)	 	Inapplicable
	310(b)	 	
        ‎‎6.08
        and ‎‎6.10(a), ‎‎6.10(b)
        and ‎‎6.10(c)

        

	312(a)	 	
        ‎‎4.01
        and ‎‎4.02(a)

        

	312(b)	 	
        ‎‎4.02(b)

        

	312(c)	 	
        ‎‎4.02(c)

        

	313(a)	 	
        ‎4.04

        

	313(b)(1)	 	Inapplicable
	313(b)(2)	 	‎Inapplicable
	313(c)	 	
        ‎‎4.04

	313(d)	 	
        ‎4.04

        

	314(a)	 	
        3.05 and ‎‎4.03

        

	314(b)	 	Inapplicable
	314(c)(1) and (2)	 	
        ‎‎11.05

        

	314(c)(3)	 	Inapplicable
	314(d)	 	Inapplicable
	314(e)	 	
        ‎‎11.05

        

	314(f)	 	Inapplicable
	315(a), (c) and (d)	 	
        ‎6.01

        

	315(b)	 	
        ‎‎5.11

        

	315(e)	 	
        ‎‎5.12

        

	316(a)(1)	 	
        ‎‎5.09

        

	316(a)(2)	 	Not required
	316(a) (last sentence)	 	
        ‎7.04

        

	316(b)	 	
        ‎‎5.07

        

	317(a)	 	
        ‎‎5.02

        

	317(b)	 	
        ‎‎3.04(a)
        and ‎‎3.04(b)

        

	318(a)	 	
        ‎‎11.07

        

 

 

*
This Cross Reference Sheet is not part of the Indenture.

 

    

    

    

 

TABLE OF CONTENTS

 

 

Page

 

	ARTICLE 1 
DEFINITIONS
	 	 
	Section 1.01 Certain Terms Defined	1
	 	 
	ARTICLE 2
	SECURITIES
	 	 
	Section 2.01 Forms Generally	8
	Section 2.02 Form of Trustee’s Certificate of Authentication	8
	Section 2.03 Amount Unlimited; Issuable in Series	9
	Section 2.04 Authentication and Delivery of Securities	12
	Section 2.05 Execution of Securities	15
	Section 2.06 Certificate of Authentication	15
	Section 2.07 Denomination and Date of Securities; Payments of Interest	15
	Section 2.08 Registration, Transfer and Exchange	17
	Section 2.09 Mutilated, Defaced, Destroyed, Lost and Stolen Securities	21
	Section 2.10 Cancellation of Securities; Destruction Thereof	22
	Section 2.11 Temporary Securities	22
	Section 2.12 Calculation Agent Determinations	23
	 	 
	ARTICLE 3
	COVENANTS OF THE ISSUER AND THE GUARANTOR
	 	 
	Section 3.01 Payment of Principal and Interest	23
	Section 3.02 Offices for Payments, Etc.	24
	Section 3.03 Appointment to Fill a Vacancy in Office of Trustee	25
	Section 3.04 Paying Agents	25
	Section 3.05 Written Statement to Trustee	26
	Section 3.06 Luxembourg Publications	26
	 	 
	ARTICLE 4
	SECURITYHOLDERS LISTS AND REPORTS BY THE ISSUER, THE GUARANTOR AND THE TRUSTEE
	 	 
	Section 4.01 Issuer and Guarantor to Furnish Trustee Information as to Names and Addresses of Securityholders	27
	Section 4.02 Preservation and Disclosure of Securityholders Lists	27
	Section 4.03 Reports by the Issuer and Guarantor	27
	Section 4.04 Reports by the Trustee	28

 

    i

    

    

 

	ARTICLE 5
	REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT
	 	 
	Section 5.01 Event of Default Defined; Acceleration of Maturity; Waiver of Default	28
	Section 5.02 Collection of Indebtedness by Trustee; Trustee May Prove Debt	31
	Section 5.03 Application of Proceeds	34
	Section 5.04 Suits for Enforcement	35
	Section 5.05 Restoration of Rights on Abandonment of Proceedings	35
	Section 5.06 Limitations on Suits by Securityholders	35
	Section 5.07 Unconditional Right of Securityholders to Institute Certain Suits	36
	Section 5.08 Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default	36
	Section 5.09 Control by Securityholders	37
	Section 5.10 Waiver of Past Defaults	37
	Section 5.11 Trustee to Give Notice of Default, but May Withhold in Certain Circumstances	38
	Section 5.12 Right of Court to Require Filing of Undertaking to Pay Costs	38
	 	 
	ARTICLE 6
	CONCERNING THE TRUSTEE
	 	 
	Section 6.01 Duties and Responsibilities of the Trustee; During Default; Prior to Default	39
	Section 6.02 Certain Rights of the Trustee	40
	Section 6.03 Trustee Not Responsible for Recitals, Disposition of Securities or Application of Proceeds Thereof	42
	Section 6.04 Trustee and Agents May Hold Securities or Coupons, Collections, Etc.	42
	Section 6.05 Monies Held by Trustee	43
	Section 6.06 Compensation and Indemnification of Trustee and Its Prior Claim	43
	Section 6.07 Right of Trustee to Rely on Officer’s Certificate, Etc.	43
	Section 6.08 Conflicting Interests	44
	Section 6.09 Persons Eligible for Appointment as Trustee	45
	Section 6.10 Resignation And Removal; Appointment of Successor Trustee	45
	Section 6.11 Acceptance of Appointment by Successor Trustee	47
	Section 6.12 Merger, Conversion, Consolidation or Succession of Business of Trustee	48
	Section 6.13 Appointment of Authenticating Agent	48

 

    ii

    

    

 

	ARTICLE 7
	CONCERNING THE SECURITYHOLDERS
	 	 
	Section 7.01 Evidence of Action Taken by Securityholders	50
	Section 7.02 Proof of Execution of Instruments and of Holding of Securities	50
	Section 7.03 Holders to Be Treated as Owners	50
	Section 7.04 Securities Owned by Issuer or Guarantor Deemed Not Outstanding	51
	Section 7.05 Right of Revocation of Action Taken	51
	 	 
	ARTICLE 8
	SUPPLEMENTAL INDENTURES
	 	 
	Section 8.01 Supplemental Indentures Without Consent of Securityholders	52
	Section 8.02 Supplemental Indentures with Consent of Securityholders	54
	Section 8.03 Effect of Supplemental Indenture	55
	Section 8.04 Documents to Be Given to Trustee	56
	Section 8.05 Notation on Securities in Respect of Supplemental Indentures	56
	Section 8.06 Notification of Holders of Any Supplemental Indenture	56
	 	 
	ARTICLE 9
	CONSOLIDATION, MERGER, SALE, CONVEYANCE OR TRANSFER
	 	 
	Section 9.01 Issuer May Consolidate, Etc., on Certain Terms	56
	Section 9.02 Guarantor May Consolidate, Etc., on Certain Terms	57
	Section 9.03 Successor Person to Be Substituted	57
	Section 9.04 Opinion of Counsel to Trustee	58
	 	 
	ARTICLE 10
	SATISFACTION AND DISCHARGE OF INDENTURE; UNCLAIMED MONIES
	 	 
	Section 10.01 Satisfaction and Discharge of Indenture	58
	Section 10.02 Application by Trustee of Funds Deposited for Payment of Securities	63
	Section 10.03 Repayment of Monies Held by Paying Agent	63
	Section 10.04 Return of Monies Held by Trustee and Paying Agent Unclaimed for Two Years	63
	Section 10.05 Indemnity for U.S. Government Obligations	64
	 	 
	ARTICLE 11
	MISCELLANEOUS PROVISIONS
	 	 
	Section 11.01 Incorporators, Stockholders, Officers and Directors of Issuer and Guarantor Exempt from Individual Liability	64
	Section 11.02 Provisions of Indenture for the Sole Benefit of Parties and Holders of Securities and Coupons	65

 

    iii

    

    

 

	Section 11.03 Successors and Assigns of Issuer and Guarantor Bound by Indenture	65
	Section 11.04 Notices and Demands on Issuer, Guarantor, Trustee and Holders of  Securities and Coupons	65
	Section 11.05 Officer’s Certificates and Opinions of Counsel; Statements to Be Contained Therein	66
	Section 11.06 Payments Due on Saturdays, Sundays and Holidays	67
	Section 11.07 Conflict of Any Provision of Indenture with Trust Indenture Act of 1939	68
	Section 11.08 New York Law to Govern	68
	Section 11.09 Counterparts	68
	Section 11.10 Effect of Headings	68
	Section 11.11 Securities in a Foreign Currency	68
	Section 11.12 Judgment Currency	69
	 	 
	ARTICLE 12
	REDEMPTION OF SECURITIES AND SINKING FUNDS
	 	 
	Section 12.01 Applicability of Article	69
	Section 12.02 Notice of Redemption; Partial Redemptions	69
	Section 12.03 Payment of Securities Called for Redemption	71
	Section 12.04 Exclusion of Certain Securities from Eligibility for Selection for Redemption	72
	Section 12.05 Mandatory and Optional Sinking Funds	73
	 	 
	ARTICLE 13
	REPURCHASE OF SECURITIES AT THE OPTION OF THE HOLDER
	 	 
	Section 13.01 Applicability of Article	75
	Section 13.02 Minimum Repurchase Amount	75
	Section 13.03 Notice of Repurchase; Partial Repurchase	75
	Section 13.04 Payment of Securities Subject to Repurchase	76
	Section 13.05 Repurchase by Remarketing Entities	77
	 	 
	ARTICLE 14
	GUARANTEE
	 	 
	Section 14.01 The Guarantee	77
	Section 14.02 Guarantee Unconditional	77
	Section 14.03 Discharge; Reinstatement	79
	Section 14.04 Waiver by the Guarantor	79
	Section 14.05 Subrogation	79
	Section 14.06 Stay of Acceleration	79
	Section 14.07 Savings Clause	79

 

    iv

    

    

 

	Section 14.08 Execution and Delivery of Guarantee	80
	Section 14.09 Not Insured	80

 

    v

    

    

 

THIS INDENTURE, dated as of February 19,
2016 among JPMORGAN CHASE FINANCIAL COMPANY LLC, a Delaware limited liability company (the “Issuer”), JPMORGAN CHASE
& CO., a Delaware corporation (the “Guarantor”), and DEUTSCHE BANK TRUST COMPANY AMERICAS, a New York banking
corporation (the “Trustee”),

 

W I T N E S S E T H :

 

WHEREAS, the Issuer has duly authorized
the issue from time to time of its unsecured debentures, notes or other evidences of indebtedness to be issued in one or more series
(the “Securities”) up to such principal amount or amounts as may from time to time be authorized in accordance
with the terms of this Indenture and to provide, among other things, for the authentication, delivery and administration thereof,
the Issuer has duly authorized the execution and delivery of this Indenture;

 

WHEREAS, the Guarantor has duly authorized
the guarantee of the Securities and the execution and delivery of this Indenture as guarantor of the Securities; and

 

WHEREAS, all things necessary to make this
Indenture a valid indenture and agreement according to its terms, have been done;

 

NOW, THEREFORE:

 

In consideration of the premises and the
purchases of the Securities by the holders thereof, the Issuer, the Guarantor and the Trustee covenant and agree for the equal
and proportionate benefit of the respective holders from time to time of the Securities and of the Coupons, if any, appertaining
thereto as follows:

 

Article
1

Definitions

 

Section 1.01 Certain Terms Defined.
The following terms (except as otherwise expressly provided or unless the context otherwise clearly requires) for all purposes
of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section. All other
terms used in this Indenture that are defined in the Trust Indenture Act of 1939 or the definitions of which in the Securities
Act of 1933 are referred to in the Trust Indenture Act of 1939, including terms defined therein by reference to the Securities
Act of 1933 (except as herein otherwise expressly provided or unless the context otherwise requires), shall have the meanings assigned
to such terms in said Trust Indenture Act and in said Securities Act. All accounting terms used herein and not expressly defined
shall have the meanings assigned to such terms in accordance

 

    1

    

    

 

with generally accepted accounting principles, and the term “generally
accepted accounting principles” means such accounting principles as are generally accepted at the time of any computation.
The words “herein,” “hereof” and “hereunder” and other words of similar
import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. The terms defined in
this Article have the meanings assigned to them in this Article and include the plural as well as the singular.

 

“Attorney-in-Fact” means
(a) with respect to the Issuer, a Person who has been duly appointed as an attorney-in-fact by the Issuer and (b) with respect
to the Guarantor, a Person who has been duly appointed as an attorney-in-fact by the Guarantor.

 

“Authenticating Agent”
shall have the meaning set forth in ‎‎Section 6.13.

 

“Authorized Newspaper”
means a newspaper (which, in the case of The City of New York, will, if practicable, be The Wall Street Journal (Eastern Edition),
in the case of the United Kingdom, will, if practicable, be the Financial Times (London Edition) and, in the case of Luxembourg,
will, if practicable, be the Luxemburger Wort) published in an official language of the country of publication customarily published
at least once a day for at least five days in each calendar week and of general circulation in The City of New York, the United
Kingdom or in Luxembourg, as applicable.

 

“Board” means, (a) with
respect to the Issuer, the board of managers of the Issuer or any committee of such board duly authorized to act for such board
or any officer, manager or Attorney-in-Fact of the Issuer to whom such board or such committee shall have delegated its authority
and (b) with respect to the Guarantor, the board of directors of the Guarantor or any committee of such board duly authorized to
act for such board or any officer, director or Attorney-in-Fact of the Guarantor to whom such board or such committee shall have
delegated its authority.

 

“Board Resolution” means,
(a) with respect to the Issuer, a copy of a resolution certified by the secretary or an assistant secretary of the Issuer to have
been duly adopted by the Board of the Issuer and to be in full force and effect on the date of such certification, and delivered
to the Trustee and (b) with respect to the Guarantor, a copy of a resolution certified by the secretary or an assistant secretary
of the Guarantor to have been duly adopted by the Board of the Guarantor and to be in full force and effect on the date of such
certification, and delivered to the Trustee.

 

“Business Day” means,
unless otherwise specified pursuant to ‎‎Section 2.03, with respect to any Security, a day that in the city (or in any
of the cities, if more than one) in which amounts are payable, as specified in the form of such

 

    2

    

    

 

Security, is not a day on which
banking institutions are authorized or required by law or regulation to close or a day on which transactions in the currency in
which the Securities are payable are not conducted.

 

“Commission” means the
Securities and Exchange Commission, as from time to time constituted, created under the Securities Exchange Act of 1934, or if
at any time after the execution and delivery of this Indenture such Commission is not existing and performing the duties now assigned
to it under the Trust Indenture Act, then the body performing such duties on such date.

 

“Corporate Trust Office”
means the office of the Trustee at which the corporate trust business of the Trustee shall, at any particular time, be principally
administered, which office is, as of the date hereof, located at Deutsche Bank Trust Company Americas, Trust & Agency Services,
60 Wall Street, 16th Floor, MS: NYC60-1630, New York, New York 10005, Attn: Corporates Team Deal Manager – JPMorgan Chase
Financial Company LLC, Fax: 732-578-4635 (with copies of all notices sent to Deutsche Bank Trust Company Americas, c/o Deutsche
Bank National Trust Company, Trust & Agency Services, 100 Plaza One, MS: JCY03-0699, Jersey City, NJ 07311, Attn: Corporates
Team Deal Manager – JPMorgan Chase Financial Company LLC, Fax: 732-578-4635).

 

“Coupon” means any interest
coupon appertaining to an Unregistered Security.

 

“covenant defeasance”
shall have the meaning set forth in ‎‎Section 10.01(c).

 

“Depositary” means, with
respect to the Securities of any series issuable or issued in the form of one or more Registered Global Securities, the Person
designated as Depositary by the Issuer pursuant to ‎‎Section 2.03 until a successor Depositary shall have become such pursuant
to the applicable provisions of this Indenture, and thereafter “Depositary” shall mean or include each Person
who is then a Depositary hereunder, and if at any time there is more than one such Person, “Depositary” as used
with respect to the Securities of any such series shall mean the Depositary with respect to the Registered Global Securities of
that series.

 

“Dollar” means the coin
or currency of the United States of America as at the time of payment is legal tender for the payment of public and private debts.

 

“Event of Default” means
any event or condition specified as such in ‎‎Section 5.01.

 

“Foreign Currency” means
a currency issued by the government of a country other than the United States (or any currency unit composed of any such currencies).

 

    3

    

    

 

“Guarantee” means the
guarantee of the Securities by the Guarantor pursuant to this Indenture.

 

“Guarantor” means JPMorgan
Chase & Co., or any successor obligor pursuant to ‎Article 9, in each case unless and until the Guarantor is released from
the Guarantee pursuant to this Indenture.

 

“Holder”, “holder
of Securities”, “Securityholder” or other similar terms mean (a) in the case of any Registered Security,
the Person in whose name such Security is registered in the security register kept by the Issuer for that purpose in accordance
with the terms hereof, and (b) in the case of any Unregistered Security, the bearer of such Security, or any Coupon appertaining
thereto, as the case may be.

 

“Indenture” means this
instrument as originally executed and delivered or, if amended or supplemented as herein provided, as so amended or supplemented
or both, and shall include the forms and terms of particular series of Securities established as contemplated hereunder.

 

“interest” means when
used with respect to non-interest bearing Securities, interest payable after maturity.

 

“Issuer” means JPMorgan
Chase Financial Company LLC, a Delaware limited liability company, and, subject to ‎‎Article 9, its successors and assigns.

 

“Issuer Order” means
a written statement, request or order of the Issuer signed in its name by any one of the following: the president, the treasurer,
a managing director, an executive director, a vice president or any Attorney-in-Fact of the Issuer.

 

“Judgment Currency” shall
have the meaning set forth in ‎‎Section 11.12.

 

“Officer’s Certificate”
means (a) with respect to the Issuer, a certificate delivered to the Trustee and signed by the president, the treasurer, a managing
director, an executive director, a vice president (whether or not designated by a number or a word or words added before or after
the title “vice president”) or any other officer of the Issuer designated pursuant to authority of the Board or any
Attorney-in-Fact of the Issuer (with respect to the Issuer, the “Officers”) and (b) with respect to the Guarantor,
a certificate delivered to the Trustee and signed by the chairman of the Board, a vice chairman, the president, the chief financial
officer, a vice president (whether or not designated by a number or a word or words added before or after the title “vice
president”), a managing director, the controller, an assistant controller, the secretary, an assistant secretary or any other
officer of the Guarantor designated pursuant to authority of the Board or any Attorney-in-Fact of the Guarantor (with respect to
the Guarantor, the “Officers”).

 

    4

    

    

 

Each such certificate shall comply with Section 314 of the Trust Indenture Act
of 1939 and include the statements provided for in ‎‎Section 11.05.

 

“Opinion of Counsel”
means an opinion in writing signed by legal counsel who may be an employee of or counsel to the Issuer or the Guarantor and who
shall be satisfactory to the Trustee. Each such opinion shall comply with Section 314 of the Trust Indenture Act of 1939 and include
the statements provided for in ‎‎Section 11.05.

 

“original issue date”
of any Security (or portion thereof) means the earlier of (a) the date of such Security or (b) the date of any Security (or portion
thereof) for which such Security was issued (directly or indirectly) on registration of transfer, exchange or substitution.

 

“Original Issue Discount Security”
means any Security that provides for an amount due and payable upon a declaration of acceleration of the maturity thereof pursuant
to ‎‎Section 5.01 that will in all circumstances be less than the principal amount thereof. For the avoidance of doubt,
any Security that provides for an amount due and payable upon a declaration of acceleration of the maturity thereof pursuant to
‎‎Section 5.01 that may, in some cases, be equal to or greater than the principal amount thereof will not be an Original
Issue Discount Security.

 

“Outstanding” when used
with reference to Securities, shall, subject to the provisions of ‎‎Section
7.04, mean, as of any particular time, all Securities authenticated and delivered by the Trustee under this Indenture, except:

 

(a)            Securities
theretofore cancelled by the Trustee or delivered to the Trustee for cancellation;

 

(b)           
Securities, or portions thereof, for the payment or redemption of which monies or U.S. Government Obligations (as provided
for in ‎‎Section 10.01) in the necessary amount shall have been deposited in trust with the Trustee or with any paying
agent (other than the Issuer or the Guarantor) or shall have been set aside, segregated and held in trust by the Issuer or the
Guarantor for the holders of such Securities (if the Issuer or the Guarantor, as applicable, shall act as its own paying agent),
provided that if such Securities, or portions thereof, are to be redeemed prior to the maturity thereof, notice of such
redemption shall have been given as herein provided, or provision satisfactory to the Trustee shall have been made for giving
such notice; and

 

(c)           
Securities which shall have been paid or in substitution for which other Securities shall have been authenticated and delivered
pursuant to the terms of ‎‎Section 2.09 (except with respect to any such Security as to which proof satisfactory to the
Trustee is presented that such Security is held by a person in whose hands such Security is a legal, valid and binding obligation
of the Issuer or the Guarantor, or both).

 

    5

    

    

 

In determining whether the Holders of the
requisite principal amount of Outstanding Securities of any or all series have given any request, demand, authorization, direction,
notice, consent or waiver hereunder, the principal amount of an Original Issue Discount Security that shall be deemed to be Outstanding
for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such determination
upon a declaration of acceleration of the maturity thereof pursuant to ‎‎Section 5.01.

 

“Periodic Offering” means
an offering of Securities of a series from time to time, the specific terms of which Securities, including, without limitation,
the rate or rates of interest, if any, thereon, the stated maturity or maturities thereof and the redemption provisions, if any,
with respect thereto, are to be determined by the Issuer or its agents upon the issuance of such Securities.

 

“Person” means any individual,
corporation, partnership, joint venture, association, limited liability company, joint stock company, trust, unincorporated organization
or government or any agency or political subdivision thereof.

 

“principal” whenever
used with reference to the Securities or any Security or any portion thereof, shall be deemed to include premium, if any, any other
cash amounts payable under the Indenture, and the delivery of securities or baskets of securities under the terms of the Securities.

 

“record date” shall have
the meaning set forth in ‎‎Section 2.07.

 

“Redemption Notice Period”
shall have the meaning set forth in ‎‎Section 12.02.

 

“Reference Asset” shall
mean one or more interest rates, swap rates, securities, commodities, currencies, currency units, composite currencies, options
or futures contracts or any other rates, instruments, assets, market measures or other factors (including but not limited to the
occurrence, non-occurrence or extent of an occurrence of any event or circumstance or any contingency associated with a financial,
commercial or economic consequence) or any other measures of economic or financial risk or value, or one or more baskets, indices
or other combinations of any of the foregoing as specified in accordance with Section 2.03.

 

“Registered Global Security”
means a Security evidencing all or a part of a series of Registered Securities, issued to the Depositary for such series in accordance
with ‎‎Section 2.04, and bearing the legend prescribed in ‎‎Section 2.04.

 

“Registered Security”
means any Security registered on the Security register of the Issuer.

 

    6

    

    

 

“Registrar” means any
Person appointed by the Issuer and the Guarantor as registrar for the Securities.

 

“Required Currency” shall
have the meaning set forth in ‎‎Section 11.12.

 

“Responsible Officer”
when used with respect to the Trustee means any managing director, any director, any vice president, any assistant vice president,
any associate or any other officer or assistant officer of the Trustee with direct responsibility for the administration of this
Indenture.

 

“Security” or “Securities”
has the meaning stated in the first recital of this Indenture, or, as the case may be, Securities that have been authenticated
and delivered under this Indenture.

 

“Successor Person” shall
have the meaning set forth in Section 9.03.

 

“Trust Indenture Act of 1939”
means the Trust Indenture Act of 1939 as in force at the date as of which this instrument was originally executed, except as provided
in Sections ‎8.01 and ‎‎8.02 and except that in the event the Trust Indenture Act of 1939 is amended after such date,
“Trust Indenture Act of 1939” means, to the extent required by any such amendment, the Trust Indenture Act of 1939
as so amended.

 

“Trustee” means the Person
identified as “Trustee” in the first paragraph hereof and, subject to the provisions of ‎‎Article 6, shall
also include any successor trustee.

 

“Unregistered Security”
means any Security other than a Registered Security.

 

“U.S. Government Obligations”
shall have the meaning set forth in ‎‎Section 10.01(a).

 

“U.S. Person” means a
citizen or resident of the United States for United States federal income tax purposes, a corporation or partnership, including
an entity treated as a corporation or partnership for United States federal income tax purposes, created or organized in or under
the laws of the United States, or any state of the United States or the District of Columbia, or an estate or trust the income
of which is subject to United States federal income taxation regardless of its source.

 

“vice president” when
used with respect to a Person, means any vice president, whether or not designated by a number or a word or words added before
or after the title of “vice president.”

 

    7

    

    

 

“Yield to Maturity” means
the yield to maturity on a series of Securities, calculated at the time of issuance of such series, or, if applicable, at the most
recent redetermination of interest on such series, and calculated in accordance with accepted financial practice.

 

Article
2

Securities

 

Section 2.01 Forms Generally. The
Securities of each series and the Coupons, if any, to be attached thereto shall be substantially in such form (not inconsistent
with this Indenture) as shall be established by or pursuant to one or more Board Resolutions of the Issuer (as set forth in a Board
Resolution of the Issuer or, to the extent established pursuant to rather than set forth in a Board Resolution of the Issuer, an
Officer’s Certificate of the Issuer detailing such establishment) or in one or more indentures supplemental hereto, in each
case with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this Indenture
and may have imprinted or otherwise reproduced thereon such legend or legends or endorsements, not inconsistent with the provisions
of this Indenture, as may be required to comply with any law or with any rules or regulations pursuant thereto, or with any rules
of any securities exchange or to conform to general usage, all as may be determined by the officers executing such Securities and
Coupons, if any, as evidenced by their execution of such Securities and Coupons.

 

The definitive Securities and Coupons, if
any, shall be printed, lithographed or engraved on steel engraved borders or may be produced in any other manner, all as determined
by the officers executing such Securities, as evidenced by their execution of such Securities.

 

Section 2.02 Form of Trustee’s
Certificate of Authentication. The Trustee’s certificate of authentication on all Securities shall be in substantially
the following form:

 

“This is one of the Securities of
the series designated herein and referred to in the within-mentioned Indenture.”

 

	 	DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee
	 	 
	 	 
	 	By:	 
	 	 	Authorized Officer

 

    8

    

    

 

If at any time there shall be an Authenticating
Agent appointed with respect to any series of Securities, then the Trustee’s Certificate of Authentication to be borne by
the Securities of each such series shall be substantially as follows:

 

“This is one of the Securities referred
to in the within-mentioned Indenture.”

 

 

	 	 
	 	as Authenticating Agent

 

 

 

	 	By:	 
	 	 	Authorized Officer

 

Section 2.03 Amount Unlimited; Issuable
in Series. The aggregate principal amount of Securities which may be authenticated and delivered under this Indenture is unlimited.

 

The Securities may be issued in one or more
series, and each such series shall rank equally and pari passu with all other unsecured and unsubordinated debt of the Issuer.
There shall be established in or pursuant to one or more Board Resolutions of the Issuer (and to the extent established pursuant
to rather than set forth in a Board Resolution of the Issuer, in an Officer’s Certificate of the Issuer detailing such establishment)
or established in one or more indentures supplemental hereto, prior to the initial issuance of Securities of any series,

 

                                                         
(1)           
the designation of the Securities of the series (which shall distinguish the Securities of the series from the Securities
of all other series);

 

                                                         
(2)           
any limit upon the aggregate principal amount of the Securities of the series that may be authenticated and delivered under
this Indenture (except for Securities authenticated and delivered upon registration of, transfer of, or in exchange for, or in
lieu of, other Securities of the series pursuant to Section ‎‎2.08, ‎‎2.09, ‎‎2.11,‎8.05 or ‎‎12.03);

 

                                                         
(3)           
if the amounts of payments of principal of and/or interest on, or other amounts payable under, the Securities of the series
may be determined by reference to one or more Reference Assets, any such Reference Assets and the manner in which such amounts
shall be determined;

 

                                                         
(4)           
if other than Dollars, the coin or currency in which the Securities of that series are denominated (including, but not limited
to, any Foreign Currency);

 

    9

    

    

 

                                                         
(5)           
the date or dates on which the principal of or other amounts due under the Securities of the series is payable or the method
by which such date or dates shall be determined;

 

                                                         
(6)           
the rate or rates at which the Securities of the series shall bear interest, if any, or the method by which such rate or
rates shall be determined, the date or dates from which such interest shall accrue, the interest payment dates on which such interest
shall be payable and (in the case of Registered Securities) the record dates for the determination of Holders to whom interest
is payable;

 

                                                         
(7)           
the place or places where the principal of, any interest on or other amounts due under the Securities or delivery of any
Securities or basket of Securities, as the case may be, of the series shall be payable (if other than as provided in ‎‎Section
3.02);

 

                                                         
(8)           
the right, if any, of the Issuer to redeem Securities, in whole or in part, at its option and the period or periods within
which, the price or prices at which and any terms and conditions, including the Redemption Notice Period, upon which Securities
of the series may be so redeemed, pursuant to any sinking fund or otherwise;

 

                                                         
(9)           
the obligation, if any, of the Issuer to redeem, purchase or repay Securities of the series pursuant to any mandatory redemption,
sinking fund or analogous provisions or at the option of a Holder thereof and the price or prices at which and the period or periods
within which and any terms and conditions upon which Securities of the series shall be redeemed, purchased or repaid, in whole
or in part, pursuant to such obligation;

 

                                                         
(10)          if
other than denominations of $1,000 and any integral multiple thereof in the case of Registered Securities, or $1,000 and $5,000
in the case of Unregistered Securities, the denominations in which Securities of the series shall be issuable;

 

                                                         
(11)         
if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall
be payable upon declaration of acceleration of the maturity thereof pursuant to ‎‎Section 5.01 or provable in bankruptcy
pursuant to ‎‎Section 5.02;

 

                                                         
(12)         
any trustees, depositaries, authenticating or paying agents, transfer agents or Registrars or any other agents with respect
to the Securities of such series;

 

    10

    

    

 

                                                         
(13)         
if other than the coin or currency in which the Securities of that series are denominated, the coin or currency in which
payment of the principal of or interest on the Securities of such series shall be payable;

 

                                                         
(14)         
if the principal of, interest on, or other amounts payable under, if any, the Securities of such series are to be payable,
at the election of the Issuer or a holder thereof, in a coin or currency other than that in which the Securities are denominated,
the period or periods within which, and the terms and conditions upon which, such election may be made;

 

                                                         
(15)          whether the Securities of the series will be issuable as Registered Securities (and if so, whether such Securities will
be issuable as Registered Global Securities) or Unregistered Securities (with or without Coupons), or any combination of the foregoing,
any restrictions applicable to the offer, sale, transfer, exchange or delivery of Unregistered Securities or Registered Securities
or the payment of interest thereon and, if other than as provided in ‎‎Section 2.08, the terms upon which Unregistered
Securities of any series may be exchanged for Registered Securities of such series and vice versa;

 

                                                         
(16)         
whether and under what circumstances the Issuer will pay additional amounts on the Securities of the series held by a Person
who is not a U.S. Person in respect of any tax, assessment or governmental charge withheld or deducted and, if so, whether the
Issuer will have the option to redeem such Securities in order to avoid the obligation to pay future additional amounts;

 

                                                         
(17)         
if the Securities of such series are to be issuable in definitive form (whether upon original issue or upon exchange of
a temporary Security of such series) only upon receipt of certain certificates or other documents or satisfaction of other conditions,
then the form and terms of such certificates, documents or conditions;

 

                                                         
(18)         
any addition to, elimination of or other change in the events of default or covenants with respect to the Securities of
such series, including making events of default or covenants inapplicable or changing the remedies available to Holders of the
Securities of such series upon an event of default or a failure by the Issuer or the Guarantor to perform a covenant; and

 

                                                         
(19)         
any other terms of the series, including provisions for payment by wire transfers if any, or modifications of the definition
of Business Day (which terms shall not be inconsistent with the provisions of this Indenture).

 

    11

    

    

 

All Securities of any one series and Coupons,
if any, appertaining thereto, shall be substantially identical, except in the case of Registered Securities as to denomination
and except as may otherwise be provided by or pursuant to the Board Resolution of the Issuer or Officer’s Certificate of
the Issuer referred to above or as set forth in any such indenture supplemental hereto. All Securities of any one series need not
be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by
or pursuant to such Board Resolution, such Officer’s Certificate or in any such indenture supplemental hereto.

 

Section 2.04 Authentication and Delivery
of Securities. The Issuer may deliver Securities of any series having attached thereto appropriate Coupons, if any, executed
by the Issuer to the Trustee for authentication together with the applicable documents referred to below in this Section, and the
Trustee shall thereupon authenticate and deliver such Securities to or upon the order of the Issuer (contained in the Issuer Order
referred to below in this Section) or pursuant to such procedures acceptable to the Trustee and to such recipients as may be specified
from time to time by an Issuer Order. The maturity date, original issue date, interest rate and any other terms of the Securities
of such series and Coupons, if any, appertaining thereto (including Redemption Notice Periods) shall be determined by or pursuant
to such Issuer Order and procedures. In authenticating such Securities and accepting the additional responsibilities under this
Indenture in relation to such Securities, the Trustee shall be entitled to receive (in the case of subparagraphs ‎‎(ii),
‎‎(iii) and ‎‎(iv) below only at or before the time of the first request of the Issuer to the Trustee
to authenticate Securities of such series) and (subject to ‎‎Section
6.01) shall be fully protected in relying upon, unless and until such documents have been superseded or revoked:

 

                                                
(i)           
an Issuer Order requesting such authentication and setting forth delivery instructions if the Securities and Coupons, if
any, are not to be delivered to the Issuer, provided that, with respect to Securities of a series subject to a Periodic
Offering, (a) such Issuer Order may be delivered by the Issuer to the Trustee prior to the delivery to the Trustee of such Securities
for authentication and delivery, (b) the Trustee shall authenticate and deliver Securities of such series for original issue from
time to time, in an aggregate principal amount not exceeding the aggregate principal amount established for such series, pursuant
to an Issuer Order or pursuant to procedures acceptable to the Trustee as may be specified from time to time by an Issuer Order,
(c) the maturity date or dates, original issue date or dates, interest rate or rates and any other terms of Securities of such
series (including Redemption Notice Periods) shall be determined by an Issuer Order or pursuant to such procedures and (d) if provided
for in such procedures, such Issuer Order may authorize authentication and delivery pursuant to oral or electronic instructions
from the Issuer or its

 

    12

    

    

 

duly authorized agent or agents, which oral instructions shall be promptly confirmed in writing;

 

                                                 (ii)           any Board Resolution of the Issuer, Officer’s Certificate of the Issuer and/or executed supplemental indenture referred
to in Sections ‎2.01 and ‎‎2.03 by or pursuant to which the forms and terms of the Securities and Coupons, if any,
were established;

 

                                                
(iii)          an
Officer’s Certificate of the Issuer setting forth the form or forms and terms of the Securities and Coupons, if any, stating
that the form or forms and terms of the Securities and Coupons, if any, have been established pursuant to Section ‎2.01 and
‎Section 2.03 and comply with this Indenture, and covering such other matters as the Trustee may reasonably request; and

 

                                                
(iv)          at the option of the Issuer, either an Opinion of Counsel, or a letter addressed to the Trustee permitting it to rely on
an Opinion of Counsel, substantially to the effect that:

 

                                                                 (A)           
the forms of the Securities and Coupons, if any, have been duly authorized and established in conformity with the provisions
of this Indenture; and

 

                                                                
(B)           
the terms of the Securities have been duly authorized and established in conformity with the provisions of this Indenture,
or, in the case of Securities subject to a Periodic Offering, certain terms of the Securities have been established pursuant to
a Board Resolution of the Issuer, an Officer’s Certificate of the Issuer or a supplemental indenture in accordance with this
Indenture, and when such other terms as are to be established pursuant to procedures set forth in an Issuer Order shall have been
established, all such terms will have been duly authorized by the Issuer and will have been established in conformity with the
provisions of this Indenture; and

 

                                                                 (C)           
the Guarantee has been duly authorized by the Guarantor; and

 

                                                                 (D)           
when the Securities and Coupons, if any, have been executed by the Issuer and authenticated by the Trustee in accordance
with the provisions of this Indenture and delivered to and duly paid for by the purchasers thereof, the Securities and the Guarantee
will be valid and binding obligations of the Issuer and the Guarantor, respectively, enforceable in accordance with their respective
terms, and will be entitled to the benefits of this Indenture.

 

    13

    

    

 

In rendering such opinions, such counsel
may qualify any opinions as to enforceability by stating that such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium and other similar laws affecting the rights and remedies of creditors and is subject to general principles
of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). Such counsel may rely,
as to all matters governed by the laws of jurisdictions other than the State of New York and the federal law of the United States,
upon opinions of other counsel (copies of which shall be delivered to the Trustee), who shall be counsel reasonably satisfactory
to the Trustee, in which case the opinion shall state that such counsel believes he and the Trustee are entitled so to rely. Such
counsel may also state that, insofar as such opinion involves factual matters, he has relied, to the extent he deems proper, upon
certificates of officers of the Issuer, the Guarantor and their subsidiaries and certificates of public officials.

 

The Trustee shall have the right to decline
to authenticate and deliver any Securities under this Section if the Trustee, being advised by counsel, determines that such action
may not lawfully be taken by the Issuer or if the Trustee in good faith by its board of trustees, executive committee, or a trust
committee of directors or trustees or Responsible Officers shall determine that such action would expose the Trustee to personal
liability to existing Holders or would affect the Trustee’s own rights, duties or immunities under the Securities, this Indenture
or otherwise.

 

If the Issuer shall establish pursuant to
‎‎Section 2.03 that the Securities of a series are to be issued in the form of one or more Registered Global Securities,
then the Issuer shall execute and the Trustee shall, in accordance with this Section and the Issuer Order with respect to such
series, authenticate and deliver one or more Registered Global Securities that (i) shall represent and shall be denominated in
an amount equal to the aggregate principal amount of all of the Securities of such series issued and not yet cancelled, (ii) shall
be registered in the name of the Depositary for such Registered Global Security or Securities or the nominee of such Depositary,
(iii) shall be delivered by the Trustee to such Depositary or pursuant to such Depositary’s instructions and (iv) shall bear
a legend substantially to the following effect:

 

“Unless and until it is exchanged in whole
or in part for Securities in definitive registered form, this Security may not be transferred except as a whole by the Depositary
to the nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by
the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary.”

 

    14

    

    

 

Each Depositary designated pursuant to ‎‎Section
2.03 must, at the time of its designation and at all times while it serves as Depositary, be either a clearing agency registered
under the Securities Exchange Act of 1934 and any other applicable statute or regulation or a foreign clearing agency regulated
by a foreign financial regulatory authority as defined in Section 3(a)(52) of the Securities Exchange Act of 1934, including, without
limitation, Euroclear Bank SA/NV and Clearstream Banking, S.A., Luxembourg.

 

Section 2.05 Execution of Securities.
The Securities and, if applicable, each Coupon appertaining thereto shall be signed on behalf of the Issuer by the president,
the treasurer, a managing director, an executive director, a vice president or any Attorney-in-Fact of the Issuer. Such signatures
may be the manual or facsimile signatures of the present or any future such officers. Typographical and other minor errors or defects
in any such signature shall not affect the validity or enforceability of any Security that has been duly authenticated and delivered
by the Trustee.

 

In case any officer of the Issuer who shall
have signed any of the Securities or Coupons, if any, shall cease to be such officer before the Security so signed (or the Security
to which the Coupon so signed appertains) shall be authenticated and delivered by the Trustee or disposed of by the Issuer, such
Security or Coupon nevertheless may be authenticated and delivered or disposed of as though the person who signed such Security
or Coupon had not ceased to be such officer of the Issuer; and any Security or Coupon may be signed on behalf of the Issuer by
such persons as, at the actual date of the execution of such Security or Coupon, shall be the proper officers of the Issuer, although
at the date of the execution and delivery of this Indenture any such person was not such an officer.

 

Section 2.06 Certificate of Authentication.
Only such Securities as shall bear thereon a certificate of authentication substantially in the form hereinbefore recited,
executed by the Trustee by the manual signature of one of its authorized officers, shall be entitled to the benefits of this Indenture
or be valid or obligatory for any purpose. No Coupon shall be entitled to the benefits of this Indenture or shall be valid or obligatory
for any purpose until the certificate of authentication on the Security to which such Coupon appertains shall have been duly executed
by the Trustee. The execution of such certificate by the Trustee upon any Security executed by the Issuer shall be conclusive evidence
that the Security so authenticated has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits
of this Indenture.

 

Section 2.07 Denomination and Date of
Securities; Payments of Interest. The Securities of each series shall be issuable as Registered Securities or Unregistered
Securities in such denominations as shall be specified as contemplated by ‎‎Section 2.03. In the absence of any
such specifications with respect to the Registered Securities of any series, Registered Securities shall be

 

    15

    

    

 

issued in denomination
of $1,000 and any integral multiples thereof. In the absence of any such specifications with respect to the Unregistered Securities
of any series, Unregistered Securities shall be issued in denomination of $1,000 and $5,000. The Securities of each series shall
be numbered, lettered, or otherwise distinguished in such manner or in accordance with such plan as the officers of the Issuer
executing the same may determine as evidenced by the execution and authentication thereof.

 

Each Registered Security shall be dated
the date of its authentication. Each Unregistered Security shall be dated as provided in the resolution or resolutions of the Board
of the Issuer or the supplemental indenture referred to in ‎‎Section 2.03. The Securities of each series shall bear interest,
if any, from the date, and such interest shall be payable on the dates, established as contemplated by ‎‎Section 2.03.

 

The Person in whose name any Registered
Security of any series is registered at the close of business on any record date applicable to a particular series with respect
to any interest payment date for such series shall be entitled to receive the interest, if any, payable on such interest payment
date notwithstanding any transfer or exchange of such Registered Security subsequent to the record date and prior to such interest
payment date, except if and to the extent the Issuer shall default in the payment of the interest due on such interest payment
date for such series, in which case such defaulted interest shall be paid, at the Issuer’s election, (a) to the Persons in
whose names Outstanding Registered Securities for such series are registered at the close of business on a subsequent record date
(which shall be not less than ten business days prior to the date of payment of such defaulted interest) established by notice
given by mail by or on behalf of the Issuer to the holders of Registered Securities not less than 15 days preceding such subsequent
record date or (b) in any lawful manner not inconsistent with the requirements of any securities exchange on which such Registered
Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Issuer to the
Trustee of the proposed payment pursuant to this clause (b), such manner of payment shall be deemed practicable by the Trustee.
The term “record date” as used with respect to any interest payment date (except a date for payment of defaulted
interest) for the Securities of any series shall mean the date specified as such in the terms of the Registered Securities of such
series as contemplated by ‎‎Section 2.03, or, if no such date is so specified, if such interest payment date is the first
day of a calendar month, the fifteenth day of the next preceding calendar month or, if such interest payment date is the fifteenth
day of a calendar month, the first day of such calendar month, whether or not such record date is a Business Day.

 

Any defaulted interest payable in respect
of any Unregistered Security shall be payable pursuant to such procedures as may be satisfactory to the Trustee in such manner
that there is no discrimination as between the holders of

 

    16

    

    

 

Registered Securities and Unregistered Securities of the same series
and notice of the payment date therefor shall be given by the Trustee in the name and at the expense of the Issuer by publication
at least once in an Authorized Newspaper in the Borough of Manhattan, The City of New York, and at least once in an Authorized
Newspaper in London (and, if required by ‎‎Section 3.06, at least once in an Authorized Newspaper in Luxembourg). In case
an Unregistered Security is surrendered for exchange for a Registered Security after the close of business on any record date for
the payment of defaulted interest and before the opening of business on the proposed date of payment of such defaulted interest,
the Coupon appertaining to such surrendered Unregistered Security and due for payment on such proposed date of payment will not
be surrendered with such surrendered Unregistered Security and interest payable on such proposed date of payment will be made only
to the holder of such Coupon on such proposed date.

 

Section 2.08 Registration, Transfer and
Exchange. The Issuer will keep or cause to be kept at an office or agency to be maintained for the purpose as provided in ‎‎Section
3.02 for each series of Securities a register or registers in which, subject to such reasonable regulations as it may prescribe,
it will register, and will register the transfer of, or cause the registration of the transfer of, Registered Securities as in
this Article provided. Such register shall be in written form in the English language or in any other form capable of being converted
into such form within a reasonable time. At all reasonable times such register or registers shall be open for inspection by the
Trustee.

 

Upon due presentation for registration of
transfer of any Registered Security of any series at any such office or agency to be maintained for the purpose as provided in
‎‎Section 3.02, the Issuer shall execute and the Trustee shall authenticate and deliver in the name of the transferee or
transferees a new Registered Security or Registered Securities of the same series, maturity date, interest rate and original issue
date in authorized denominations for a like aggregate principal amount.

 

Unregistered Securities (except for any
temporary global Unregistered Securities) and Coupons (except for Coupons attached to any temporary global Unregistered Securities)
shall be transferable by delivery.

 

At the option of the Holder thereof, Registered
Securities of any series (other than a Registered Global Security, except as set forth below) may be exchanged for a Registered
Security or Registered Securities of such series in other authorized denominations, in an equal aggregate principal amount, upon
surrender of such Registered Securities to be exchanged at the office or agency of the Issuer that shall be maintained for such
purpose in accordance with ‎‎Section 3.02 and upon payment, if the Issuer shall so require, of the charges hereinafter
provided. If the Securities of any series are issued in both registered and unregistered form, except as otherwise specified pursuant
to ‎‎Section 2.03, at the

 

    17

    

    

 

option of the Holder thereof, Unregistered Securities of any series may be exchanged for Registered
Securities of such series, maturity date and interest rate of any authorized denominations and of a like aggregate principal amount,
upon surrender of such Unregistered Securities to be exchanged at the agency of the Issuer that shall be maintained for such purpose
in accordance with ‎‎Section 3.02, with, in the case of Unregistered Securities that have Coupons attached, all unmatured
Coupons and all matured Coupons in default appertaining thereto, and upon payment, if the Issuer shall so require, of the charges
hereinafter provided. At the option of the Holder thereof, if Unregistered Securities of any series, maturity date, interest rate
and original issue date are issued in more than one authorized denomination, except as otherwise specified pursuant to ‎‎Section
2.03, such Unregistered Securities may be exchanged for Unregistered Securities of such series, maturity date, interest rate and
original issue date of other authorized denominations and of a like aggregate principal amount, upon surrender of such Unregistered
Securities to be exchanged at the agency of the Issuer that shall be maintained for such purpose in accordance with ‎‎Section
3.02 or as specified pursuant to ‎‎Section 2.03, with, in the case of Unregistered Securities that have Coupons attached,
all unmatured Coupons and all matured Coupons in default thereto appertaining, and upon payment, if the Issuer shall so require,
of the charges hereinafter provided. Unless otherwise specified pursuant to ‎‎Section 2.03, Registered Securities of any
series may not be exchanged for Unregistered Securities of such series. Whenever any Securities and the Coupons appertaining thereto,
if any, are so surrendered for exchange, the Issuer shall execute, and the Trustee shall authenticate and deliver, the Securities
and the Coupons appertaining thereto, if any, which the Holder making the exchange is entitled to receive.

 

Notwithstanding the foregoing, in case an
Unregistered Security of any series is surrendered at any such office or agency in exchange for a Registered Security of the same
series after the close of business at such office or agency on any record date and before the opening of business at such office
or agency on the relevant interest payment date, such Unregistered Security shall be surrendered without the Coupon relating to
such interest payment date or proposed date of payment, as the case may be.

 

All Registered Securities presented for
registration of transfer, exchange, redemption or payment shall (if so required by the Issuer or the Trustee) be duly endorsed
by, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Issuer and the Trustee duly
executed by, the Holder or his attorney duly authorized in writing.

 

The Issuer may require payment of a sum
sufficient to cover any tax or other governmental charge that may be imposed in connection with any exchange or registration of
transfer of Securities. No service charge shall be made for any such transaction.

 

    18

    

    

 

The Issuer shall not be required to exchange
or register a transfer of (a) any Securities of any series for a period of 15 days next preceding the first mailing of notice of
redemption of Securities of such series to be redeemed, (b) any Securities selected, called or being called for redemption in whole
or in part, except, in the case of any Security where public notice has been given that such Security is to be redeemed in part,
the portion thereof not so to be redeemed and except that an Unregistered Security may be exchanged for a Registered Security of
the same series if such Registered Security is immediately surrendered for redemption or (c) any Securities if the Holder thereof
has exercised any right to require the Issuer to repurchase such Securities, in whole or in part, except, in the case of any Security
to be repurchased in part, the portion thereof not so to be repurchased.

 

Notwithstanding any other provision of this
‎‎Section 2.08, unless and until it is exchanged in whole or in part for Securities in definitive registered form, a Registered
Global Security representing all or a portion of the Securities of a series may not be transferred except as a whole by the Depositary
for such series to a nominee of such Depositary or by a nominee of such Depositary to such Depositary or another nominee of such
Depositary or by such Depositary or any such nominee to a successor Depositary for such series or a nominee of such successor Depositary.

 

If at any time the Depositary for any Registered
Securities of a series represented by one or more Registered Global Securities notifies the Issuer that it is unwilling or unable
to continue as Depositary for such Registered Securities or if at any time the Depositary for such Registered Securities shall
no longer be eligible under ‎‎Section 2.04, the Issuer shall appoint a successor Depositary eligible under ‎‎Section
2.04 with respect to such Registered Securities. If a successor Depositary eligible under ‎‎Section 2.04 for such Registered
Securities is not appointed by the Issuer within 90 days after the Issuer receives such notice or becomes aware of such ineligibility,
the Issuer’s election pursuant to ‎‎Section 2.03 that such Registered Securities be represented by one or more Registered
Global Securities shall no longer be effective and the Issuer will execute, and the Trustee, upon receipt of an Officer’s
Certificate for the authentication and delivery of definitive Securities of such series, will authenticate and deliver, Securities
of such series in definitive registered form without coupons, in any authorized denominations, in an aggregate principal amount
equal to the principal amount of the Registered Global Security or Securities representing such Registered Securities in exchange
for such Registered Global Security or Securities.

 

The Issuer may at any time and in its sole
discretion determine that the Registered Securities of any series issued in the form of one or more Registered Global Securities
shall no longer be represented by a Registered Global Security or Securities. In such event the Issuer will execute, and the Trustee,
upon receipt of an Officer’s Certificate for the authentication and delivery of definitive

 

    19

    

    

 

Securities of such series, will
authenticate and deliver, Securities of such series in definitive registered form without coupons, in any authorized denominations,
in an aggregate principal amount equal to the principal amount of the Registered Global Security or Securities representing such
Registered Securities, in exchange for such Registered Global Security or Securities.

 

If specified by the Issuer pursuant to ‎‎Section
2.03 with respect to Securities represented by a Registered Global Security, the Depositary for such Registered Global Security
may surrender such Registered Global Security in exchange in whole or in part for Securities of the same series in definitive registered
form on such terms as are acceptable to the Issuer and such Depositary. Thereupon, the Issuer shall execute, and the Trustee shall
authenticate and deliver, without service charge,

 

                                                   (i)           
to the Person specified by such Depositary a new Registered Security or Securities of the same series, of any authorized
denominations as requested by such Person, in an aggregate principal amount equal to and in exchange for such Person’s beneficial
interest in the Registered Global Security; and

 

                                                  
(ii)           to such Depositary a new Registered Global Security in a denomination equal to the difference, if any, between the principal
amount of the surrendered Registered Global Security and the aggregate principal amount of Registered Securities authenticated
and delivered pursuant to clause ‎2.08(i) above.

 

Upon the exchange of a Registered Global
Security for Securities in definitive registered form without coupons, in authorized denominations, such Registered Global Security
shall be cancelled by the Trustee or an agent of the Issuer or the Trustee. Securities in definitive registered form without coupons
issued in exchange for a Registered Global Security pursuant to this ‎‎Section 2.08 shall be registered in such names and
in such authorized denominations as the Depositary for such Registered Global Security, pursuant to instructions from its direct
or indirect participants or otherwise, shall instruct the Trustee or an agent of the Issuer or the Trustee. The Trustee or such
agent shall deliver such Securities to or as directed by the Persons in whose names such Securities are so registered.

 

All Securities issued upon any transfer
or exchange of Securities shall be valid obligations of the Issuer (and the Guarantee on such Securities shall be a valid obligation
of the Guarantor), evidencing the same debt, and entitled to the same benefits under this Indenture, as the Securities surrendered
upon such transfer or exchange.

 

Notwithstanding anything herein or in the
terms of any series of Securities to the contrary, neither the Issuer nor the Trustee (which shall rely on an Officer’s

 

    20

    

    

 

Certificate
and an Opinion of Counsel) shall be required to exchange any Unregistered Security for a Registered Security if such exchange would
result in adverse United States federal income tax consequences to the Issuer or the Guarantor (including, without limitation,
the inability of the Issuer to deduct from its income, as computed for United States federal income tax purposes, the interest
payable on the Unregistered Securities) under then applicable United States federal income tax laws.

 

Section 2.09 Mutilated, Defaced, Destroyed,
Lost and Stolen Securities. In case any temporary or definitive Security or any Coupon appertaining to any Security shall become
mutilated, defaced or be destroyed, lost or stolen, the Issuer in its discretion may execute, and upon the written request of any
officer of the Issuer, the Trustee shall authenticate and deliver, a new Security of the same series, maturity date, interest rate
and original issue date, bearing a number or other distinguishing symbol not contemporaneously outstanding, in exchange and substitution
for the mutilated or defaced Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen with Coupons
corresponding to the Coupons appertaining to the Security so mutilated, defaced, destroyed, lost or stolen, or in exchange or substitution
for the Security to which such mutilated, defaced, destroyed, lost or stolen Coupon appertained, with Coupons appertaining thereto
corresponding to the Coupons so mutilated, defaced, destroyed, lost or stolen. In every case the applicant for a substitute Security
or Coupon shall furnish to the Issuer, to the Guarantor and to the Trustee and any agent of the Issuer, the Guarantor or the Trustee
such security or indemnity as may be required by them to indemnify and defend and to save each of them harmless and, in every case
of destruction, loss or theft, evidence to their satisfaction of the destruction, loss or theft of such Security or Coupon and
of the ownership thereof.

 

Upon the issuance of any substitute Security
or Coupon, the Issuer may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed
in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. In case any Security
or Coupon that has matured or is about to mature or has been called for redemption in full, as the case may be, shall become mutilated
or defaced or be destroyed, lost or stolen, the Issuer may, instead of issuing a substitute Security or Coupon, pay or authorize
the payment of the same (without surrender thereof except in the case of a mutilated or defaced Security or Coupon), if the applicant
for such payment shall furnish to the Issuer, to the Guarantor and to the Trustee and any agent of the Issuer, the Guarantor or
the Trustee such security or indemnity as any of them may require to save each of them harmless, and, in every case of destruction,
loss or theft, the applicant shall also furnish to the Issuer and the Trustee and any agent of the Issuer or the Trustee evidence
to their satisfaction of the destruction, loss or theft of such Security or Coupon and of the ownership thereof.

 

    21

    

    

 

Every substitute Security or Coupon of any
series issued pursuant to the provisions of this Section by virtue of the fact that any such Security or Coupon is destroyed, lost
or stolen shall constitute an additional contractual obligation of the Issuer, whether or not the destroyed, lost or stolen Security
or Coupon shall be at any time enforceable by anyone and shall be entitled to all the benefits of (but shall be subject to all
the limitations of rights set forth in) this Indenture equally and proportionately with any and all other Securities or Coupons
of such series duly authenticated and delivered hereunder. All Securities and Coupons shall be held and owned upon the express
condition that, to the extent permitted by law, the foregoing provisions are exclusive with respect to the replacement or payment
of mutilated, defaced or destroyed, lost or stolen Securities and Coupons and shall preclude any and all other rights or remedies
notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment of
negotiable instruments or other securities without their surrender.

 

Section 2.10 Cancellation of Securities;
Destruction Thereof. All Securities and Coupons surrendered for payment, retirement, redemption, registration of transfer or
exchange, or for credit against any payment in respect of a sinking or analogous fund, if surrendered to the Issuer or any agent
of the Issuer or the Trustee, shall be delivered to the Trustee for cancellation or, if surrendered to the Trustee, shall be cancelled
by it; and no Securities or Coupons shall be issued in lieu thereof except as expressly permitted by any of the provisions of this
Indenture. The Trustee shall destroy cancelled Securities and Coupons held by it and deliver a certificate of destruction to the
Issuer. If the Issuer shall acquire any of the Securities or Coupons, such acquisition shall not operate as a redemption or satisfaction
of the indebtedness represented by such Securities or Coupons unless and until the same are delivered to the Trustee for cancellation.

 

Section 2.11 Temporary Securities. Pending
the preparation of definitive Securities for any series, the Issuer may execute and the Trustee shall authenticate and deliver
temporary Securities for such series (printed, lithographed, typewritten or otherwise reproduced, in each case in form satisfactory
to the Trustee). Temporary Securities of any series shall be issuable as Registered Securities without Coupons, or as Unregistered
Securities with or without Coupons attached thereto, of any authorized denomination, and substantially in the form of the definitive
Securities of such series but with such omissions, insertions and variations as may be appropriate for temporary Registered Securities,
all as may be determined by the Issuer with the concurrence of the Trustee. Temporary Securities may contain such references to
any provisions of this Indenture as may be appropriate. Every temporary Security shall be executed by the Issuer and be authenticated
by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities.
Without unreasonable delay the Issuer shall execute and shall furnish definitive Securities of such series and thereupon temporary
Registered Securities of such series may be surrendered in exchange therefor without charge at each office or

 

    22

    

    

 

agency to be maintained
by the Issuer for that purpose pursuant to ‎‎Section 3.02 and in the case of Unregistered Securities together with
any unmatured Coupons and any matured Coupons in default appertaining thereto, at any agency maintained by the Issuer for such
purpose as specified pursuant to ‎‎Section 2.03, and the Trustee shall authenticate and deliver in exchange for
such temporary Securities of such series a like aggregate principal amount of definitive Securities of the same series having authorized
denominations and, in the case of Unregistered Securities, having attached thereto any appropriate Coupons. Until so exchanged,
the temporary Securities of any series and any unmatured Coupons appertaining thereto shall be entitled to the same benefits under
this Indenture as definitive Securities of such series and any unmatured Coupons appertaining thereto unless otherwise established
pursuant to ‎‎Section 2.03. The provisions of this Section are subject to any restrictions or limitations on the
issue and delivery of temporary Unregistered Securities of any series that may be established pursuant to ‎‎Section
2.03 (including any provision that Unregistered Securities of such series initially be issued in the form of a single global Unregistered
Security to be delivered to a depositary or agency located outside the United States and the procedures pursuant to which definitive
or global Unregistered Securities of such series would be issued in exchange for such temporary global Unregistered Security).

 

Section 2.12 Calculation Agent Determinations.
Except as otherwise specified as contemplated by ‎Section 2.03, with respect to the Securities of each series, a calculation
agent appointed by the Issuer shall make all necessary calculations and determinations in connection with the Securities of such
series, including calculations and determinations relating to any payments on the Securities of such series. All determinations
made by such calculation agent shall, in the absence of manifest error, be conclusive for all purposes and binding on the Issuer,
the Guarantor and the Holders of Securities of such series.

 

Article
3

Covenants of the Issuer and the Guarantor

 

Section 3.01 Payment of Principal and
Interest. The Issuer covenants and agrees for the benefit of each series of Securities that it will duly and punctually pay
or cause to be paid the principal of, and interest on, each of the Securities of such series (together with any additional amounts
payable pursuant to the terms of such Securities) at the place or places, at the respective times and in the manner provided in
such Securities and in the Coupons, if any, appertaining thereto and in this Indenture. The interest on Unregistered Securities
with Coupons attached (together with any additional amounts payable pursuant to the terms of such Unregistered Securities) shall
be payable only upon presentation and surrender of the several Coupons for such interest installments as are evidenced thereby
as they severally mature. Except as specified as contemplated in ‎‎Section 2.03, the

 

    23

    

    

 

interest on any temporary Unregistered
Securities (together with any additional amounts payable pursuant to the terms of such temporary Unregistered Securities) shall
be paid, as to the installments of interest evidenced by Coupons attached thereto, if any, only upon presentation and surrender
thereof, and, as to the other installments of interest, if any, only upon presentation of such Securities for notation thereon
of the payment of such interest, in each case subject to any restrictions that may be established pursuant to ‎‎Section
2.03. The interest on Registered Securities (together with any additional amounts payable pursuant to the terms of such Securities)
shall be payable only to or upon the written order of the Holders thereof and, at the option of the Issuer, may be paid by wire
transfer or by mailing checks for such interest payable to or upon the written order of such Holders at their last addresses as
they appear on the registry books of the Issuer.

 

Section 3.02 Offices for Payments, Etc.
So long as any Registered Securities are authorized for issuance pursuant to this Indenture or are outstanding hereunder, the
Issuer will maintain in the Borough of Manhattan, The City of New York, the following for each series: an office or agency (a)
where the Registered Securities may be presented for payment and (b) where the Registered Securities may be presented for registration
of transfer and for exchange as in this Indenture provided.

 

The Issuer will maintain one or more offices
or agencies in a city or cities located outside the United States (including any city in which such an agency is required to be
maintained under the rules of any stock exchange on which the Securities of such series are listed) where the Unregistered Securities,
if any, of each series and Coupons, if any, appertaining thereto may be presented and surrendered for payment. No payment on any
Unregistered Security or Coupon will be made upon presentation of such Unregistered Security or Coupon at an agency of the Issuer
within the United States nor will any payment be made by transfer to an account in, or by mail to an address in, the United States
unless pursuant to applicable United States laws and regulations then in effect, such payment can be made without adverse tax consequences
to the Issuer or the Guarantor. Notwithstanding the foregoing, payments in Dollars on Unregistered Securities of any series and
Coupons appertaining thereto which are payable in Dollars may be made at an agency of the Issuer maintained in the Borough of Manhattan,
The City of New York if such payment in Dollars at each agency maintained by the Issuer outside the United States for payment on
such Unregistered Securities is illegal or effectively precluded by exchange controls or other similar restrictions.

 

The Issuer will maintain in the Borough
of Manhattan, The City of New York, an office or agency where notices and demands to or upon the Issuer or the Guarantor in respect
of the Securities of any series, the Coupons appertaining thereto or this Indenture may be served.

 

    24

    

    

 

The Issuer will give to the Trustee written
notice of the location of any such office or agency and of any change of location thereof. In case the Issuer shall fail to maintain
any such office or agency or shall fail to give such notice of the location or of any change in the location thereof, presentations
and demands may be made and notices may be served at the Corporate Trust Office.

 

The Issuer or the Guarantor may from time
to time designate one or more additional offices or agencies where the Securities of a series and any Coupons appertaining thereto
may be presented for payment, where the Securities of that series may be presented for exchange as provided in this Indenture and
pursuant to ‎‎Section 2.03 and where the Registered Securities of that series may be presented for registration of transfer
as in this Indenture provided, and the Issuer or the Guarantor, as the case may be, may from time to time rescind any such designation,
as the Issuer or the Guarantor, as the case may be, may deem desirable or expedient; provided, however, that no such designation
or rescission shall in any manner relieve the Issuer of its obligation to maintain the agencies provided for in this Section. The
Issuer, or the Guarantor, as the case may be, will give to the Trustee prompt written notice of any such designation or rescission
thereof.

 

Section 3.03 Appointment to Fill a Vacancy
in Office of Trustee. The Issuer, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in
the manner provided in ‎‎Section 6.10, a Trustee, so that there shall at all times be a Trustee with respect to
each series of Securities hereunder.

 

Section 3.04 Paying Agents. Whenever
the Issuer or the Guarantor shall appoint a paying agent other than the Trustee with respect to the Securities of any series, it
will cause such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee,
subject to the provisions of this Section,

 

(a)           that
it will hold all sums received by it as such agent for the payment of the principal of or interest on the Securities of such series
(whether such sums have been paid to it by the Issuer, the Guarantor or any other obligor on the Securities of such series) in
trust for the benefit of the holders of the Securities of such series or the Coupons appertaining thereto, if any, or of the Trustee,
and

 

(b)           that it will give the Trustee notice of any failure by the Issuer, the Guarantor or any other obligor on the Securities
of such series to make any payment of the principal of or interest on the Securities of such series when the same shall be due
and payable.

 

The Issuer or the Guarantor will, on or
prior to each due date of the principal of or interest on the Securities of such series, deposit with the paying agent a sum or
sums in the required currencies sufficient to pay such principal or

 

    25

    

    

 

interest so becoming due, and (unless such paying agent is
the Trustee) the Issuer or the Guarantor, as the case may be, will promptly notify the Trustee of any failure to take such action.

 

If the Issuer or the Guarantor shall act
as its own paying agent with respect to the Securities of any series, it will, on or before each due date of the principal of or
interest on the Securities of such series, set aside, segregate and hold in trust for the benefit of the Holders of the Securities
of such series or the Coupons appertaining thereto a sum sufficient to pay such principal or interest so becoming due. The Issuer
or the Guarantor, as the case may be, will promptly notify the Trustee of any failure to take such action.

 

Anything in this Section to the contrary
notwithstanding, but subject to ‎‎Section 10.01, the Issuer or the Guarantor may at any time, for the purpose of obtaining
a satisfaction and discharge with respect to one or more or all series of Securities hereunder, or for any other reason, pay or
cause to be paid to the Trustee all sums held in trust for any such series by the Issuer, the Guarantor or any paying agent hereunder,
as required by this Section, such sums to be held by the Trustee upon the trusts herein contained.

 

Anything in this Section to the contrary
notwithstanding, the agreement to hold sums in trust as provided in this Section is subject to the provisions of Sections ‎‎10.03
and ‎‎10.04.

 

Section 3.05 Written Statement to Trustee.
Each of the Issuer and the Guarantor will deliver to the Trustee on or before May 1 in each year (beginning with May 1, 2016)
a written statement, signed by one of its Officers (which need not comply with ‎‎Section
11.05) pursuant to Section 314 of the Trust Indenture Act of 1939 stating that in the course of the performance of his or
her duties as an Officer of the Issuer or the Guarantor, as the case may be, he or she would normally have knowledge of any default
by the Issuer or the Guarantor, as the case may be, in the performance of any covenants contained in this Indenture, stating whether
or not he or she has knowledge of any such default and, if so specifying each such default of which the signer has knowledge and
the nature thereof.

 

Section 3.06 Luxembourg Publications.
In the event of the publication of any notice pursuant to Section ‎‎5.11,
‎‎6.10(a), ‎‎6.11, ‎‎8.02,
‎‎10.04, ‎‎12.02 or ‎‎12.05, the party making such publication in the Borough of Manhattan,
The City of New York and London shall also, to the extent that notice is required to be given to Holders of Securities of any series
by applicable Luxembourg law or stock exchange regulation, as evidenced by an Officer’s Certificate of the Issuer or the
Guarantor, as applicable, delivered to such party, make a similar publication in Luxembourg.

 

    26

    

    

 

Article
4

Securityholders Lists and Reports by the
Issuer, the Guarantor and the Trustee

 

Section 4.01 Issuer and Guarantor to
Furnish Trustee Information as to Names and Addresses of Securityholders. The Guarantor covenants and agrees that it will cause
the Issuer to furnish or cause to be furnished, and the Issuer covenants and agrees that it will furnish or cause to be furnished,
to the Trustee a list in such form as the Trustee may reasonably require of the names and addresses of the Holders of the Registered
Securities of such series pursuant to Section 312 of the Trust Indenture Act of 1939:

 

(a)           semiannually, no later than January 15 and July 15 in each year, and

 

(b)           at
such other times as the Trustee may request in writing, within 30 days after receipt by the Issuer or the Guarantor, as applicable,
of any such request as of a date not more than 15 days prior to the time such information is furnished,

 

provided that if and so long as the Trustee shall be
the Registrar for such series and all of the Securities of any series are Registered Securities, such list shall not be required
to be furnished.

 

Section 4.02 Preservation and Disclosure
of Securityholders Lists. (a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information
as to the names and addresses of the holders of each series of Securities contained in the most recent list furnished to it as
provided in ‎‎Section 4.01. The Trustee may destroy
any list furnished to it as provided in ‎‎Section 4.01
upon receipt of a new list so furnished.

 

(b)           The rights of Holders to communicate with other Holders with respect to the Indenture or the Securities are as provided
by the Trust Indenture Act of 1939.

 

(c)           None
of the Issuer, the Guarantor or the Trustee will be held accountable by reason of any disclosure of information as to names and
addresses of Holders made pursuant to the Trust Indenture Act of 1939.

 

Section 4.03 Reports by the Issuer and
Guarantor. The Issuer and Guarantor shall provide the Trustee and file with the Commission, and transmit to Holders, such information,
documents and other reports as may be required by the Trust Indenture Act of 1939; provided that any such information, documents
or reports filed electronically with the Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 shall
be deemed filed with, and delivered to, the Trustee

 

    27

    

    

 

and transmitted to the Holders at the same time as filed with the Commission.
Delivery of such reports, information and documents to the Trustee and transmission thereof to the Holders is for informational
purposes only and shall not constitute a representation or warranty as to the accuracy or completeness of the reports, information
or documents. The Trustee’s receipt of such reports, information or documents shall not constitute constructive notice of
any information contained therein or determinable from information contained therein, including the Issuer’s or the Guarantor’s
compliance with any of its covenants hereunder (as to which the Trustee is entitled to conclusively rely exclusively on an Officer’s
Certificate).

 

Section 4.04 Reports by the Trustee.
Any Trustee’s report required under Section 313(a) of the Trust Indenture Act of 1939 shall be transmitted on or before
January 15 in each year beginning January 15, 2017, as provided in Section 313(c) of the Trust Indenture Act of 1939, so long as
any Securities are Outstanding hereunder, and shall be dated as of a date convenient to the Trustee no more than 60 days prior
thereto. The Issuer shall file a copy of each such report, at the time of such transmission, with each stock exchange upon which
any Securities are listed and with the Commission in accordance with Section 313(d) of the Trust Indenture Act of 1939.

 

Article
5

Remedies of the Trustee and Securityholders on Event of Default

 

Section 5.01 Event of Default Defined;
Acceleration of Maturity; Waiver of Default. Except as may be otherwise provided pursuant to ‎Section 2.03 for Securities
of any series, “Event of Default” with respect to Securities of any series wherever used herein, means each
one of the following events which shall have occurred and be continuing (whatever the reason for such Event of Default and whether
it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court
or any order, rule or regulation of any administrative or governmental body, except as provided in clause (f)):

 

                                              
(a)           
default in the payment of any installment of interest upon any of the Securities of such series as and when the same shall
become due and payable, and continuance of such default for a period of 30 days; or

 

                                              
(b)           
default in the payment of all or any part of the principal or other amounts on any of the Securities of such series as and
when the same shall become due and payable either at maturity, upon any redemption, by declaration or otherwise; or

 

                                              
(c)           
default in the performance, or breach, of any covenant or warranty of the Issuer in respect of the Securities of such series
(other than

 

    28

    

    

 

a covenant or warranty in respect of the Securities of such series a default in whose performance or whose breach is
elsewhere in this Section specifically dealt with), and continuance of such default or breach for a period of 90 days after there
has been given, by registered or certified mail, to the Issuer and the Guarantor, by the Trustee or to the Issuer, the Guarantor
and the Trustee by the holders of at least 25% in aggregate principal amount of the Outstanding Securities of all series affected
thereby, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice
of Default” hereunder; or

 

                                              
(d)           
a court having jurisdiction in the premises shall enter a decree or order for relief in respect of the Issuer in an involuntary
case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or appointing a receiver, liquidator,
assignee, custodian, trustee, sequestrator (or similar official) of the Issuer or for any substantial part of its property or ordering
the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of 60 consecutive
days; or

 

                                              
(e)           
the Issuer shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter
in effect, or consent to the entry of an order for relief in an involuntary case under any such law, or consent to the appointment
or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of the Issuer
or for any substantial part of its property, or make any general assignment for the benefit of creditors; or

 

                                              
(f)            
the Guarantee ceases to be in full force and effect, other than in accordance with the terms of the Indenture, or the Guarantor
denies or disaffirms its obligations under the Guarantee, provided that no Event of Default described in this clause ‎(f)
of ‎Section 5.01 shall occur as a result of, or because it is related directly or indirectly to, the insolvency of the Guarantor
or the commencement of any proceedings relative to the Guarantor under Title 11 of the United States Code, or the appointment of
a receiver for the Guarantor under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 or the Federal
Deposit Insurance Corporation having separately repudiated the Guarantee in any receivership of the Guarantor, or the commencement
of any other applicable federal or state bankruptcy, insolvency, resolution or other similar law, or a receiver, assignee or trustee
in bankruptcy or reorganization, liquidator, sequestrator or similar official having been appointed for or having taken possession
of the Guarantor or its property, or the institution of any other comparable judicial or regulatory

 

    29

    

    

 

proceedings relative to the
Guarantor, or to the creditors or property of the Guarantor; or

 

                                              
(g)           
any other Event of Default provided in the supplemental indenture under which such series of Securities is issued or in
the form of Security for such series.

 

If an Event of Default described in clauses ‎(a), ‎‎(b),
‎‎(c), (f) or ‎(g) above occurs and is continuing, then, and in each and every such case, except for any series the
principal of which shall have already become due and payable, either the Trustee or the Holders of not less than 25% in aggregate
principal amount of the Securities of all series affected thereby then Outstanding hereunder (treated as one class), by notice
in writing to the Issuer and the Guarantor (and to the Trustee if given by Securityholders), may declare the entire principal (or,
if the Securities of any such affected series are Original Issue Discount Securities, such portion of the principal amount as may
be specified in the terms of such series) of all Securities of such affected series and the interest accrued thereon, if any, to
be due and payable immediately, and upon any such declaration the same shall become immediately due and payable. If an Event of
Default described in clauses ‎‎(d) or ‎‎(e) occurs and is continuing, then and in each and every such case, unless
the principal of all the Securities shall have already become due and payable, the entire principal (or, if any Securities are
Original Issue Discount Securities, such portion of the principal as may be specified in the terms thereof) of all the Securities
then Outstanding and interest accrued thereon, if any, shall automatically, and without any declaration or other action on the
part of the Trustee or any Holder, become immediately due and payable.

 

The foregoing provisions, however, are subject
to the condition that if, at any time after the principal (or, if the Securities are Original Issue Discount Securities, such portion
of the principal as may be specified in the terms thereof) of the Securities of any series (or of all the Securities, as the case
may be) shall have been so declared, or automatically become, due and payable, and before any judgment or decree for the payment
of the monies due shall have been obtained or entered as hereinafter provided, the Issuer or the Guarantor shall pay or shall deposit
with the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of such series (or of all
the Securities, as the case may be) and the principal of any and all Securities of each such series (or of all the Securities,
as the case may be) which shall have become due otherwise than by acceleration (with interest upon such principal and, to the extent
that payment of such interest is enforceable under applicable law, on overdue installments of interest, at the same rate as the
rate of interest or Yield to Maturity (in the case of Original Issue Discount Securities) specified in the Securities of each such
series (or at the respective rates of interest or Yields to Maturity of all the Securities, as the case may be) to the date of
such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the Trustee, its agents, attorneys

 

    30

    

    

 

and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee except as a result of negligence
or willful misconduct, and if any and all Events of Default under the Indenture, other than the non-payment of the principal of
Securities which shall have become due by acceleration, shall have been cured, waived or otherwise remedied as provided herein,
then and in every such case the Holders of a majority in aggregate principal amount of all the Securities of each such series (or
of all the Securities, as the case may be) then Outstanding (in each case treated as one class), by written notice to the Issuer,
the Guarantor and the Trustee, may waive all defaults with respect to each such series (or with respect to all the Securities,
as the case may be) and rescind and annul such declaration or automatic acceleration, as the case may be, and its consequences,
but no such waiver or rescission and annulment shall extend to or shall affect any subsequent default or shall impair any right
consequent thereon.

 

For all purposes under this Indenture, if
a portion of the principal of any Original Issue Discount Securities shall have been accelerated and declared due and payable pursuant
to the provisions hereof, then, from and after such declaration, unless such declaration has been rescinded and annulled, the principal
amount of such Original Issue Discount Securities shall be deemed, for all purposes hereunder, to be such portion of the principal
thereof as shall be due and payable as a result of such acceleration, and payment of such portion of the principal thereof as shall
be due and payable as a result of such acceleration, together with interest, if any, thereon and all other amounts owing thereunder,
shall constitute payment in full of such Original Issue Discount Securities.

 

Section 5.02 Collection of Indebtedness
by Trustee; Trustee May Prove Debt. The Issuer covenants that (a) in case default shall be made in the payment of any installment
of interest on any of the Securities of any series when such interest shall have become due and payable, and such default shall
have continued for a period of 30 days or (b) in case default shall be made in the payment of all or any part of the principal
of any of the Securities of any series when the same shall have become due and payable, whether upon maturity of the Securities
of such series or upon any redemption or by declaration or otherwise, then upon demand of the Trustee, the Issuer will pay to the
Trustee for the benefit of the Holders of the Securities of such series the whole amount that then shall have become due and payable
on all Securities of such series, and such Coupons, if any, for principal or interest, as the case may be (with interest to the
date of such payment upon the overdue principal and, to the extent that payment of such interest is enforceable under applicable
law, on overdue installments of interest at the same rate as the rate of interest or Yield to Maturity (in the case of Original
Issue Discount Securities) specified in the Securities of such series); and in addition thereto, such further amount as shall be
sufficient to cover the costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor
Trustee, their respective agents, attorneys and counsel, and any

 

    31

    

    

 

expenses and liabilities incurred, and all advances made, by the
Trustee and each predecessor Trustee except as a result of its negligence or willful misconduct.

 

Until such demand is made by the Trustee,
the Issuer may pay the principal of and interest on the Securities of any series to the registered holders, whether or not the
principal of, and interest on, if any, the Securities of such series be overdue.

 

In case the Issuer shall fail forthwith
to pay such amounts upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered
to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute
any such action or proceedings to judgment or final decree, and may enforce any such judgment or final decree against the Issuer
or other obligor upon the Securities and collect in the manner provided by law out of the property of the Issuer or other obligor
upon the Securities, wherever situated, the monies adjudged or decreed to be payable.

 

In case there shall be pending proceedings
relative to the Issuer under Title 11 of the United States Code or any other applicable Federal or state bankruptcy, insolvency
or other similar law, or in case a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or similar
official shall have been appointed for or taken possession of the Issuer or its property, or in case of any other comparable judicial
proceedings relative to the Issuer, or to the creditors or property of the Issuer, the Trustee, irrespective of whether the principal
of any Securities of any series shall then be due and payable as therein expressed or by declaration or otherwise and irrespective
of whether the Trustee shall have made any demand pursuant to the provisions of this Section, shall be entitled and empowered,
by intervention in such proceedings or otherwise:

 

(a)           
to file and prove a claim or claims for the whole amount of principal and interest (or, if the Securities of any series
are Original Issue Discount Securities, such portion of the principal amount as may be specified in the terms of such series)
owing and unpaid in respect of the Securities of any series, and to file such other papers or documents as may be necessary or
advisable in order to have the claims of the Trustee (including any claim for reasonable compensation to the Trustee and each
predecessor Trustee, and their respective agents, attorneys and counsel, and for reimbursement of all expenses and liabilities
incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of negligence or willful misconduct)
and of the Securityholders allowed in any judicial proceedings relative to the Issuer, or to the creditors or property of the
Issuer,

 

(b)           
unless prohibited by applicable law and regulations, to vote on behalf of the holders of the Securities of any series in
any election of a trustee or a

 

    32

    

    

 

standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings
or Person performing similar functions in comparable proceedings, and

 

(c)           
to collect and receive any monies or other property payable or deliverable on any such claims, and to distribute all amounts
received with respect to the claims of the Securityholders and of the Trustee on their behalf; and any trustee, receiver, or liquidator,
custodian or other similar official is hereby authorized by each of the Securityholders to make payments to the Trustee, and,
in the event that the Trustee shall consent to the making of payments directly to the Securityholders, to pay to the Trustee such
amounts as shall be sufficient to cover reasonable compensation to the Trustee, each predecessor Trustee and their respective
agents, attorneys and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and each
predecessor Trustee except as a result of negligence or willful misconduct, and all other amounts due the Trustee and each predecessor
Trustee pursuant to ‎‎Section 6.06.

 

Nothing herein contained shall be deemed
to authorize the Trustee to exercise any remedy against the Issuer or the Guarantor as a result of, or because it is related directly
or indirectly to, the insolvency of the Guarantor or the commencement of any proceedings relative to the Guarantor under Title
11 of the United States Code, or the appointment of a receiver for the Guarantor under Title II of the Dodd-Frank Wall Street Reform
and Consumer Protection Act of 2010 or the Federal Deposit Insurance Corporation having separately repudiated the Guarantee in
any receivership of the Guarantor, or the commencement of any other applicable federal or state bankruptcy, insolvency, resolution
or other similar law, or a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or similar official
having been appointed for or having taken possession of the Guarantor or its property, or the institution of any other comparable
judicial or regulatory proceedings relative to the Guarantor, or to the creditors or property of the Guarantor.

 

Nothing herein contained shall be deemed
to authorize the Trustee to authorize or consent to or vote for or accept or adopt on behalf of any Securityholder any plan of
reorganization, arrangement, adjustment or composition affecting the Securities or Coupons appertaining to such Securities of any
series or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Securityholder in
any such proceeding except, as aforesaid, to vote for the election of a trustee in bankruptcy or similar Person.

 

All rights of action and of asserting claims
under this Indenture, or under any of the Securities of any series or Coupons appertaining to such Securities, may be enforced
by the Trustee without the possession of any of the Securities of such series or Coupons appertaining to such Securities or the
production thereof on any trial or other proceedings relative thereto, and any such action or

 

    33

    

    

 

proceedings instituted by the Trustee
shall be brought in its own name as trustee of an express trust, and any recovery of judgment, subject to the payment of the expenses,
disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be for
the ratable benefit of the Holders of the Securities or Coupons appertaining to such Securities in respect of which such action
was taken.

 

In any proceedings brought by the Trustee
(and also any proceedings involving the interpretation of any provision of this Indenture to which the Trustee shall be a party)
the Trustee shall be held to represent all the Holders of the Securities in respect of which such action was taken, and it shall
not be necessary to make any Holders of such Securities parties to any such proceedings.

 

Section 5.03 Application of Proceeds.
Any monies collected by the Trustee pursuant to this Article in respect of any series shall be applied in the following order
at the date or dates fixed by the Trustee and, in case of the distribution of such monies on account of principal or interest,
upon presentation of the several Securities and Coupons appertaining to such Securities in respect of which monies have been collected
and stamping (or otherwise noting) thereon the payment, or issuing Securities of such series in reduced principal amounts in exchange
for the presented Securities of like series if only partially paid, or upon surrender thereof if fully paid:

 

FIRST: To the payment of all amounts
due to the Trustee under ‎this Indenture;

 

SECOND: In case the principal
of the Securities in respect of which monies have been collected shall not have become and be then due and payable, to the payment
of interest on the Securities of such series in default in the order of the maturity of the installments of such interest, with
interest (to the extent that such interest has been collected by the Trustee) upon the overdue installments of interest at the
same rate as the rate of interest or Yield to Maturity (in the case of Original Issue Discount Securities) specified in such Securities,
such payments to be made ratably to the Persons entitled thereto, without discrimination or preference;

 

THIRD: In case the principal of
the Securities of such series in respect of which monies have been collected shall have become and shall be then due and payable,
to the payment of the whole amount then owing and unpaid upon all the Securities of such series for principal and interest, with
interest upon the overdue principal, and (to the extent that such interest has been collected by the Trustee) upon overdue installments
of interest at the same rate as the rate of interest or Yield to Maturity (in the case of Original Issue Discount Securities) specified
in the Securities of such series; and in case such monies shall be insufficient to pay in full the

 

    34

    

    

 

whole amount so due and unpaid
upon the Securities of such series, then to the payment of such principal and interest or Yield to Maturity, without preference
or priority of principal over interest or Yield to Maturity, or of interest or Yield to Maturity over principal, or of any installment
of interest over any other installment of interest, or of any Security of such series over any other Security of such series, ratably
to the aggregate of such principal and accrued and unpaid interest or Yield to Maturity; and

 

FOURTH: To the payment of the
remainder, if any, to the Issuer, the Guarantor or any other Person lawfully entitled thereto.

 

Section 5.04 Suits for Enforcement. In
case an Event of Default has occurred, has not been waived and is continuing, the Trustee may in its discretion proceed to protect
and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual
to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement
of any covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture or to
enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.

 

Section 5.05 Restoration of Rights on
Abandonment of Proceedings. In case the Trustee shall have proceeded to enforce any right under this Indenture and such proceedings
shall have been discontinued or abandoned for any reason, or shall have been determined adversely to the Trustee, then and in every
such case the Issuer, the Guarantor and the Trustee shall be restored respectively to their former positions and rights hereunder,
and all rights, remedies and powers of the Issuer, the Guarantor, the Trustee and the Securityholders shall continue as though
no such proceedings had been taken.

 

Section 5.06 Limitations on Suits by
Securityholders. No Holder of any Security of any series or of any Coupon appertaining thereto shall have any right by virtue
or by availing of any provision of this Indenture to institute any action or proceeding at law or in equity or in bankruptcy or
otherwise upon or under or with respect to this Indenture, or for the appointment of a trustee, receiver, liquidator, custodian
or other similar official or for any other remedy hereunder, unless such Holder previously shall have given to the Trustee written
notice of default and of the continuance thereof, as hereinbefore provided, and unless also the Holders of not less than 25% in
aggregate principal amount of the Securities of each affected series then Outstanding (treated as a single class) shall have made
written request upon the Trustee to institute such action or proceedings in its own name as trustee hereunder and shall have offered
to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or
thereby and the Trustee for 60 days after its receipt of such notice, request and offer of indemnity shall have failed to institute
any such action

 

    35

    

    

 

or proceeding and no direction inconsistent with such written request shall have been given to the Trustee pursuant
to ‎‎Section 5.09; it being understood and intended,
and being expressly covenanted by the taker and Holder of every Security or Coupon with every other taker and Holder and the Trustee,
that no one or more Holders of Securities of any series or Coupons appertaining to such Securities shall have any right in any
manner whatever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other
such Holder of Securities of that or any other series or Coupons appertaining to such Securities, or to obtain or seek to obtain
priority over or preference to any other such Holder or to enforce any right under this Indenture, except in the manner herein
provided and for the equal, ratable and common benefit of all Holders of Securities of the applicable series and Coupons appertaining
to such Securities.

 

For the protection and enforcement of the
provisions of this Section, each and every Securityholder and the Trustee shall be entitled to such relief as can be given either
at law or in equity.

 

Section 5.07 Unconditional Right of Securityholders
to Institute Certain Suits. Notwithstanding any other provision in this Indenture and any provision of any Security or Coupon,
the right of any Holder of any Security or Coupon to receive payment of the principal of and interest on such Security or Coupon
on or after the respective due dates expressed in such Security or Coupon, or to institute suit for the enforcement of any such
payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder.

 

Section 5.08 Powers and Remedies Cumulative;
Delay or Omission Not Waiver of Default. Except as provided in ‎‎Section 5.06, no right or remedy herein conferred
upon or reserved to the Trustee or to the Securityholders is intended to be exclusive of any other right or remedy, and every right
and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder
or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or
otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy.

 

No delay or omission of the Trustee or of
any Securityholder to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall
impair any such right or power or shall be construed to be a waiver of any such Event of Default or an acquiescence therein; and,
subject to ‎‎Section 5.06, every power and remedy given by this Indenture or by law to the Trustee or to the Securityholders
may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.

 

    36

    

    

 

Section 5.09 Control by Securityholders.
The Holders of a majority in aggregate principal amount of the Securities of each series affected (with all such series voting
as a single class) at the time Outstanding shall have the right to direct the time, method, and place of conducting any proceeding
for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to the Securities
of such series by this Indenture; provided that such direction shall not be otherwise than in accordance with law and the
provisions of this Indenture and provided further that (subject to the provisions of ‎‎Section
6.01) the Trustee shall have the right to decline to follow any such direction if the Trustee, being advised by counsel,
shall determine that the action or proceeding so directed may not lawfully be taken or if the Trustee in good faith by the executive
committee, or a trust committee of directors or Responsible Officers of the Trustee shall determine that the action or proceedings
so directed would involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions
or forbearances specified in or pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities
of all series so affected not joining in the giving of said direction, it being understood that (subject to ‎‎Section
6.01) the Trustee shall have no duty to ascertain whether or not such actions or forbearances are unduly prejudicial to
such Holders.

 

Nothing in this Indenture shall impair the
right of the Trustee in its discretion to take any action deemed proper by the Trustee and which is not inconsistent with such
direction or directions by Securityholders.

 

Section 5.10 Waiver of Past Defaults.
Prior to the declaration of the acceleration of the maturity of the Securities of any series as provided in ‎‎Section
5.01, the Holders of a majority in aggregate principal amount of the Securities of all series at the time Outstanding with respect
to which an Event of Default shall have occurred and be continuing (voting as a single class) may on behalf of the Holders of all
such Securities waive any past default or Event of Default described in ‎‎Section 5.01 and its consequences except
a default in respect of a covenant or provision hereof which cannot be modified or amended without the consent of the Holder of
each Security affected. In the case of any such waiver, the Issuer, the Guarantor, the Trustee and the Holders of all such Securities
shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent
or other default or impair any right consequent thereon.

 

Upon any such waiver, such default shall
cease to exist and be deemed to have been cured and not to have occurred, and any Event of Default arising therefrom shall be deemed
to have been cured, and not to have occurred for every purpose of this Indenture; but no such waiver shall extend to any subsequent
or other default or Event of Default or impair any right consequent thereon.

 

    37

    

    

 

Section 5.11 Trustee to Give Notice of
Default, but May Withhold in Certain Circumstances. The Trustee shall, within 90 days after the occurrence of a default with
respect to the Securities of any series, give notice of all defaults with respect to that series known to the Trustee (i) if any
Unregistered Securities of a series affected are then Outstanding, to the Holders thereof, (A) by mail to such Holders who have
filed their names and addresses with the Trustee within the two years preceding the notice at such addresses as were so furnished
to the Trustee and (B) either through the customary notice provisions of the clearing system or systems through which beneficial
interests in such Unregistered Securities are owned if such Unregistered Securities are held only in global form or by publication
at least once in an Authorized Newspaper in the Borough of Manhattan, The City of New York, and at least once in an Authorized
Newspaper in London (and, if required by ‎‎Section 3.06, at least once in an Authorized Newspaper in Luxembourg),
and (ii) if any Registered Securities of a series affected are then Outstanding, by mailing notice to the Holders of then Outstanding
Registered Securities of each series affected at their addresses as they shall appear on the registry books, unless in each case
such defaults shall have been cured before the mailing or publication of such notice (the term “defaults” for
the purpose of this Section being hereby defined to mean any event or condition which is, or with notice or lapse of time or both
would become, an Event of Default); provided that, except in the case of default in the payment of the principal of, interest
on or any other amounts due under any of the Securities of such series, or in the payment of any sinking fund installment on such
series, the Trustee shall be protected in withholding such notice if and so long as the executive committee, or a trust committee
of directors or trustees and/or Responsible Officers of the Trustee in good faith determines that the withholding of such notice
is in the interests of the Securityholders of such series.

 

Section 5.12 Right of Court to Require
Filing of Undertaking to Pay Costs. In lieu of the provisions set forth in Section 315(e) of the Trust Indenture Act of 1939,
all parties to this Indenture agree, and each Holder of any Security or Coupon by his acceptance thereof shall be deemed to have
agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture
or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any party litigant
in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs,
including reasonable attorneys’ fees and expenses, against any party litigant in such suit, having due regard to the merits
and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any
suit instituted by the Issuer, the Guarantor or the Trustee, to any suit instituted by any Securityholder or group of Securityholders
in any series holding in the aggregate more than 10% in aggregate principal amount of the Securities of such series or to any suit
instituted by any Securityholder for the enforcement of the payment of the principal of or interest

 

    38

    

    

 

on any Security or Coupon on
or after the due date expressed in such Security or Coupon.

 

Article
6

Concerning the Trustee

 

Section 6.01 Duties and Responsibilities
of the Trustee; During Default; Prior to Default. With respect to the Holders of any series of Securities issued hereunder,
the Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a particular series and after the
curing or waiving of all Events of Default which may have occurred with respect to such series, undertakes to perform such duties
and only such duties as are specifically set forth in this Indenture. In case an Event of Default with respect to the Securities
of a series has occurred (which has not been cured or waived) the Trustee shall exercise with respect to such series of Securities
such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a
prudent man would exercise or use under the circumstances in the conduct of his own affairs.

 

No provision of this Indenture shall be
construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act or its own willful
misconduct except that

 

(a)           
prior to the occurrence of an Event of Default with respect to the Securities of any series and after the curing or waiving
of all such Events of Default with respect to such series which may have occurred:

 

(i)           
the duties and obligations of the Trustee with respect to the Securities of any series shall be determined solely by the
express provisions of this Indenture, and the Trustee shall not be liable except for the performance of such duties and obligations
as are specifically set forth in this Indenture, and no implied duties or obligations shall be read into this Indenture against
the Trustee; and

 

(ii)           
in the absence of bad faith on the part of the Trustee, the Trustee may conclusively rely, as to the truth of the statements
and the correctness of the opinions expressed therein, upon any statements, notices, certificates or opinions furnished to the
Trustee and conforming to the requirements of this Indenture; but in the case of any such statements, notices, certificates or
opinions which by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a
duty to examine the same to determine whether or not they conform to the requirements of this Indenture;

 

    39

    

    

 

(b)           
the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers
of the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and

 

(c)           
the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance
with the direction of a majority of the Holders relating to the time, method and place of conducting any proceeding for any remedy
available to the Trustee, or exercising any trust power conferred upon the Trustee, under this Indenture.

 

None of the provisions contained in this
Indenture shall require the Trustee to expend or risk its own funds or otherwise incur financial liability in the performance of
any of its duties or in the exercise of any of its rights or powers, if there shall be reasonable ground for believing that the
repayment of such funds or indemnity satisfactory to it against such liability is not reasonably assured to it.

 

The provisions of this ‎‎Section
6.01 are in furtherance of and subject to Section 315 of the Trust Indenture Act of 1939.

 

Section 6.02 Certain Rights of the Trustee.
In furtherance of and subject to the Trust Indenture Act of 1939, and subject to ‎‎Section
6.01:

 

(a)           
the Trustee may conclusively rely and shall be fully protected in acting or refraining from acting upon any resolution,
Officer’s Certificate, Issuer Order or any other certificate, statement, instrument, opinion, report, notice, request, consent,
order, bond, debenture, note, coupon, security or other paper or document believed by it to be genuine and to have been signed
or presented by the proper party or parties;

 

(b)           
any request, direction, order or demand of the Issuer or the Guarantor mentioned herein shall be sufficiently evidenced
by an Officer’s Certificate of the Issuer or the Guarantor, as applicable (unless other evidence in respect thereof be herein
specifically prescribed); and any resolution of the Board of the Issuer or the Guarantor may be evidenced to the Trustee by a
copy thereof certified by the secretary or an assistant secretary of the Issuer or the Guarantor, as applicable, to have been
duly adopted by the Board of the Issuer or the Guarantor, as applicable, and to be in full force and effect on the date thereof;

 

(c)           
the Trustee may consult with counsel of its choosing and any advice of such counsel or any Opinion of Counsel shall be
full and complete authorization and protection in respect of any action taken, suffered or omitted to be taken by it hereunder
in good faith and in accordance with such advice or Opinion of Counsel;

 

    40

    

    

 

(d)           
the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the
request, order or direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders
shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might
be incurred therein or thereby;

 

(e)           
the Trustee shall not be liable for any action taken or omitted by it in good faith and believed by it to be authorized
or within the discretion, rights or powers conferred upon it by this Indenture;

 

(f)           
prior to the occurrence of an Event of Default hereunder and after the curing or waiving of all Events of Default, the
Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or
other paper or document unless requested in writing so to do by the Holders of not less than a majority in aggregate principal
amount of the Securities of all series affected then Outstanding; provided that, if the payment within a reasonable time
to the Trustee of the costs, expenses or liabilities likely to be incurred by it in the making of such investigation is, in the
opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture, the
Trustee may require indemnity satisfactory to it against such expenses or liabilities as a condition to proceeding; the reasonable
expenses of every such investigation shall be paid by the Issuer or, if paid by the Trustee or any predecessor Trustee, shall
be repaid by the Issuer upon demand; and

 

(g)           
the Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or
through agents, attorneys, custodians or nominees not regularly in its employ and the Trustee shall not be responsible for any
misconduct or negligence on the part of any such agent, attorney, custodian or nominee appointed with due care by it hereunder.

 

(h)           
In no event shall the Trustee be liable for the selection of investments or for investment losses incurred thereon. The
Trustee shall have no liability in respect of losses incurred as a result of the liquidation of any investments prior to its stated
maturity or failure to provide timely written direction (if any).

 

(i)           
The Trustee shall not be charged with knowledge of an Event of Default unless a Responsible Officer of the Trustee has
actual knowledge or the Trustee has received written notice thereof.

 

(j)           
Anything in this Indenture to the contrary notwithstanding, in no event shall the Trustee be liable for special, punitive,
indirect or consequential

 

    41

    

    

 

loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee
has been advised of the likelihood of such loss or damage and regardless of the form of action.

 

(k)           
Whether or not therein expressly so provided, every provision of this Indenture relating to the conduct or affecting the
liability of or affording protection to the Trustee shall be subject to the provisions of this Article 6.

 

(l)           
In no event shall the Trustee be liable for any failure or delay in the performance of its obligations under this Indenture
or any related documents because of circumstances beyond the Trustee’s control, including, but not limited to, a failure,
termination, or suspension of a clearing house, securities depositary, settlement system or central payment system in any applicable
part of the world or acts of God, flood, war (whether declared or undeclared), civil or military disturbances or hostilities,
nuclear or natural catastrophes, political unrest, explosion, severe weather or accident, earthquake, terrorism, fire, riot, labor
disturbances, strikes or work stoppages for any reason, embargo, government action, including any laws, ordinances, regulations
or the like (whether domestic, federal, state, county or municipal or foreign) that delay, restrict or prohibit the providing
of the services contemplated by this Indenture or any related documents, or the unavailability of communications or computer facilities,
the failure of equipment or interruption of communications or computer facilities, or the unavailability of the Federal Reserve
Bank wire or telex or other wire or communication facility, or any other causes beyond the Trustee’s control whether or
not of the same class or kind as specified above.

 

Section 6.03 Trustee Not Responsible
for Recitals, Disposition of Securities or Application of Proceeds Thereof. The recitals contained herein and in the Securities
or Coupons, except the Trustee’s certificate of authentication, shall be taken as the statements of the Issuer or the Guarantor,
as applicable, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations
as to the validity or sufficiency of this Indenture or of the Securities or Coupons. The Trustee shall not be accountable for the
use or application by the Issuer of any of the Securities or of the proceeds thereof.

 

Section 6.04 Trustee and Agents May Hold
Securities or Coupons, Collections, Etc. The Trustee or any agent of the Issuer, the Guarantor or the Trustee, in its individual
or any other capacity, may become the owner or pledgee of Securities or Coupons with the same rights it would have if it were not
the Trustee or such agent and, subject to Sections ‎‎6.08
and ‎‎6.13, if operative, may otherwise deal with the Issuer or the Guarantor and receive, collect, hold and retain
collections from the Issuer or the Guarantor with the same rights it would have if it were not the Trustee or such agent.

 

    42

    

    

 

Section 6.05 Monies Held by Trustee.
Subject to the provisions of ‎‎Section 10.04 hereof, all monies received by the Trustee shall, until used or
applied as herein provided, be held in trust for the purposes for which they were received, but need not be segregated from other
funds except to the extent required by mandatory provisions of law. Neither the Trustee nor any agent of the Issuer, the Guarantor
or the Trustee shall be under any liability for interest on any monies received by it hereunder except such as it may agree in
writing with the Issuer or the Guarantor to pay thereon.

 

Section 6.06 Compensation and Indemnification
of Trustee and Its Prior Claim. Each of the Issuer and the Guarantor, jointly and severally, covenants and agrees to pay to
the Trustee from time to time, and the Trustee shall be entitled to, reasonable compensation (which shall not be limited by any
provision of law in regard to the compensation of a trustee of an express trust) and each of the Issuer and the Guarantor, jointly
and severally, covenants and agrees to pay or reimburse the Trustee and each predecessor Trustee upon its request for all reasonable
expenses, disbursements and advances incurred or made by or on behalf of it in accordance with any of the provisions of this Indenture
(including the reasonable compensation and the expenses and disbursements of its counsel and of all agents and other Persons not
regularly in its employ) except any such expense, disbursement or advance as may arise from its negligence or willful misconduct.
Each of the Issuer and the Guarantor, jointly and severally, also covenants to indemnify the Trustee and each predecessor Trustee
and each of their respective officers, directors, employees, representatives and agents for, and to hold it harmless against, any
loss, liability, claim, obligation or expense incurred without negligence or willful misconduct on its part, arising out of or
in connection with the acceptance or administration of this Indenture or the trusts hereunder and its duties hereunder, including
the costs and expenses of defending itself against or investigating any claim of liability in the premises. The obligations of
the Issuer and the Guarantor under this Section to compensate and indemnify the Trustee and each predecessor Trustee and to pay
or reimburse the Trustee and each predecessor Trustee for expenses, disbursements and advances shall constitute additional indebtedness
hereunder. Such additional indebtedness shall be a senior claim to that of the Securities or Coupons upon all property and funds
held or collected by the Trustee as such, except funds held in trust for the benefit of the Holders of particular Securities or
Coupons, and the Securities or Coupons are hereby subordinated to such senior claim. The Issuer’s and the Guarantor’s
obligations pursuant to this ‎‎Section 6.06 shall survive the earlier termination of this Indenture or resignation
or removal of the Trustee.

 

Section 6.07 Right of Trustee to Rely
on Officer’s Certificate, Etc. Subject to Sections ‎‎6.01
and ‎‎6.02, whenever in the administration of the trusts of this Indenture the Trustee shall deem it necessary or
desirable that a matter be proved or established prior to taking or suffering or omitting any action hereunder, such matter (unless
other evidence in respect thereof be herein

 

    43

    

    

 

specifically prescribed) may, in the absence of negligence or willful misconduct on
the part of the Trustee, be deemed to be conclusively proved and established by an Officer’s Certificate of the Issuer or
the Guarantor, as applicable, delivered to the Trustee, and such certificate, in the absence of negligence or willful misconduct
on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted by it under the provisions
of this Indenture upon the faith thereof.

 

Section 6.08 Conflicting Interests. The
following indentures are hereby specifically described for the purposes of excluding such indentures and this Indenture with respect
to Securities of any other series from the operation of Section 310(b)(1) of the Trust Indenture Act of 1939: (i) the Indenture
dated as of July 1, 1986, as amended or supplemented, between the Guarantor and the Trustee, (ii) the Indenture dated as of December
1, 1989 between the Guarantor and the Trustee (as supplemented by the Agreement of Resignation, Appointment and Acceptance, dated
as of March 29, 1996), (iii) the Indenture dated as of May 25, 2001, as amended or supplemented, between the Guarantor and the
Trustee, (iv) the Indenture dated as of October 21, 2010, as amended or supplemented, between the Guarantor and the Trustee, (v)
the Warrant Indenture, as amended or supplemented, to be entered into among the Issuer, the Guarantor and Deutsche Bank Trust Company
Americas, as trustee and (vi) this Indenture with respect to the Securities of any other series, and there shall also be so excluded
any other indenture or indentures under which other securities, or certificates of interest or participation in other securities,
of the Issuer are outstanding if (i) this Indenture, with respect to Securities of such series, and, if applicable, this Indenture
with respect to such other series issued pursuant to this Indenture and such other indenture or indentures are wholly unsecured,
and such other indenture or indentures are hereafter qualified under the Trust Indenture Act of 1939, unless the Commission shall
have found and declared by order pursuant to Section 305(b) or Section 307(c) of such Trust Indenture Act of 1939 that differences
exist between the provisions of this Indenture with respect to Securities of such series and one or more other series, or the provisions
of this Indenture and the provisions of such other indenture or indentures which are so likely to involve a material conflict of
interest as to make it necessary in the public interest or for the protection of investors to disqualify the Trustee from acting
as such under this Indenture with respect to Securities of such series and such other series, or under this Indenture or such other
indenture or indentures, or (ii) the Issuer shall have sustained the burden of proving, on application to the Commission and after
opportunity for hearing thereon, that trusteeship under this Indenture with respect to Securities of such series and such other
series, or under this Indenture and such other indenture or indentures is not so likely to involve material conflict of interest
as to make it necessary in the public interest or for the protection of investors to disqualify the Trustee from acting as such
under this Indenture with respect to Securities of such series and such other series, or under this Indenture and such other indentures.

 

    44

    

    

 

Section 6.09 Persons Eligible for Appointment
as Trustee. The Trustee for each series of Securities hereunder shall at all times be a corporation organized and doing business
under the laws of the United States of America or of any State or the District of Columbia having a combined capital and surplus
of at least $50,000,000, and which is authorized under such laws to exercise corporate trust powers and is subject to supervision
or examination by Federal, State or District of Columbia authority. Such corporation shall have its principal place of business
in the Borough of Manhattan, The City of New York, if there be such a corporation in such location willing to act upon reasonable
and customary terms and conditions. If such corporation publishes reports of condition at least annually, pursuant to law or to
the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section, the combined capital
and surplus of such corporation shall be deemed to be its combined capital and surplus as set forth in its most recent report of
condition so published. In case at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section,
the Trustee shall resign immediately in the manner and with the effect specified in ‎‎Section 6.10.

 

The provisions of this ‎‎Section
6.09 are in furtherance of and subject to Section 310(a) of the Trust Indenture Act of 1939.

 

Section 6.10 Resignation And Removal;
Appointment of Successor Trustee. (a) The Trustee, or any trustee or trustees hereafter appointed, may at any time resign with
respect to one or more or all series of Securities by giving written notice of resignation to the Issuer and the Guarantor and
(i) if any Unregistered Securities of a series affected are then Outstanding, by giving notice of such resignation to the Holders
thereof (A) to such Holders who have filed their names and addresses with the Trustee within the two years preceding the notice
at such addresses as were so furnished to the Trustee and (B) either through the customary notice provisions of the clearing system
or systems through which beneficial interests in such Unregistered Securities are owned if such Unregistered Securities are held
only in global form or by publication at least once in an Authorized Newspaper in the Borough of Manhattan, The City of New York,
and at least once in an Authorized Newspaper in London (and, if required by ‎‎Section 3.06, at least once in an
Authorized Newspaper in Luxembourg), and (ii) if any Registered Securities of a series affected are then Outstanding,by notice
of such resignation to the Holders of then Outstanding Registered Securities of each series affected at their addresses as they
shall appear on the registry books. Upon receiving such notice of resignation, the Issuer and the Guarantor shall promptly appoint
a successor trustee or trustees with respect to the applicable series by written instrument in duplicate, executed by authority
of their respective Boards, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor
trustee or trustees. If no successor trustee shall have been so appointed with respect to any series and have accepted appointment
within 30 days after such notice of resignation, the resigning trustee, at the expense of the

 

    45

    

    

 

Issuer and Guarantor, may petition
any court of competent jurisdiction for the appointment of a successor trustee, or any Securityholder who has been a bona fide
Holder of a Security or Securities of the applicable series for at least six months may, subject to the provisions of ‎‎Section
5.12, on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor
trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.

 

(b)           
In case at any time any of the following shall occur:

 

(i)           
the Trustee shall fail to comply with the provisions of Section 310(b) of the Trust Indenture Act of 1939 with respect
to any series of Securities after written request therefor by the Issuer, the Guarantor or by any Securityholder who has been
a bona fide Holder of a Security or Securities of such series for at least six months; or

 

(ii)           
the Trustee shall cease to be eligible in accordance with the provisions of ‎‎Section
6.09 and Section 310(a) of the Trust Indenture Act of 1939 and shall fail to resign after written request therefor by the
Issuer, the Guarantor or by any Securityholder; or

 

(iii)           
the Trustee shall become incapable of acting with respect to any series of Securities, or shall be adjudged a bankrupt
or insolvent, or a receiver or liquidator of the Trustee or of its property shall be appointed, or any public officer shall take
charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation;

 

then, in any such case, the Issuer and the Guarantor may remove
the Trustee with respect to the applicable series of Securities and appoint a successor trustee for such series by written instrument,
in duplicate, executed by order of the Board of the Issuer and the Board of the Guarantor, one copy of which instrument shall be
delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of Section 315(e) of the
Trust Indenture Act of 1939, any Securityholder who has been a bona fide Holder of a Security or Securities of such series for
at least six months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for
the removal of the Trustee and the appointment of a successor trustee with respect to such series. Such court may thereupon, after
such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee.

 

(c)           
Any resignation or removal of the Trustee with respect to any series and any appointment of a successor trustee with respect
to such series pursuant to any of the provisions of this ‎‎Section 6.10 shall become effective upon acceptance of appointment
by the successor trustee as provided in ‎‎Section 6.11.

 

    46

    

    

 

Section 6.11 Acceptance of Appointment
by Successor Trustee. Any successor trustee appointed as provided in ‎‎Section 6.10 shall execute and deliver
to the Issuer, the Guarantor and to its predecessor trustee an instrument accepting such appointment hereunder, and thereupon the
resignation or removal of the predecessor trustee with respect to all or any applicable series shall become effective and such
successor trustee, without any further act, deed or conveyance, shall become vested with all rights, powers, duties and obligations
with respect to such series of its predecessor hereunder, with like effect as if originally named as trustee for such series hereunder;
but, nevertheless, on the written request of the Issuer, the Guarantor or the successor trustee, upon payment of its charges then
unpaid, the trustee ceasing to act shall, subject to ‎‎Section 10.04, pay over to the successor trustee all monies
at the time held by it hereunder and shall execute and deliver an instrument transferring to such successor trustee all such rights,
powers, duties and obligations. Upon request of any such successor trustee, the Issuer and the Guarantor shall execute any and
all instruments in writing for more fully and certainly vesting in and confirming to such successor trustee all such rights and
powers. Any trustee ceasing to act shall, nevertheless, retain a prior claim upon all property or funds held or collected by such
trustee to secure any amounts then due it pursuant to the provisions of ‎‎Section 6.06.

 

If a successor trustee is appointed with
respect to the Securities of one or more (but not all) series, the Issuer, the Guarantor, the predecessor Trustee and each successor
trustee with respect to the Securities of any applicable series shall execute and deliver an indenture supplemental hereto which
shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties
of the predecessor Trustee with respect to the Securities of any series as to which the predecessor Trustee not retiring shall
continue to be vested in the predecessor Trustee, and shall add to or change any of the provisions of this Indenture as shall be
necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood
that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the same trust and that each
such Trustee shall be trustee of a trust or trusts under separate indentures.

 

No successor trustee with respect to any
series of Securities shall accept appointment as provided in this ‎‎Section 6.11 unless at the time of such acceptance
such successor trustee shall be qualified under Section 310(b) of the Trust Indenture Act of 1939 and eligible under the provisions
of ‎‎Section 6.09.

 

Upon acceptance of appointment by any successor
trustee as provided in this Section, the Issuer shall mail notice thereof (a) if any Unregistered Securities of a series affected
are then Outstanding, to the Holders thereof, (A) by mail to such Holders who have filed their names and addresses with the Trustee
within the two years preceding the notice at such addresses as were so furnished to the Trustee and (B) either through the customary
notice provisions of the clearing

 

    47

    

    

 

system or systems through which beneficial interests in such Unregistered Securities are owned
if such Unregistered Securities are held only in global form or by publication at least once in an Authorized Newspaper in the
Borough of Manhattan, The City of New York and at least once in an Authorized Newspaper in London (and, if required by ‎‎Section
3.06, at least once in an Authorized Newspaper in Luxembourg), and (b) if any Registered Securities of a series affected are then
Outstanding, by mailing notice to the Holders of then Outstanding Registered Securities of each series affected at their addresses
as they shall appear on the registry books. If the acceptance of appointment is substantially contemporaneous with the resignation,
then the notice called for by the preceding sentence may be combined with the notice called for by ‎‎Section 6.10. If the
Issuer fails to give such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee
shall cause such notice to be given at the expense of the Issuer.

 

Section 6.12 Merger, Conversion, Consolidation
or Succession of Business of Trustee. Any corporation into which the Trustee may be merged or converted or with which it may
be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party,
or any corporation succeeding to the corporate trust business of the Trustee, shall be the successor of the Trustee hereunder,
provided that such corporation shall be qualified under Section 310(b) of the Trust Indenture Act of 1939 and eligible under
the provisions of ‎‎Section 6.09, without the execution
or filing of any paper or any further act on the part of any of the parties hereto, anything herein to the contrary notwithstanding.

 

In case at the time such successor to the
Trustee shall succeed to the trusts created by this Indenture any of the Securities of any series shall have been authenticated
but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor Trustee and
deliver such Securities so authenticated; and, in case at that time any of the Securities of any series shall not have been authenticated,
any successor to the Trustee may authenticate such Securities either in the name of any predecessor hereunder or in the name of
the successor Trustee; and in all such cases such certificate shall have the full force of the certificate of the Trustee stated
anywhere else in the Securities of such series or in this Indenture; provided that the right to adopt the certificate of
authentication of any predecessor Trustee or to authenticate Securities of any series in the name of any predecessor Trustee shall
apply only to its successor or successors by merger, conversion or consolidation.

 

Section 6.13 Appointment of Authenticating
Agent. As long as any Securities of a series remain Outstanding, the Trustee may, by an instrument in writing, appoint with
the approval of the Issuer and the Guarantor an authenticating agent (the “Authenticating Agent”) which shall
be authorized to act on behalf of the Trustee to authenticate Securities, including Securities issued

 

    48

    

    

 

upon exchange, registration
of transfer, partial redemption or pursuant to ‎‎Section 2.09. Securities of each such series authenticated by such
Authenticating Agent shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as
if authenticated by the Trustee. Whenever reference is made in this Indenture to the authentication and delivery of Securities
of any series by the Trustee or to the Trustee’s Certificate of Authentication, such reference shall be deemed to include
authentication and delivery on behalf of the Trustee by an Authenticating Agent for such series and a Certificate of Authentication
executed on behalf of the Trustee by such Authenticating Agent. Such Authenticating Agent shall at all times be a corporation organized
and doing business under the laws of the United States of America or of any State, authorized under such laws to exercise corporate
trust powers, having a combined capital and surplus of at least $50,000,000 (determined as provided in ‎‎Section
6.09 with respect to the Trustee) and subject to supervision or examination by Federal or State authority.

 

Any corporation into which any Authenticating
Agent may be merged or converted, or with which it may be consolidated, or any corporation resulting from any merger, conversion
or consolidation to which any Authenticating Agent shall be a party, or any corporation succeeding to the corporate agency business
of any Authenticating Agent, shall continue to be the Authenticating Agent with respect to all series of Securities for which it
served as Authenticating Agent without the execution or filing of any paper or any further act on the part of the Trustee or such
Authenticating Agent. Any Authenticating Agent may at any time, and if it shall cease to be eligible shall, resign by giving written
notice of resignation to the Trustee and to the Issuer and the Guarantor.

 

Upon receiving such a notice of resignation
or upon such a termination, or in case at any time any Authenticating Agent shall cease to be eligible in accordance with the provisions
of this ‎‎Section 6.13 with respect to one or more series of Securities, the Trustee shall upon receipt of an Issuer Order
appoint a successor Authenticating Agent and the Issuer shall provide notice of such appointment to all Holders of Securities of
such series in the manner and to the extent provided in ‎‎Section 11.04. Any successor Authenticating Agent upon acceptance
of its appointment hereunder shall become vested with all rights, powers, duties and responsibilities of its predecessor hereunder,
with like effect as if originally named as Authenticating Agent. Each of the Issuer and the Guarantor, jointly and severally, agrees
to pay to the Authenticating Agent for such series from time to time reasonable compensation. The Authenticating Agent for the
Securities of any series shall have no responsibility or liability for any action taken by it as such at the direction of the Trustee.

 

Sections ‎‎6.02, ‎‎6.03,
‎‎6.04, ‎‎6.06, ‎‎6.09 and ‎7.03 shall
be applicable to any Authenticating Agent.

 

    49

    

    

 

Article
7

Concerning the Securityholders

 

Section 7.01 Evidence of Action Taken
by Securityholders. Any request, demand, authorization, direction, notice, consent, waiver or other action provided by this
Indenture to be given or taken by a specified percentage in principal amount of the Securityholders of any or all series may be
embodied in and evidenced by one or more instruments of substantially similar tenor signed by such specified percentage of Securityholders
in person or by agent duly appointed in writing; and, except as herein otherwise expressly provided, such action shall become effective
when such instrument or instruments are delivered to the Trustee. Proof of execution of any instrument or of a writing appointing
any such agent shall be sufficient for any purpose of this Indenture and (subject to Sections ‎ ‎‎6.01
and ‎‎6.02) conclusive in favor of the Trustee, the Issuer and the Guarantor, if made in the manner provided in
this Article.

 

Section 7.02 Proof of Execution of Instruments
and of Holding of Securities. Subject to Sections ‎‎6.01
and ‎‎6.02, the fact and date of the execution of any instrument by a Securityholder or his agent or proxy and the
amount and numbers of Securities of any series held by the person so executing any instrument by a Securityholder or his agent
or proxy and the amount and numbers of any Security or Securities for such series may also be proven in accordance with such reasonable
rules and regulations as may be prescribed by the Trustee for such series or in any other manner which the Trustee for such series
may deem sufficient.

 

Section 7.03 Holders to Be Treated as
Owners. The Issuer, the Guarantor and the Trustee and any agent of the Issuer, the Guarantor or the Trustee shall deem and
treat the Person in whose name any Security shall be registered upon the Security register for such series as the absolute owner
of such Security (whether or not such Security shall be overdue and notwithstanding any notation of ownership or other writing
thereon) for the purpose of receiving payment of or on account of the principal of and, subject to the provisions of this Indenture,
interest on such Security and for all other purposes; and none of the Issuer, the Guarantor, the Trustee or any agent of the Issuer,
the Guarantor or the Trustee shall be affected by any notice to the contrary. The Issuer, the Guarantor, the Trustee and any agent
of the Issuer, the Guarantor or the Trustee may treat the Holder of any Unregistered Security and the Holder of any Coupon as the
absolute owner of such Unregistered Security or Coupon (whether or not such Unregistered Security or Coupon shall be overdue),
for the purpose of receiving payment thereof or on account thereof and for all other purposes and neither the Issuer, the Guarantor
the Trustee, nor any agent of the Issuer, the Guarantor or the Trustee shall be affected by any notice to the contrary. All such
payments so made to any such Person, or upon his order, shall be valid, and, to the extent of

 

    50

    

    

 

the sum or sums so paid, effectual
to satisfy and discharge the liability for monies payable upon any such Unregistered Security or Coupon.

 

Section 7.04 Securities Owned by Issuer
or Guarantor Deemed Not Outstanding. In determining whether the Holders of the requisite aggregate principal amount of Outstanding
Securities of any or all series have concurred in any direction, consent or waiver under this Indenture, Securities that are owned
by the Issuer or the Guarantor with respect to which such determination is being made or by any Person directly or indirectly controlling
or controlled by or under direct or indirect common control with the Issuer or the Guarantor with respect to which such determination
is being made shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for
the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver, only Securities
which the Trustee actually knows are so owned shall be so disregarded. Securities so owned which have been pledged in good faith
may be regarded as Outstanding if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act
with respect to such Securities and that the pledgee is not the Issuer or the Guarantor or any Person directly or indirectly controlling
or controlled by or under direct or indirect common control with the Issuer or the Guarantor. In case of a dispute as to such right,
the advice of counsel shall be full protection in respect of any decision made by the Trustee in accordance with such advice. Upon
request of the Trustee, the Issuer or the Guarantor shall furnish to the Trustee promptly an Officer’s Certificate listing
and identifying all Securities, if any, known by the Issuer or the Guarantor to be owned or held by or for the account of any of
the above described Persons; and, subject to Sections ‎‎‎6.01
and ‎‎6.02, the Trustee shall be entitled to accept such Officer’s Certificate as conclusive evidence of the
facts therein set forth and of the fact that all Securities not listed therein are Outstanding for the purpose of any such determination.

 

Section 7.05 Right of Revocation of Action
Taken. At any time prior to (but not after) the evidencing to the Trustee, as provided in ‎‎Section 7.01, of
the taking of any action by the Holders of the percentage in aggregate principal amount of the Outstanding Securities of any or
all series, as the case may be, specified in this Indenture in connection with such action, any Holder of a Security the serial
number of which is shown by the evidence to be included among the serial numbers of the Securities the Holders of which have consented
to such action may, by filing written notice at the Corporate Trust Office and upon proof of holding as provided in this Article,
revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the Holder of any Security shall
be conclusive and binding upon such Holder and upon all future Holders and owners of such Security and of any Securities issued
in exchange or substitution therefor or on registration or transfer thereof, irrespective of whether or not any notation in regard
thereto is made upon any such Security. Any action taken by the Holders of the percentage in aggregate principal amount

 

    51

    

    

 

of the
Securities of any or all series, as the case may be, specified in this Indenture in connection with such action shall be conclusively
binding upon the Issuer, the Guarantor, the Trustee and the Holders of all the Securities affected by such action.

  

Article
8

Supplemental Indentures

 

Section 8.01 Supplemental Indentures
Without Consent of Securityholders. The Issuer and the Guarantor, when authorized by resolutions of their respective Boards
(which resolutions may provide general terms or parameters for such action and may provide that the specific terms of such action
may be determined in accordance with or pursuant to an Issuer Order or an Officer’s Certificate of the Guarantor, as applicable),
and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform
to the provisions of the Trust Indenture Act of 1939 as in force at the date of the execution thereof) for one or more of the following
purposes:

 

(a)           
to convey, transfer, assign, mortgage or pledge to the Trustee any property or assets as security for the Securities of
one or more series or the Guarantee with respect to the Securities of one or more series;

 

(b)           
to evidence the succession of a Successor Person to the Issuer or the Guarantor, as applicable, or successive successions,
and the assumption by the Successor Person of the covenants, agreements and obligations of the Issuer or the Guarantor, as applicable,
pursuant to ‎‎Article 9;

 

(c)           
to add to the covenants of the Issuer or the Guarantor such further covenants, restrictions, conditions or provisions as
the Issuer, the Guarantor and the Trustee shall consider to be for the protection of the Holders of Securities or Coupons, and
to make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions
or provisions an Event of Default permitting the enforcement of all or any of the several remedies provided in this Indenture
as herein set forth; provided that in respect of any such additional covenant, restriction, condition or provision such
supplemental indenture may provide for a particular period of grace after default (which period may be shorter or longer than
that allowed in the case of other defaults) or may provide for an immediate enforcement upon such an Event of Default or may limit
the remedies available to the Trustee upon such an Event of Default or may limit the right of the Holders of a majority in aggregate
principal amount of the Securities of such series to waive such an Event of Default;

 

    52

    

    

 

(d)           
to cure any ambiguity or to correct or supplement any provision contained herein or in any supplemental indenture which
may be defective or inconsistent with any other provision contained herein or in any supplemental indenture; or to make any change
to this Indenture or the Securities or under any supplemental indenture as the Issuer and the Guarantor may deem necessary or
desirable and which shall not materially and adversely affect the interests of the holders of the Securities;

 

(e)           
to add to, change or eliminate any of the provisions of this Indenture in respect of all or any Securities of any series
(and if such addition, change or elimination is to apply with respect to less than all Securities of any series, stating that
it is expressly being made to apply solely with respect to such Securities within such series), provided that any such
addition, change or elimination (a) shall neither (i) apply to any Security issued prior to the execution of such supplemental
indenture and entitled to the benefit of such provision nor (ii) modify the rights of any Holder of such Security with respect
to such provision or (b) shall become effective only when there is no such Security Outstanding;

 

(f)           
to conform the text of this Indenture or the Securities of any series to any provision of the section entitled “Description
of Debt Securities” or any similarly captioned section in the prospectus, as supplemented by any applicable prospectus supplement,
relating to the offering of such series of Securities;

 

(g)           
to establish the form or terms of Securities of any series or of the Coupons appertaining to such Securities as permitted
by Sections ‎2.01 and ‎‎2.03; and

 

(h)           
to evidence and provide for the acceptance of appointment hereunder by a successor trustee with respect to the Securities
of one or more series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or
facilitate the administration of the trusts hereunder by more than one trustee, pursuant to the requirements of ‎‎Section
6.11.

 

The Trustee is hereby authorized to join
with the Issuer and the Guarantor in the execution of any such supplemental indenture, to make any further appropriate agreements
and stipulations which may be therein contained and to accept the conveyance, transfer, assignment, mortgage or pledge of any property
thereunder, but the Trustee shall not be obligated to enter into any such supplemental indenture which affects the Trustee’s
own rights, duties or immunities under this Indenture or otherwise.

 

Any supplemental indenture authorized by
the provisions of this Section may be executed without the consent of the Holders of any of the Securities at the time outstanding,
notwithstanding any of the provisions of ‎‎Section 8.02.

 

    53

    

    

 

Section 8.02 Supplemental Indentures
with Consent of Securityholders. With the consent (evidenced as provided in ‎‎Article 7) of the Holders of not
less than a majority in aggregate principal amount of the Securities at the time Outstanding of all series affected by such supplemental
indenture (voting as one class), the Issuer and the Guarantor, when authorized by resolutions of their respective Boards (which
resolutions may provide general terms or parameters for such action and may provide that the specific terms of such action may
be determined in accordance with or pursuant to an Issuer Order or an Officer’s Certificate of the Guarantor, as applicable),
and the Trustee may, from time to time and at any time, enter into an indenture or indentures supplemental hereto (which shall
conform to the provisions of the Trust Indenture Act of 1939 as in force at the date of execution thereof) for the purpose of adding
any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture
or of modifying in any manner the rights of the Holders of the Securities of each such series or the Coupons appertaining to such
Securities; provided that no such supplemental indenture shall (a) extend the final maturity of any Security, (b) reduce
the principal amount thereof, (c) reduce the rate or extend the time of payment of interest thereon or other amounts due thereunder,
(d) change the method in which amounts of payments of principal, interest or other amounts due thereon are determined, (e) reduce
any amount payable on redemption thereof, (f) make the principal thereof (including any amount in respect of original issue discount),
or interest thereon payable in any coin or currency other than that provided in the Securities and Coupons or in accordance with
the terms thereof, (g) modify or amend any provisions for converting any currency into any other currency as provided in the Securities
or Coupons or in accordance with the terms thereof, (h) reduce the amount of the principal of an Original Issue Discount Security
that would be due and payable upon an acceleration of the maturity thereof pursuant to ‎‎Section 5.01 or the amount
thereof provable in bankruptcy pursuant to ‎‎Section 5.02,
(i) alter the provisions of Section ‎‎11.11 or ‎‎11.12, impair or affect the right of any Securityholder
to institute suit for the payment thereof or, if the Securities provide therefor, impair or affect any right of repayment at the
option of the Securityholder, (j) make any change in the Guarantee that would adversely affect the Holders of the Securities of
such series or release the Guarantor from the Guarantee other than pursuant to the terms of this Indenture or (k) reduce the aforesaid
percentage of Securities of any series, the consent of the Holders of which is required for any such supplemental indenture, in
each case without the consent of the Holder of each Security so affected.

 

A supplemental indenture which changes or
eliminates any covenant or other provision of this Indenture which has expressly been included solely for the benefit of one or
more particular series of Securities, or which modifies the rights of the holders of Securities of such series with respect to
such covenant or other provision, shall be deemed not to affect the rights under this Indenture of the holders of any other series.

 

    54

    

    

 

Upon the request of the Issuer and the Guarantor,
accompanied by a copy of the resolutions of their respective Boards (which resolutions may provide general terms or parameters
for such action and may provide that the specific terms of such action may be determined in accordance with or pursuant to an Issuer
Order or an Officer’s Certificate of the Guarantor, as applicable) certified by the secretary or an assistant secretary or
any Attorney-in-Fact of the Issuer or the Guarantor, as applicable, authorizing the execution of any such supplemental indenture,
and upon the filing with the Trustee of evidence of the consent of Securityholders as aforesaid and other documents, if any, required
by ‎‎Section 7.01, the Trustee shall join with the Issuer and the Guarantor in the execution of such supplemental indenture
unless such supplemental indenture affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise,
in which case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture.

 

It shall not be necessary for the consent
of the Securityholders under this Section to approve the particular form of any proposed supplemental indenture, but it shall be
sufficient if such consent shall approve the substance thereof.

 

Promptly after the execution by the Issuer,
the Guarantor and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee shall give
notice thereof (i) if any Unregistered Securities of a series affected are then Outstanding, to the Holders thereof, (A) by mail
to such Holders who have filed their names and addresses with the Trustee within the two years preceding the notice at such addresses
as were so furnished to the Trustee and (B) either through the customary notice provisions of the clearing system or systems through
which beneficial interests in such Unregistered Securities are owned if such Unregistered Securities are held only in global form
or by publication at least once in an Authorized Newspaper in the Borough of Manhattan, The City of New York, and at least once
in an Authorized Newspaper in London (and, if required by ‎‎Section 3.06, at least once in an Authorized Newspaper in Luxembourg),
(ii) if any Registered Securities of a series affected are then Outstanding, by mailing notice thereof by first class mail to the
Holders of then Outstanding Registered Securities of each series affected at their addresses as they shall appear on the registry
books, and in each case such notice shall set forth in general terms the substance of such supplemental indenture. Any failure
of the Trustee to give such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any
such supplemental indenture.

 

Section 8.03 Effect of Supplemental Indenture.
Upon the execution of any supplemental indenture pursuant to the provisions hereof, this Indenture shall be and be deemed to
be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities
under this Indenture of the Trustee, the Issuer, the Guarantor and the Holders of Securities of each series affected thereby shall
thereafter be determined, exercised

 

    55

    

    

 

and enforced hereunder subject in all respects to such modifications and amendments, and all
the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this
Indenture for any and all purposes.

 

Section 8.04 Documents to Be Given to
Trustee. The Trustee, subject to the provisions of Sections ‎6.01
and ‎‎6.02, may receive an Officer’s Certificate and an Opinion of Counsel as conclusive evidence that any
supplemental indenture executed pursuant to this ‎‎Article 8 complies with the applicable provisions of this Indenture.

 

Section 8.05 Notation on Securities in
Respect of Supplemental Indentures. Securities of any series authenticated and delivered after the execution of any supplemental
indenture pursuant to the provisions of this Article may bear a notation for such series as to any matter provided for by such
supplemental indenture or as to any action taken by Securityholders. If the Issuer shall so determine, new Securities of any series
so modified as to conform, in the opinion of the Board of the Issuer, to any modification of this Indenture contained in any such
supplemental indenture may be prepared by the Issuer, authenticated by the Trustee and delivered in exchange for the Securities
of such series then Outstanding.

 

Section 8.06 Notification of Holders
of Any Supplemental Indenture. Upon the execution of any supplemental indenture pursuant to the provisions hereof, the Issuer
shall provide notice to the Holders of Securities of each series affected thereby of such supplemental indenture within 60 business
days, provided that if such supplemental indenture has been filed with the Commission, notice shall be deemed to have been
given.

 

Article
9

Consolidation, Merger, Sale, Conveyance or Transfer

 

Section 9.01 Issuer May Consolidate,
Etc., on Certain Terms. The Issuer covenants that it will not merge or consolidate with any other Person or sell, convey or
transfer all or substantially all of its assets to any other Person, unless (i) either the Issuer shall be the continuing company
in the case of a merger or consolidation, or the successor Person in the case of a merger or consolidation (if other than the Issuer)
(including an affiliate of the Guarantor) or the Person to whom such assets are sold, conveyed or transferred in the case of a
sale, conveyance or transfer (including an affiliate of the Guarantor) shall be a corporation or limited liability company organized
under the laws of the United States of America or any State thereof or the District of Columbia and shall expressly assume the
due and punctual payment of the principal of, interest on and other amounts due under all the Securities and Coupons, if any, according
to

 

    56

    

    

 

their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this Indenture to
be performed or observed by the Issuer, by supplemental indenture satisfactory to the Trustee, executed and delivered to the Trustee
by such Person, and (ii) no Event of Default and no event which, with notice or lapse of time or both, would become an Event of
Default shall have occurred and be continuing, immediately after such merger or consolidation, or such sale, conveyance or transfer.

 

Section 9.02 Guarantor May Consolidate,
Etc., on Certain Terms. The Guarantor covenants that it will not merge or consolidate with any other Person or sell, convey
or transfer all or substantially all of its assets to any other Person (other than the Issuer), unless (i) either the Guarantor
shall be the continuing corporation in the case of a merger or consolidation, or the successor corporation in the case of a merger
or consolidation (if other than the Guarantor) or the Person to whom such assets are sold, conveyed or transferred in the case
of a sale, conveyance or transfer shall be a corporation organized under the laws of the United States of America or any State
thereof or the District of Columbia and shall expressly assume the full and unconditional guarantee of the full and punctual payment
of the principal of, interest on and other amounts due under all the Securities and Coupons, if any, according to their tenor,
and the due and punctual performance and observance of all of the covenants and conditions of this Indenture to be performed or
observed by the Guarantor, by supplemental indenture satisfactory to the Trustee, executed and delivered to the Trustee by such
corporation, and (ii) no Event of Default and no event which, with notice or lapse of time or both, would become an Event of Default
shall have occurred and be continuing, immediately after such merger or consolidation, or such sale, conveyance or transfer. For
purposes of this paragraph, any transfer of material assets of the Guarantor to any other Person that occurs as a result of, or
because it is related directly or indirectly to, any proceedings relative to the Guarantor under Title 11 of the United States
Code or under a receivership under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 or under any
other applicable federal or state bankruptcy, insolvency, resolution or other similar law shall be deemed to be a sale, conveyance
or transfer of all or substantially all of the Guarantor’s assets.

 

Section 9.03 Successor Person to Be Substituted.
In case of any such consolidation, merger, sale, conveyance or transfer, and upon any such assumption by the successor Person
or the Person to whom such sale, conveyance or transfer is made (each such successor Person or such Person to whom such sale, conveyance
or transfer is made referred to herein as a “Successor Person”), such Successor Person shall succeed to and
be substituted for the Issuer or the Guarantor, as applicable, with the same effect as if it had been named herein as the Issuer
or the Guarantor, as applicable.

 

    57

    

    

 

Such Successor Person of the Issuer may
cause to be signed, and may issue either in its own name or in the name of JPMorgan Chase Financial Company LLC any or all of the
Securities issuable hereunder, together with any Coupons appertaining thereto, which theretofore shall not have been signed by
the Issuer and delivered to the Trustee; and, upon the order of such Successor Person of the Issuer instead of the Issuer and subject
to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver any
Securities, together with any Coupons appertaining thereto, which previously shall have been signed and delivered by the officers
of the Issuer to the Trustee for authentication, and any Securities, together with any Coupons appertaining thereto, which such
Successor Person of the Issuer thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the Securities
so issued, together with any Coupons appertaining thereto shall in all respects have the same legal rank and benefit under this
Indenture as the Securities and Coupons theretofore or thereafter issued in accordance with the terms of this Indenture as though
all of such Securities and Coupons had been issued at the date of the execution hereof.

 

In case of any such consolidation, merger,
sale, conveyance or transfer, such changes in phraseology and form (but not in substance) may be made in the Securities and Coupons
thereafter to be issued as may be appropriate.

 

In the event of any such sale, conveyance
or transfer, the Issuer, the Guarantor or any Successor Person which shall theretofore have become such in the manner described
in this Article shall be discharged from all obligations and covenants under this Indenture and the Securities and may be liquidated
and dissolved.

 

Section 9.04 Opinion of Counsel to Trustee.
The Trustee, subject to the provisions of Sections ‎6.01
and ‎‎6.02, may receive an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale,
conveyance or transfer, and any such assumption, and any such liquidation or dissolution complies with the applicable provisions
of ‎‎Article 9.

 

Article
10

Satisfaction and Discharge of Indenture; Unclaimed Monies

 

Section 10.01 Satisfaction and Discharge
of Indenture. (a) If at any time (i) the Issuer or the Guarantor shall have paid or caused to be paid the principal of, interest
on and any other amounts due under all the Securities of any series Outstanding hereunder and all unmatured Coupons appertaining
thereto (other than Securities of such series and Coupons appertaining thereto which have been destroyed, lost or stolen and which
have been replaced or paid as provided in ‎‎Section 2.09 and other than Securities for whose payment money has theretofore

 

    58

    

    

 

been deposited in trust or segregated and held in trust by any paying agent and thereafter repaid to the Issuer or the Guarantor
or discharged from such trust, as provided in ‎‎Section 10.04), as and when the same shall have become due and payable,
or (ii) the Issuer shall have delivered to the Trustee for cancellation all Securities of any series theretofore authenticated
and all unmatured Coupons appertaining thereto (other than any Securities of such series and all unmatured Coupons appertaining
thereto which shall have been destroyed, lost or stolen and which shall have been replaced or paid as provided in ‎‎Section
2.09) or (iii) in the case of any series of Securities where the exact amount (including the currency of payment) of principal
of and interest due on which can be determined at the time of making the deposit referred to in clause (B) below, (A) all the Securities
of such series and all unmatured Coupons appertaining thereto not theretofore delivered to the Trustee for cancellation shall have
become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within
one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and (B) the Issuer or the Guarantor
shall have irrevocably deposited or caused to be deposited with the Trustee as trust funds the entire amount in cash (other than
monies repaid by the Trustee or any paying agent to the Issuer or the Guarantor in accordance with ‎‎Section 10.04)
or, in the case of any series of Securities the payments on which may only be made in Dollars, direct obligations of the United
States of America, backed by its full faith and credit (“U.S. Government Obligations”), maturing as to principal
and interest at such times and in such amounts as will insure the availability of cash, or a combination thereof, sufficient in
the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered
to the Trustee, to pay (1) the principal, interest and other amounts on all Securities of such series and Coupons appertaining
thereto on each date that such principal or interest is due and payable and (2) any mandatory sinking fund payments on the dates
on which such payments are due and payable in accordance with the terms of the Indenture and the Securities of such series; and
if, in any such case, the Issuer or the Guarantor shall also pay or cause to be paid all other sums payable hereunder by the Issuer
or the Guarantor, then this Indenture shall cease to be of further effect (except as to (i) rights of registration of transfer
and exchange of Securities of such series and of Coupons appertaining thereto and the Issuer’s right of optional redemption,
if any, (ii) substitution of mutilated, defaced, destroyed, lost or stolen Securities or Coupons, (iii) rights of holders of Securities
and Coupons appertaining thereto to receive payments of principal thereof and interest thereon, upon the original stated due dates
therefor (but not upon acceleration), and remaining rights of the Holders to receive mandatory sinking fund payments, if any, (iv)
the rights, obligations, duties and immunities of the Trustee hereunder, (v) the rights of the Holders of Securities of such series
and Coupons appertaining thereto as beneficiaries hereof with respect to the property so deposited with the Trustee payable to
all or any of them, and (vi) the obligations of the Issuer under ‎‎Section 3.02) and the Trustee, on demand of the
Issuer or the Guarantor, as the case may be, accompanied by an Officer’s

 

    59

    

    

 

Certificate of the Issuer or the Guarantor, as the
case may be, and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the satisfaction and
discharge of this Indenture contemplated by this provision have been complied with, and at the cost and expense of the Issuer or
the Guarantor, as the case may be, shall execute proper instruments acknowledging such satisfaction of and discharging this Indenture;
provided that the rights of Holders of the Securities and Coupons to receive amounts in respect of principal of and interest
on the Securities and Coupons held by them shall not be delayed longer than required by then applicable mandatory rules or policies
of any securities exchange upon which the Securities and Coupons are listed. Each of the Issuer and the Guarantor, jointly and
severally, agrees to reimburse the Trustee for any costs or expenses thereafter reasonably and properly incurred and to compensate
the Trustee for any services thereafter reasonably and properly rendered by the Trustee in connection with this Indenture or the
Securities of such series and Coupons appertaining thereto.

 

(b)           
The following provisions shall apply to the Securities of each series unless specifically otherwise provided in a Board
Resolution of the Issuer, Officer’s Certificate of the Issuer or indenture supplemental hereto provided pursuant to ‎‎Section
2.03. In addition to discharge of the Indenture pursuant to the next preceding paragraph, in the case of any series of Securities
the exact amounts (including the currency of payment) of principal of and interest due on which can be determined at the time
of making the deposit referred to in clause ‎(i) below, the Issuer and the Guarantor shall be deemed to have paid and discharged
the entire indebtedness on all the Securities of such a series and the Coupons appertaining thereto on the 91st day after the
date of the deposit referred to in clause ‎(i) below, and the provisions of this Indenture with respect to the Securities
of such series and Coupons appertaining thereto shall no longer be in effect (except as to (1) rights of registration of transfer
and exchange of Securities of such series and of Coupons appertaining thereto and the Issuer’s right of optional redemption,
if any, (2) substitution of mutilated, defaced, destroyed, lost or stolen Securities or Coupons, (3) rights of holders of Securities
and Coupons appertaining thereto to receive payments of principal thereof and interest thereon, upon the original stated due dates
therefor (but not upon acceleration), and remaining rights of the Holders to receive mandatory sinking fund payments, if any,
(4) the rights, obligations, duties and immunities of the Trustee hereunder, (5) the rights of the holders of Securities of such
series and Coupons appertaining thereto as beneficiaries hereof with respect to the property so deposited with the Trustee payable
to all or any of them and (6) the obligations of the Issuer under ‎‎Section 3.02) and the Trustee, at the expense of the
Issuer or the Guarantor, as the case may be, shall at the Issuer’s or the Guarantor’s request, as the case may be,
execute proper instruments acknowledging the same, if

 

(i)           
with reference to this provision, the Issuer or the Guarantor has irrevocably deposited or caused to be irrevocably deposited
with the

 

    60

    

    

 

Trustee
as trust funds in trust, specifically pledged as security for, and dedicated solely to, the benefit of the holders of the Securities
of such series and Coupons appertaining thereto (A) cash in an amount, or (B) in the case of any series of Securities the payments
on which may only be made in Dollars, U.S. Government Obligations, maturing as to principal and interest at such times and in
such amounts as will insure the availability of cash or (C) a combination thereof, sufficient, in the opinion of a nationally
recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay
(1) the principal, interest and other amounts due on all Securities of such series and Coupons appertaining thereto on each date
that such principal, interest or other amounts is due and payable and (2) any mandatory sinking fund payments on the dates on
which such payments are due and payable in accordance with the terms of the Indenture and the Securities of such series;

 

(ii)           
such deposit will not result in a breach or violation of, or constitute a default under, any agreement or instrument to
which the Issuer or the Guarantor is a party or by which it is bound;

 

(iii)           
the Issuer or the Guarantor has delivered to the Trustee an Opinion of Counsel based on the fact that (x) the Issuer or
the Guarantor, as the case may be, has received from, or there has been published by, the Internal Revenue Service a ruling or
(y) since the date hereof, there has been a change in the applicable United States federal income tax law, in either case to the
effect that, and such opinion shall confirm that, the beneficial owners of the Securities of such series and Coupons appertaining
thereto will not recognize income, gain or loss for United States federal income tax purposes as a result of such deposit, defeasance
and discharge and will be subject to United States federal income tax on the same amounts and in the same manner and at the same
times, as would have been the case if such deposit, defeasance and discharge had not occurred; and

 

(iv)           
the Issuer or the Guarantor has delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each
stating that all conditions precedent provided for relating to the defeasance contemplated by this provision have been complied
with.

 

(c)           
The Issuer and the Guarantor shall be released from their obligations under ‎‎Section 9.01 and ‎Section 9.02,
respectively, and any other Sections applicable to such Securities that are determined pursuant to ‎Section 2.03 to be subject
to this provision; with respect to the Securities of any series, and any Coupons appertaining thereto, Outstanding on and after
the date the conditions set forth below are satisfied (hereinafter, “covenant defeasance”). For this purpose,

 

    61

    

    

 

such covenant defeasance means that, with respect to the Outstanding Securities of any Series, the Issuer and the Guarantor may
omit to comply with and shall have no liability in respect of any term, condition or limitation set forth in such Section, whether
directly or indirectly by reason of any reference elsewhere herein to such Section or by reason of any reference in such Section
to any other provision herein or in any other document and such omission to comply shall not constitute an Event of Default under
‎‎Section 5.01, but the remainder of this Indenture and such Securities and Coupons shall be unaffected thereby. The following
shall be the conditions to application of this subsection ‎‎(c) of this ‎‎Section 10.01:

 

(i)           
The Issuer or the Guarantor has irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust
for the purpose of making the following payments, specifically pledged as security for, and dedicated solely to, the benefit of
the holders of the Securities of such series and Coupons appertaining thereto, (A) cash in an amount, or (B) in the case of any
series of Securities the payments on which may only be made in Dollars, U.S. Government Obligations maturing as to principal and
interest at such times and in such amounts as will insure the availability of cash or (C) a combination thereof, sufficient, in
the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered
to the Trustee, to pay (1) the principal, interest and other amounts due on all Securities of such series and Coupons appertaining
thereto and (2) any mandatory sinking fund payments on the day on which such payments are due and payable in accordance with the
terms of the Indenture and the Securities of such series.

 

(ii)           
No Event of Default or event which with notice or lapse of time or both would become an Event of Default with respect to
the Securities shall have occurred and be continuing on the date of such deposit or, insofar as subsections ‎5.01(d) and ‎5.01(e)
are concerned, at any time during the period ending on the 91st day after the date of such deposit (it being understood that this
condition shall not be deemed satisfied until the expiration of such period).

 

(iii)           
Such covenant defeasance shall not cause the Trustee to have a conflicting interest for purposes of the Trust Indenture
Act of 1939 with respect to any securities of the Issuer or the Guarantor.

 

(iv)           
Such covenant defeasance shall not result in a breach or violation of, or constitute a default under, this Indenture or
any other agreement or instrument to which the Issuer or the Guarantor is a party or by which it is bound.

 

    62

    

    

 

(v)           
Such covenant defeasance shall not cause any Securities then listed on any registered national securities exchange under
the Securities Exchange Act of 1934, as amended, to be delisted.

 

(vi)           
The Issuer or the Guarantor, as the case may be, shall have delivered to the Trustee an Opinion of Counsel to the effect
that the beneficial owners of the Securities of such series and Coupons appertaining thereto will not recognize income, gain or
loss for United States federal income tax purposes as a result of such covenant defeasance and will be subject to United States
federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such covenant
defeasance had not occurred.

 

(vii)           
The Issuer or the Guarantor, as the case may be, shall have delivered to the Trustee an Officer’s Certificate of
the Issuer or the Guarantor, as the case may be, and an Opinion of Counsel, each stating that all conditions precedent provided
for relating to the covenant defeasance contemplated by this provision have been complied with.

 

Section 10.02 Application by Trustee
of Funds Deposited for Payment of Securities. Subject to ‎‎Section 10.04, all monies deposited with the Trustee
pursuant to ‎‎Section 10.01 shall be held in trust and applied by it to the payment, either directly or through
any paying agent (including the Issuer or the Guarantor acting as its own paying agent), to the Holders of the particular Securities
of such series and of Coupons appertaining thereto for the payment or redemption of which such monies have been deposited with
the Trustee, of all sums due and to become due thereon for principal and interest; but such money need not be segregated from other
funds except to the extent required by law.

 

Section 10.03 Repayment of Monies Held
by Paying Agent. In connection with the satisfaction and discharge of this Indenture with respect to Securities of any series,
all monies then held by any paying agent under the provisions of this Indenture with respect to such series of Securities shall,
upon demand of the Issuer or the Guarantor, as the case may be, be repaid to it or paid to the Trustee and thereupon such paying
agent shall be released from all further liability with respect to such monies.

 

Section 10.04 Return of Monies Held by
Trustee and Paying Agent Unclaimed for Two Years. Any monies deposited with or paid to the Trustee or any paying agent for
the payment of the principal of or interest on any Security of any series or Coupons attached thereto and not applied but remaining
unclaimed for two years after the date upon which such principal or interest shall have become due and payable, shall, upon the
written request of the Issuer or the Guarantor, as the case may be, and unless otherwise required by mandatory provisions of applicable
escheat or abandoned or unclaimed property law, be

 

    63

    

    

 

repaid to the Issuer or the Guarantor, as the case may be, by the Trustee for
such series or such paying agent, and the Holder of the Securities of such series and of any Coupons appertaining thereto shall,
unless otherwise required by mandatory provisions of applicable escheat or abandoned or unclaimed property laws, thereafter look
only to the Issuer (except with respect to the Guarantee) or the Guarantor, as the case may be, for any payment which such Holder
may be entitled to collect, and all liability of the Trustee or any paying agent with respect to such monies shall thereupon cease;
provided, however, that the Trustee or such paying agent, before being required to make any such repayment, with respect
to monies deposited with it for any payment (a) in respect of Registered Securities of any series, shall at the expense of the
Issuer or the Guarantor, as the case may be, mail by first-class mail to Holders of such Securities at their addresses as they
shall appear on the Security register, and (b) in respect of Unregistered Securities of any series, shall at the expense of the
Issuer or the Guarantor, as the case may be, either give (A) by mail to Holders of such Securities who have filed their names and
addresses with the Trustee within the two years preceding the notice at such addresses as were so furnished to the Trustee and
(B) either through the customary notice provisions of the clearing system or systems through which beneficial interests in such
Unregistered Securities are owned if such Unregistered Securities are held only in global form or cause to be published once, in
an Authorized Newspaper in the Borough of Manhattan, The City of New York and once in an Authorized Newspaper in London (and if
required by ‎‎Section 3.06, once in an Authorized Newspaper in Luxembourg), notice, that such monies remain and
that, after a date specified therein, which shall not be less than thirty days from the date of such mailing or publication, any
unclaimed balance of such money then remaining will be repaid to the Issuer or the Guarantor, as the case may be.

 

Section 10.05 Indemnity for U.S. Government
Obligations. The Issuer shall pay and indemnify, and if the Issuer has not paid and indemnified, the Guarantor shall pay and
indemnify, the Trustee against any tax, fee or other charge imposed on or assessed against the U.S. Government Obligations deposited
pursuant to ‎‎Section 10.01 or the principal or interest received in respect of such obligations. The Issuer’s
and Guarantor’s obligations pursuant to this Section 10.05 shall survive the earlier termination of this Indenture or resignation
or removal of the Trustee.

 

Article
11

Miscellaneous Provisions

 

Section 11.01 Incorporators, Stockholders,
Officers and Directors of Issuer and Guarantor Exempt from Individual Liability. No recourse under or upon any obligation,
covenant or agreement contained in this Indenture, including the Guarantee, or in any Security, or because of any indebtedness
evidenced

 

    64

    

    

 

thereby, shall be had against any incorporator, as such or against any past, present or future stockholder, officer or
director, as such, of the Issuer, of the Guarantor or of any successor, either directly or through the Issuer, the Guarantor or
any successor, under any rule of law, statute or constitutional provision or by the enforcement of any assessment or by any legal
or equitable proceeding or otherwise, all such liability being expressly waived and released by the acceptance of the Securities
and the Coupons appertaining thereto by the Holders thereof and as part of the consideration for the issue of the Securities and
the Coupons appertaining thereto.

 

Section 11.02 Provisions of Indenture
for the Sole Benefit of Parties and Holders of Securities and Coupons. Nothing in this Indenture or in the Securities or in
the Coupons appertaining thereto, expressed or implied, shall give or be construed to give to any person, firm or corporation,
other than the parties hereto and their successors and the holders of the Securities or Coupons, any legal or equitable right,
remedy or claim under this Indenture or under any covenant or provision herein contained, all such covenants and provisions being
for the sole benefit of the parties hereto and their successors and of the holders of the Securities.

 

Section 11.03 Successors and Assigns
of Issuer and Guarantor Bound by Indenture. All the covenants, stipulations, promises and agreements in this Indenture made
by or on behalf of the Issuer or the Guarantor shall bind its successors and assigns, whether so expressed or not.

 

Section 11.04 Notices and Demands on
Issuer, Guarantor, Trustee and Holders of Securities and Coupons. Any notice or demand which by any provision of this Indenture
is required or permitted to be given or served by the Trustee or by the Holders of Securities or Coupons to or on the Issuer or
the Guarantor must be in writing and may be given or served by fax, by email in a PDF format or by being deposited postage prepaid,
first class mail (except as otherwise specifically provided herein) addressed (until another address of the Issuer is filed by
the Issuer with the Trustee) to (a) in the case of the Issuer, JPMorgan Chase Financial Company LLC, 383 Madison Avenue, Floor
21, New York, New York 10179, Attention: Secretary and (ii) in the case of the Guarantor, JPMorgan Chase & Co., 270 Park Avenue,
40th Floor, New York, New York 10017-2070, Attention: Finance Controllers — Interentity Analysis Group. Any notice,
direction, request or demand by the Issuer, the Guarantor or any Securityholder to or upon the Trustee shall be deemed to have
been sufficiently given or made, for all purposes, if given or made at the Corporate Trust Office marked to the attention of the
Corporate Trust Department.

 

Where this Indenture provides for notice
to Holders of Registered Securities, such notice shall be sufficiently given (unless otherwise herein expressly provided) if in
writing and faxed, emailed or mailed, first class postage

 

    65

    

    

 

prepaid, to each Holder entitled thereto, at his last address as it appears
in the Security register. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any
defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders.
Where this Indenture provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive
such notice, either before or after the event, and such waiver shall be the equivalent of such notice. Waivers of notice by Holders
shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in reliance
upon such waiver.

 

Where this Indenture provides for notice
to Holders of Unregistered Securities, such notice shall be sufficiently given (unless otherwise herein expressly provided) if
given by the following methods: (A) by mail to such Holders who have filed their names and addresses with the Trustee within the
two years preceding the notice at such addresses as were so furnished to the Trustee and (B) either through the customary notice
provisions of the clearing system or systems through which beneficial interests in such Unregistered Securities are owned if such
Unregistered Securities are held only in global form or by publication at least once in an Authorized Newspaper in the Borough
of Manhattan, The City of New York, and at least once in an Authorized Newspaper in London (and, if required by ‎‎Section
3.06, at least once in an Authorized Newspaper in Luxembourg).

 

In case, by reason of the suspension of
or irregularities in regular mail service, it shall be impracticable to mail notice to the Issuer, the Guarantor and holders of
Securities when such notice is required to be given pursuant to any provision of this Indenture, then any manner of giving such
notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice.

 

Section 11.05 Officer’s Certificates
and Opinions of Counsel; Statements to Be Contained Therein. Upon any application or demand by the Issuer or the Guarantor
to the Trustee to take any action under any of the provisions of this Indenture, the Issuer, the Guarantor, or both, as the case
may be, shall furnish to the Trustee such Officer’s Certificate of the Issuer, the Guarantor, or both, as the case may be,
stating that all conditions precedent provided for in this Indenture relating to the proposed action have been complied with and
such Opinion of Counsel of the Issuer, the Guarantor, or both, as the case may be, stating that in the opinion of such counsel
all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the
furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application
or demand, no additional certificate or opinion need be furnished.

 

    66

    

    

 

Each certificate or opinion provided for
in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant provided for in this Indenture
shall include (a) a statement that the person making such certificate or opinion has read such covenant or condition, (b) a brief
statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such
certificate or opinion are based, (c) a statement that, in the opinion of such person, he has made such examination or investigation
as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied
with and (d) a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.

 

Any certificate, statement or opinion of
an officer of the Issuer or the Guarantor may be based, insofar as it relates to legal matters, upon a certificate or opinion of
or representations by counsel, unless such officer knows that the certificate or opinion or representations with respect to the
matters upon which his certificate, statement or opinion may be based as aforesaid are erroneous, or in the exercise of reasonable
care should know that the same are erroneous. Any certificate, statement or opinion of counsel may be based, insofar as it relates
to factual matters, information with respect to which is in the possession of the Issuer or the Guarantor, as applicable, upon
the certificate, statement or opinion of or representations by an officer or officers of the Issuer or Guarantor, as applicable,
unless such counsel knows that the certificate, statement or opinion or representations with respect to the matters upon which
his certificate, statement or opinion may be based as aforesaid are erroneous.

 

Any certificate, statement or opinion of
an officer of the Issuer, an officer of the Guarantor or of counsel may be based, insofar as it relates to accounting matters,
upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of the Issuer or the
Guarantor, unless such officer or counsel, as the case may be, knows that the certificate or opinion or representations with respect
to the accounting matters upon which his certificate, statement or opinion may be based as aforesaid are erroneous, or in the exercise
of reasonable care should know that the same are erroneous.

 

Any certificate or opinion of any independent
firm of public accountants filed with and directed to the Trustee shall contain a statement that such firm is independent.

 

Section 11.06 Payments Due on Saturdays,
Sundays and Holidays. If the date of maturity of interest on or principal of the Securities of any series or any Coupons appertaining
thereto or the date fixed for redemption or repayment of any such Security shall not be a Business Day, then payment of interest
or principal need not be made on such date, but may be made on the next succeeding Business Day with the same force and effect
as if made on the date of maturity or

 

    67

    

    

 

the date fixed for redemption, and no interest shall accrue for the period after such date
(unless otherwise specified).

 

Section 11.07 Conflict of Any Provision
of Indenture with Trust Indenture Act of 1939. If and to the extent that any provision of this Indenture limits, qualifies
or conflicts with the duties imposed by, or with another provision (an “incorporated provision”) included in
this Indenture by operation of, Sections 310 to 318, inclusive, of the Trust Indenture Act of 1939, such imposed duties or incorporated
provision shall control.

 

Section 11.08 New York Law to Govern.
This Indenture and each Security and Coupon and the Guarantee shall be deemed to be a contract under the laws of the State
of New York, and for all purposes shall be construed in accordance with the laws of such State, except as may otherwise be required
by mandatory provisions of law.

 

Section 11.09 Counterparts. This
Indenture may be executed in any number of counterparts, each of which shall be an original; but such counterparts shall together
constitute but one and the same instrument.

 

Section 11.10 Effect of Headings. The
Article and Section headings herein and the Table of Contents are for convenience only and shall not affect the construction hereof.

 

Section 11.11 Securities in a Foreign
Currency. Unless otherwise specified in an Officer’s Certificate of the Issuer delivered pursuant to ‎‎Section
2.03 of this Indenture with respect to a particular series of Securities, whenever for purposes of this Indenture any action may
be taken by the Holders of a specified percentage in aggregate principal amount of Securities of all series or all series affected
by a particular action at the time Outstanding and, at such time, there are Outstanding Securities of any series which are denominated
in a coin or currency other than Dollars, then the principal amount of Securities of such series which shall be deemed to be Outstanding
for the purpose of taking such action shall be that amount of Dollars that could be obtained for such amount on such reasonable
basis of exchange and as of such date as the Issuer may specify in a written notice to the Trustee. The provisions of this paragraph
shall apply in determining the equivalent principal amount in respect of Securities of a series denominated in a currency other
than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.

 

All decisions and determinations of the
Issuer regarding the Market Exchange Rate or any alternative determination provided for in the preceding paragraph shall be in
its sole discretion and shall, in the absence of manifest error, be conclusive to the extent permitted by law for all purposes
and irrevocably binding upon the Issuer and all Holders.

 

    68

    

    

 

Section 11.12 Judgment Currency. Each
of the Issuer and the Guarantor agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if for
the purpose of obtaining judgment in any court it is necessary to convert the sum due in respect of the principal of or interest
on the Securities of any series (the “Required Currency”) into a currency in which a judgment will be rendered
(the “Judgment Currency”), the rate of exchange used shall be the rate at which in accordance with normal banking
procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the day on which
final unappealable judgment is entered, unless such day is not a New York Banking Day, then, to the extent permitted by applicable
law, the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase
in The City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which
final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency (i)
shall not be discharged or satisfied by any tender, or any recovery pursuant to any judgment (whether or not entered in accordance
with subsection (a)), in any currency other than the Required Currency, except to the extent that such tender or recovery shall
result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such
payments, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in the Required
Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed
to be payable and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture. For purposes
of the foregoing, “New York Banking Day” means any day except a Saturday, Sunday or a legal holiday in The City
of New York or a day on which banking institutions in The City of New York are authorized or required by law or executive order
to close.

 

Article
12

Redemption of Securities and Sinking Funds

 

Section 12.01 Applicability of Article.
The provisions of this Article shall be applicable to the Securities of any series that are redeemable before their maturity
or to any sinking fund for the retirement of Securities of a series except as otherwise specified as contemplated by ‎‎Section
2.03 for Securities of such series.

 

Section 12.02 Notice of Redemption; Partial
Redemptions. Notice of redemption to the Holders of Registered Securities of any series to be redeemed as a whole or in part
at the option of the Issuer shall be given by mailing notice of such redemption by first class mail, postage prepaid or otherwise
delivered, to such Holders of Securities of such series at their last addresses as they shall appear upon the registry books at
least 30 days and not more than 60 days prior to

 

    69

    

    

 

the date fixed for redemption, or within such other redemption notice period as
has been designated for any Securities of such series pursuant to ‎Section 2.03 or ‎2.04 (the “Redemption
Notice Period”). Notice of redemption to the Holders of Unregistered Securities to be redeemed as a whole or in part,
who have filed their names and addresses with the Trustee or the Registrar, as applicable, within two years preceding such notice
of redemption, shall be given by mailing notice of such redemption, by first class mail, postage prepaid, at least 30 and not more
than 60 days prior to the date fixed for redemption or within any applicable Redemption Notice Period to such Holders at such addresses
as were so furnished to the Trustee or the Registrar, as the case may be, (and, in the case of any such notice given by the Issuer,
the Trustee or the Registrar, as the case may be, shall make such information available to the Issuer for such purpose). Notice
of redemption to all other Holders of Unregistered Securities shall be published in an Authorized Newspaper in the Borough of Manhattan,
The City of New York and in an Authorized Newspaper in London (and, if required by ‎‎Section 3.06, in an Authorized
Newspaper in Luxembourg), in each case, once in each of three successive calendar weeks, the first publication to be not less than
30 nor more than 60 days prior to the date fixed for redemption or within any applicable Redemption Notice Period; provided
that notice to Holders of Unregistered Securities held only in global form may be made, at the option of the Issuer, through the
customary notice provisions of the clearing system or systems through which beneficial interests in such Unregistered Securities
are owned. Any notice which is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether
or not the Holder receives the notice. Failure to give notice by mail, or any defect in the notice to the Holder of any Security
of a series designated for redemption as a whole or in part shall not affect the validity of the proceedings for the redemption
of any other Security of such series.

 

The notice of redemption to each such Holder
shall specify the principal amount of each Security of such series held by such Holder to be redeemed, the date fixed for redemption,
the redemption price (or if not then ascertainable, the manner of calculation thereof), the place or places of payment, that payment
will be made upon presentation and surrender of such Securities and, in the case of Securities with Coupons attached thereto, of
all Coupons appertaining thereto maturing after the date fixed for redemption, that such redemption is pursuant to the mandatory
or optional sinking fund, or both, if such be the case, that interest accrued to the date fixed for redemption will be paid as
specified in such notice and that on and after said date interest thereon or on the portions thereof to be redeemed will cease
to accrue. In case any Security of a series is to be redeemed in part only the notice of redemption shall state the portion of
the principal amount thereof to be redeemed and shall state that on and after the date fixed for redemption, upon surrender of
such Security and, in the case of Securities with Coupons attached thereto, of all Coupons appertaining thereto maturing after
the date fixed for redemption, in the case of definitive Securities, a new Security or

 

    70

    

    

 

Securities or Coupons, as the case may be,
of such series in principal amount equal to the unredeemed portion thereof will be issued.

 

The notice of redemption of Securities of
any series to be redeemed at the option of the Issuer shall be given by the Issuer, or at the Issuer’s request and with at
least 15 days’ notice to the Registrar, by the Registrar in the name and at the expense of the Issuer.

 

On or before the redemption date specified
in the notice of redemption given as provided in this Section, the Issuer will deposit with the Trustee or with one or more paying
agents (or, if the Issuer is acting as its own paying agent, set aside, segregate and hold in trust as provided in ‎‎Section
3.04) an amount of money or other property sufficient to redeem on the redemption date all the Securities of such series so called
for redemption at the appropriate redemption price, together with accrued interest to the date fixed for redemption. If less than
all the Outstanding Securities of a series are to be redeemed, the Issuer will deliver to the Trustee and the Registrar at least
60 days prior to the date fixed for redemption an Officer’s Certificate stating the aggregate principal amount of Securities
to be redeemed.

 

If fewer than all the Securities of a series
are to be redeemed, the Registrar shall select, in such manner as it shall deem appropriate and fair, and in accordance with the
procedures of the Depositary, if any, Securities of such series to be redeemed in part. Securities may be redeemed in part in multiples
equal to the minimum authorized denomination for Securities of such series or any multiple thereof. The Registrar shall promptly
notify the Issuer in writing of the Securities of such series selected for redemption and, in the case of any Securities of such
series selected for partial redemption, the principal amount thereof to be redeemed. For all purposes of this Indenture, unless
the context otherwise requires, all provisions relating to the redemption of Securities of any series shall relate, in the case
of any Security redeemed or to be redeemed only in part, to the portion of the principal amount of such Security which has been
or is to be redeemed.

 

Section 12.03 Payment of Securities Called
for Redemption. If notice of redemption has been given as above provided, the Securities or portions of Securities specified
in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price,
together with interest accrued to the date fixed for redemption, and on and after said date (unless the Issuer shall default in
the payment of such Securities at the redemption price, together with interest accrued to said date) interest on the Securities
or portions of Securities so called for redemption shall cease to accrue, and the unmatured Coupons, if any, appertaining thereto
shall be void, and, except as provided in Sections ‎‎6.05 and ‎‎10.04, such Securities shall cease
from and after the date fixed for redemption to be entitled to any benefit or security under this

 

    71

    

    

 

Indenture, and the Holders thereof
shall have no right in respect of such Securities except the right to receive the redemption price thereof and unpaid interest
to the date fixed for redemption. On presentation and surrender of such Securities at a place of payment specified in said notice,
together with all Coupons, if any, appertaining thereto maturing after the date fixed for redemption, said Securities with, in
the case of any Unregistered Securities that have Coupons attached, all matured Coupons in default appertaining thereto or the
specified portions thereof shall be paid and redeemed by the Issuer at the applicable redemption price, together with interest
accrued thereon to the date fixed for redemption; provided that any payment of interest becoming due on or prior to the
date fixed for redemption shall be payable in the case of Securities with Coupons attached thereto, to the Holders of the Coupons
for such interest upon surrender thereof, and in the case of Registered Securities, to the Holders of such Securities registered
as such on the relevant record date subject to the terms and provisions of ‎‎Section 2.04 hereof.

 

If any Security called for redemption shall
not be so paid upon surrender thereof for redemption, the principal shall, until paid or duly provided for, bear interest from
the date fixed for redemption at the rate of interest or Yield to Maturity (in the case of an Original Issue Discount Security)
borne by the Security.

 

If any Security with Coupons attached thereto
is surrendered for redemption and is not accompanied by all appurtenant Coupons maturing after the date fixed for redemption, the
surrender of such missing Coupon or Coupons may be waived by the Issuer and the Trustee, if there be furnished to each of them
such security or indemnity as they may require to save each of them harmless.

 

In the case of definitive Securities, upon
presentation of any Security or Coupons appertaining thereto redeemed in part only, the Issuer shall execute and the Trustee shall
authenticate and deliver to or on the order of the Holder thereof, at the expense of the Issuer, a new Security or Securities of
such series together with all Coupons, if any, appertaining thereto, of authorized denominations, in principal amount equal to
the unredeemed portion of the Security or Coupons appertaining thereto so presented.

 

Section 12.04 Exclusion of Certain Securities
from Eligibility for Selection for Redemption. Securities shall be excluded from eligibility for selection for redemption if
they are identified by registration and certificate number in an Officer’s Certificate of the Issuer delivered to the Trustee
at least 30 days prior to the last date on which notice of redemption may be given as being owned of record and/or beneficially
by, and not pledged or hypothecated by, either (a) the Issuer or (b) an entity specifically identified in such written statement
as directly or indirectly controlling or controlled by or under direct or indirect common control with the Issuer.

 

    72

    

    

 

Section 12.05 Mandatory and Optional
Sinking Funds. The minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein
referred to as a “mandatory sinking fund payment,” and any payment in excess of such minimum amount provided for by
the terms of the Securities of any series is herein referred to as an “optional sinking fund payment”. The date on
which a sinking fund payment is to be made is herein referred to as the “sinking fund payment date.”

 

In lieu of making all or any part of any
mandatory sinking fund payment with respect to any series of Securities in cash, the Issuer may at its option (a) deliver to the
Trustee Securities of such series theretofore purchased or otherwise acquired (except upon redemption pursuant to the mandatory
sinking fund) by the Issuer or receive credit for Securities of such series (not previously so credited) theretofore purchased
or otherwise acquired (except as aforesaid) by the Issuer and delivered to the Trustee for cancellation pursuant to ‎‎Section
2.10, (b) receive credit for optional sinking fund payments (not previously so credited) made pursuant to this Section, or (c)
receive credit for Securities of such series (not previously so credited) redeemed by the Issuer through any optional redemption
provision contained in the terms of such series. Securities so delivered or credited shall be received or credited by the Trustee
at the sinking fund redemption price specified in such Securities.

 

On or before the sixtieth day next preceding
each sinking fund payment date or the 30th day next preceding the last day of any applicable Redemption Notice Period relating
to a sinking fund payment date for any series, the Issuer will deliver to the Trustee an Officer’s Certificate (which need
not contain the statements required by ‎‎Section 11.05)
(a) specifying the portion of the mandatory sinking fund payment to be satisfied by payment of cash and the portion to be satisfied
by credit of Securities of such series and the basis for such credit, (b) stating that none of the Securities of such series has
theretofore been so credited, (c) stating that no defaults in the payment of interest or Events of Default with respect to such
series have occurred (which have not been waived or cured) and are continuing and (d) stating whether or not the Issuer intends
to exercise its right to make an optional sinking fund payment with respect to such series and, if so, specifying the amount of
such optional sinking fund payment which the Issuer intends to pay on or before the next succeeding sinking fund payment date.
Any Securities of such series to be credited and required to be delivered to the Trustee in order for the Issuer to be entitled
to credit therefor as aforesaid which have not theretofore been delivered to the Trustee shall be delivered for cancellation pursuant
to ‎‎Section 2.10 to the Trustee with such Officer’s Certificate (or reasonably promptly thereafter if acceptable
to the Trustee). Such Officer’s Certificate shall be irrevocable and upon its delivery the Issuer shall become unconditionally
obligated to make all the cash payments or payments therein referred to, if any, on or before the next succeeding sinking fund
payment date. Failure of the Issuer, on or before any such sixtieth day or thirtieth day, if

 

    73

    

    

 

applicable, to deliver such Officer’s
Certificate and Securities specified in this paragraph, if any, shall not constitute a default but shall constitute, on and as
of such date, the irrevocable election of the Issuer (i) that the mandatory sinking fund payment for such series due on the next
succeeding sinking fund payment date shall be paid entirely in cash without the option to deliver or credit Securities of such
series in respect thereof and (ii) that the Issuer will make no optional sinking fund payment with respect to such series as provided
in this Section.

 

If the sinking fund payment or payments
(mandatory or optional or both) to be made in cash on the next succeeding sinking fund payment date plus any unused balance of
any preceding sinking fund payments made in cash shall exceed $50,000 (or the equivalent thereof in any Foreign Currency) or a
lesser sum in Dollars (or the equivalent thereof in any Foreign Currency) if the Issuer shall so request with respect to the Securities
of any particular series, such cash shall be applied on the next succeeding sinking fund payment date to the redemption of Securities
of such series at the sinking fund redemption price together with accrued interest to the date fixed for redemption. If such amount
shall be $50,000 (or the equivalent thereof in any Foreign Currency) or less and the Issuer makes no such request then it shall
be carried over until a sum in excess of $50,000 (or the equivalent thereof in any Foreign Currency) is available. The Trustee
shall select, in the manner provided in ‎‎Section 12.02, for redemption on such sinking fund payment date a sufficient
principal amount of Securities of such series to absorb said cash, as nearly as may be, and shall (if requested in writing by the
Issuer) inform the Issuer of the serial numbers of the Securities of such series (or portions thereof) so selected. Securities
shall be excluded from eligibility for redemption under this Section if they are identified by registration and certificate number
in an Officer’s Certificate delivered to the Trustee at least 60 days prior to the sinking fund payment date or at least
30 days prior to the last day of any applicable Redemption Notice Period relating to a sinking fund payment date as being owned
of record and beneficially by, and not pledged or hypothecated by either (a) the Issuer or (b) an entity specifically identified
in such Officer’s Certificate as directly or indirectly controlling or controlled by or under direct or indirect common control
with the Issuer. The Trustee, in the name and at the expense of the Issuer (or the Issuer, if it shall so request the Trustee in
writing) shall cause notice of redemption of the Securities of such series to be given in substantially the manner provided in
‎‎Section 12.02 (and with the effect provided in ‎‎Section 12.03) for the redemption of Securities of such series
in part at the option of the Issuer. The amount of any sinking fund payments not so applied or allocated to the redemption of Securities
of such series shall be added to the next cash sinking fund payment for such series and, together with such payment, shall be applied
in accordance with the provisions of this Section. Any and all sinking fund monies held on the stated maturity date of the Securities
of any particular series (or earlier, if such maturity is accelerated), which are not held for the payment or redemption of particular
Securities of such series shall be applied, together with other monies, if necessary, sufficient for the purpose, to the

 

    74

    

    

 

payment
of the principal of, and interest on, the Securities of such series at maturity.

 

On or before each sinking fund payment date,
the Issuer shall pay to the Trustee in cash or shall otherwise provide for the payment of all interest accrued to the date fixed
for redemption on Securities to be redeemed on the next following sinking fund payment date.

 

The Trustee shall not redeem or cause to
be redeemed any Securities of a series with sinking fund monies or provide notice of redemption of Securities for such series by
operation of the sinking fund during the continuance of a default in payment of interest on such Securities or of any Event of
Default except that, where the giving of notice of redemption of any Securities shall theretofore have been made, the Trustee shall
redeem or cause to be redeemed such Securities, provided that it shall have received from the Issuer a sum sufficient for
such redemption. Except as aforesaid, any monies in the sinking fund for such series at the time when any such default or Event
of Default shall occur, and any monies thereafter paid into the sinking fund, shall, during the continuance of such default or
Event of Default, be deemed to have been collected under ‎‎Article 5 and held for the payment of all such Securities. In
case such Event of Default shall have been waived as provided in ‎‎Section 5.10 or the default cured on or before the sixtieth
day preceding the sinking fund payment date in any year, such monies shall thereafter be applied on the next succeeding sinking
fund payment date in accordance with this Section to the redemption of such Securities.

 

Article
13

Repurchase of Securities at the Option of the Holder

 

Section 13.01 Applicability of Article.
The provisions of this Article shall be applicable to Securities of any series that are subject to repurchase at the option
of the Holders thereof before their maturity except as otherwise specified as contemplated by ‎Section 2.03 for Securities
of such series.

 

Section 13.02 Minimum Repurchase Amount.
The terms of the Securities may require a Holder to request a minimum amount or number of Securities to be repurchased on any date
fixed for repurchase.

 

Section 13.03 Notice of Repurchase; Partial
Repurchase. Notice and confirmation of a required repurchase by the Issuer of Securities of any series to be repurchased as
a whole or in part at the option of the Holders shall be given by each Holder in the manner and at the time specified in the terms
of such Securities.

 

    75

    

    

 

The notice of repurchase from each such
Holder shall specify the principal amount or number of each Security of such series held by such Holder to be repurchased and that
arrangements will be made for the presentation and surrender of such Securities and, in the case of Securities with Coupons attached
thereto, of all Coupons appertaining thereto maturing after the date fixed for repurchase and that on and after said date interest
thereon or on the portions thereof to be repurchased will cease to accrue.

 

On or before the repurchase date specified
in the terms of the Securities as provided for in this Section, the Issuer will deposit with the Trustee or with one or more paying
agents (or, if the Issuer is acting as its own paying agent, set aside, segregate and hold in trust as provided in ‎Section
3.04) an amount of money or other property sufficient to repurchase on the repurchase date all the Securities of such series submitted
for repurchase at the appropriate repurchase price, together with accrued interest, if any, to the date fixed for repurchase.

 

Section 13.04 Payment of Securities Subject
to Repurchase. If notice of repurchase has been given as above provided, the Securities or portions of Securities specified
in such notice shall become due and payable on the date and at the place set forth in the terms of such Securities at the applicable
repurchase price, together with interest accrued, if any, to the date fixed for repurchase, and on and after said date (unless
the Issuer shall default in the payment of such Securities at the repurchase price, together with interest accrued to said date,
if any) interest on the Securities or portions of Securities so subject to repurchase shall cease to accrue, and the unmatured
Coupons, if any, appertaining thereto shall be void, and, except as provided in Sections ‎6.05 and ‎10.04,
such Securities shall cease from and after the date fixed for repurchase to be entitled to any benefit or security under this Indenture,
and the Holders thereof shall have no right in respect of such Securities except the right to receive the repurchase price thereof
and unpaid interest, if any, to the date fixed for repurchase. On presentation and surrender of such Securities at a place of payment
specified in the terms of such Securities, together with all Coupons, if any, appertaining thereto maturing after the date fixed
for repurchase, said Securities with, in the case of any Unregistered Securities that have Coupons attached, all matured Coupons
in default appertaining thereto or the specified portions thereof shall be paid and repurchased by the Issuer at the applicable
repurchase price, together with interest accrued thereon, if any, to the date fixed for repurchase; provided that any payment
of interest becoming due on or prior to the date fixed for repurchase shall be payable in the case of Securities with Coupons attached
thereto, to the Holders of the Coupons for such interest upon surrender thereof, and in the case of Registered Securities, to the
Holders of such Securities registered as such on the relevant record date subject to the terms and provisions of ‎Section
2.04 hereof.

 

    76

    

    

 

If any Security called for repurchase shall
not be so paid upon surrender thereof for repurchase, the principal shall, until paid or duly provided for, bear interest from
the date fixed for repurchase at the rate of interest or Yield to Maturity (in the case of an Original Issue Discount Security)
borne by the Security.

 

If any Security with Coupons attached thereto
is surrendered for repurchase and is not accompanied by all appurtenant Coupons maturing after the date fixed for repurchase, the
surrender of such missing Coupon or Coupons may be waived by the Issuer and the Trustee, if there be furnished to each of them
such security or indemnity as they may require to save each of them harmless.

 

Section 13.05 Repurchase by Remarketing
Entities. The Issuer may elect, in a manner reasonably satisfactory to the Trustee, with respect to any Securities subject
to repurchase at the option of the Holders thereof before their maturity to designate one or more remarketing entities to purchase,
at a price equal to the repurchase price, Securities of such series from the Holders thereof who give notice and surrender their
Securities in accordance with this Article.

 

Article
14

Guarantee

 

Section 14.01 The Guarantee. The
Guarantor hereby irrevocably, fully and unconditionally guarantees, on an unsecured basis, the full and punctual payment (whether
at the stated maturity or upon redemption, repurchase at the option of the Holders or acceleration) of the principal of, interest
on, and all other amounts payable under the Indenture and each Security and Coupon, if any. Upon failure by the Issuer to pay punctually
any such amount, the Guarantor shall forthwith on demand pay the amount not so paid at the same place and in the same manner that
applies to payments made by the Issuer under this Indenture. This Guarantee is a guarantee of payment and not of collection.

 

Section 14.02 Guarantee Unconditional.
The obligations of the Guarantor hereunder are unconditional and absolute and, without limiting the generality of the foregoing,
will not be released, discharged or otherwise affected by:

 

(a) any extension, renewal,
settlement, compromise, waiver or release in respect of any obligation of the Issuer under this Indenture or any Security or Coupon,
by operation of law or otherwise;

 

(b) any modification or amendment
of or supplement to this Indenture or any Security or Coupon;

 

    77

    

    

 

(c) any change in the corporate
existence, structure or ownership of the Issuer, or any insolvency, bankruptcy, reorganization or other similar proceeding affecting
the Issuer or its assets or any resulting release or discharge of any obligation of the Issuer contained in this Indenture or any
Security or Coupon;

 

(d) the existence of any claim,
set-off or other rights that the Guarantor may have at any time against the Issuer, the Trustee or any other Person, whether in
connection with this Indenture or any unrelated transactions, provided that nothing herein prevents the assertion of any
such claim by separate suit or compulsory counterclaim;

 

(e) any invalidity or unenforceability
relating to or against the Issuer for any reason of this Indenture or any Security or Coupon, or any provision of applicable law
or regulation purporting to prohibit the payment by the Issuer of the principal of, interest on or other amounts on any Security
or Coupon; or

 

(f) subject to clause (b)
of the proviso below, any other act or omission to act or delay of any kind by the Issuer, the Trustee or any other Person or any
other circumstance whatsoever which might, but for the provisions of this paragraph, constitute a legal or equitable discharge
of or defense to the Guarantor’s obligations hereunder;

 

provided, however, that:

 

(a) under no circumstances will
the Guarantor be liable at any time or place to any Holder under this Article,

 

(i) for any amount of any payment
that the Issuer is excused from making under the terms of any Security or Coupon or this Indenture, for so long as the Issuer shall
be excused under such terms; or

 

(ii) for any amount in excess of
the amount actually due and owing by the Issuer to such Holder at such time and place, including but not limited to any set-off
to which the Issuer would be entitled; and

 

(b) in addition but not in limitation
of (a) above, any defense or counterclaim of the Issuer (other than any resulting solely from, or available to the Guarantor solely
on account of, the insolvency of the Issuer or the status of the Issuer as the debtor or subject of a bankruptcy or insolvency
proceeding) shall also be available to the Guarantor to the same extent that such defense or counterclaim is available to the Issuer

 

    78

    

    

 

and
may be asserted as a defense or counterclaim by the Guarantor, in each case whether or not asserted by the Issuer.

 

Section 14.03 Discharge; Reinstatement.
The Guarantor’s obligations under this Article 14 will remain in full force and effect until the principal of, interest
on and other amounts on the Securities and Coupons, if any, have been paid in full. If at any time any payment of the principal
of, interest on, or other amounts on any Security or Coupon is rescinded or must be otherwise restored or returned upon the insolvency,
bankruptcy or reorganization of the Issuer or otherwise, the Guarantor’s obligations hereunder with respect to such payment
will be reinstated as though such payment had been due but not made at such time.

 

Section 14.04 Waiver by the Guarantor.
The Guarantor irrevocably waives acceptance hereof, presentment, demand, protest and any notice not provided for herein, as
well as any requirement that at any time any action be taken by any Person against the Issuer or any other Person. The Guarantor
hereby agrees that, in the event of a default in payment of the principal of, interest on, and all other amounts payable under
any Security or Coupon, whether at its stated maturity, by declaration of acceleration, call for redemption or otherwise, legal
proceedings may be instituted by the Trustee on behalf of, or by, the Holder of such Security or Coupon, subject to the terms and
conditions set forth in this Indenture, directly against the Guarantor to enforce this Guarantee without first proceeding against
the Issuer.

 

Section 14.05 Subrogation. Upon making
any payment with respect to any obligation of the Issuer under this Article, the Guarantor shall be subrogated to the rights of
the payee against the Issuer with respect to such obligation, provided that the Guarantor may not enforce any right of subrogation
with respect to such payment so long as any amount payable by the Issuer hereunder or under the Securities or Coupons, if any,
remains unpaid.

 

Section 14.06 Stay of Acceleration. If
acceleration of the time for payment of any amount payable by the Issuer under this Indenture or the Securities is stayed upon
the insolvency, bankruptcy or reorganization of the Issuer, all such amounts otherwise subject to acceleration under the terms
of this Indenture are nonetheless payable by the Guarantor hereunder forthwith on demand by the Trustee or the Holders.

 

Section 14.07 Savings Clause. Notwithstanding
anything to the contrary in this Article, the Guarantor, and by its acceptance of Securities, each Holder, hereby confirms that
it is the intention of all such parties that the Guarantee not constitute a fraudulent conveyance under applicable fraudulent conveyance
provisions of the United States Bankruptcy Code or any comparable provision of state law. To effectuate that intention, the Trustee,
the Holders and the Guarantor

 

    79

    

    

 

hereby irrevocably agree that the obligations of the Guarantor under the Guarantee are limited to
the maximum amount that would not render the Guarantor’s obligations subject to avoidance under applicable fraudulent conveyance
provisions of the United States Bankruptcy Code or any comparable provision of state law.

 

Section 14.08 Execution and Delivery
of Guarantee. The execution by the Guarantor of this Indenture evidences the Guarantee, whether or not the person signing as
an officer of the Guarantor still holds that office at the time of authentication of any Security. The delivery of any Security
by the Trustee after authentication constitutes due delivery of the Guarantee set forth in this Indenture on behalf of the Guarantor.

 

Section 14.09 Not Insured. This Guarantee
is not insured by the Federal Deposit Insurance Corporation of the United States of America.

 

    80

    

    

 

IN WITNESS WHEREOF the parties hereto have
caused this Indenture to be duly executed and attested, all dated as of February 19, 2016.

 

	 	JPMORGAN CHASE FINANCIAL COMPANY LLC, as Issuer
	 	 
	 	 
	 	By:	/s/ Patrick Dempsey
	 	Name: Patrick Dempsey
	 	Title:   Treasurer & Managing Director  

                    

 

 

	Attest:  	 
	 	 
	 	 
	By:	/s/ Aisling DeSola	 
	Name: Aisling DeSola	 
	Title:   Vice President and Secretary 
	 

 

 

	 	JPMORGAN CHASE & CO., as Guarantor  
	 	 
	 	 
	 	By:	/s/ Peter W. Smith
	 	Name:  Peter W. Smith
	 	Title:    Managing Director & Attorney-in-Fact

 

 

	Attest:  	 
	 	 
	 	 
	By:	/s/ Stephen B. Grant	 
	Name: Stephen B. Grant	 
	Title:   Assistant Corporate Secretary	 

 

    

    

    

 

	 	DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee
	 	 
	 	 
	 	By:	/s/ Linda Reale
	 	Name:Linda Reale
	 	Title:  Vice President
	 	 
	 	 	 
	 	By:	/s/ Wanda Camacho
	 	Name:Wanda Camacho
	 	Title:  Vice President

 

 

	Attest:  	 
	 	 
	 	 
	By:	/s/ Annie Jaghatspanyan	 
	Name: Annie Jaghatspanyan	 
	Title:   Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]